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 A. Introduction 
Small Peptides with a β-Hairpin Structure*
 
1. Introduction 
 
In recent years, β-hairpin peptides have been studied in detail. β-turns are the most 
common element of non-repetitive structure recognised in proteins.1 They consist of 
supersecondary structural elements in which two antiparallel adjacent peptide β-sheets are 
linked by a short loop. The loop size can vary; the majority of β-hairpins have loops of two 
to six residues,2 whereby the most common loop size is two. Their dihedral angels 
(Table 1) classify them.3  
 
Turn Type Φ (i+1) Ψ (i+1) Φ (i+2) Ψ (i+2) 
Type I β -60 -30 -90 0 
Type I´β 60 30 90 0 
Type I´ β 60 30 90 0 
Type II´ β 60 -120 -90 0 
Table 1: Most common hydrogen bonded β-turns in β-hairpins and their dihedral angels 
 
                                                 
* The results of this chapter have been published: S. Miltschitzky and B. Koenig, OPPI 2005, in press. 
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Figure 1: Illustration of the four residues in a β-turn demonstrating the Φ and Ψ angels of the (i+1) residue 
 
The two number nomenclature was introduced by Sibanda & Thornton using symbols of 
the form X:Y.4 X is defined as the number of residues in the connecting segment if strand 
residues have at least one of their NH or CO main chain groups involved in the hydrogen 
bonding pattern. Y is defined as the number of residues in the connecting segment, when 
the strand residues have both their NH and CO main chain group involved. If both 
hydrogen bonds are formed, then X=Y. If only a single hydrogen bond is formed between 
the terminal NH of the first strand and the CO of the second strand, then Y = X+2. In 
protein structures, 2:2 β-hairpins are most abundant, followed by 3:5 β-hairpins and 4:4 β-
hairpins.5
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Figure 2: Schematic representation of a 2:2 and a 3:5 β-hairpin structure in proteins. R = amino acid side 
chain 
 
To understand the formation of β-hairpins, it is necessary to analyze the energy 
contribution of the intrinsic secondary structure propensities of the different amino acids. In 
addition, interstrand side-chain side-chain interactions, in two structurally different regions 
of this secondary structure, the β-strand and the turn region, have to be considered. This 
review will recapitulate the genesis of linear and cyclic, non-aggregating peptides and 
peptidomimetics that display β-sheet folding within this decade.6 The following sections 
will focus on studies that have investigated the effect of turn-sequences, interstrand 
hydrogen bonding, side-chain interactions, and cyclization of the β-hairpin structure and its 
stability. 
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 2. Stabilized α-Peptides with a β-Hairpin Structure and their Biological Application 
 
Autonomously folding β-hairpins have emerged recently as vehicles for probing local 
interactions in β-sheet folding and assembly,7 and as building blocks in protein design.8 
This section will focus on electrostatic and hydrophobic side-chain-side-chain interactions 
stabilizing the β-hairpin structure and leading to autonomously folding. It is generally 
believed, that salt bridges contribute significantly to the stability of the native state of the 
protein. An elongated version of the de novo designed β-hairpin peptide, BH8, has allowed 
Ramirez-Alvarado et al. to gain insight into the role of electrostatic interactions in β-hairpin 
stability.9 A Lys-Glu electrostatic pair has been introduced by adding a residue at the 
beginning and at the N-terminal and C-terminal strands of the β-hairpin structure, in both 
orientations. The two resulting peptides and controls having Ala residues at theses positions 
and different combinations of Ala with Lys, or Glu residues, were analyzed under different 
pH and ionic strength conditions. The investigated peptides had the following amino acid 
sequences: 
 
BH8 (1a):   Arg-Gly-Ile-Thr-Val-Asn-Gly-Lys-Thr-Tyr-Gly-Arg 
BHKE (1b):  Arg-Gly-Lys-Ile-Thr-Val-Asn-Gly-Lys-Thr-Tyr-Glu-Gly-Arg 
BHEK (1c):  Arg-Gly-Glu-Ile-Thr-Val-Asn-Gly-Lys-Thr-Tyr-Lys-Gly-Arg 
BHKA (1d):  Arg-Gly-Lys-Ile Thr-Val-Asn-Gly-Lys-Thr-Tyr-Ala-Gly-Arg 
BHAE (1e):  Arg-Gly-Ala-Ile-Thr-Val-Asn-Gly-Lys-Thr-Tyr-Glu-Gly-Arg 
BHAA (1f):  Arg-Gly-Ala-Ile-Thr-Val-Asn-Gly-Lys-Thr-Tyr-Ala-Gly-Arg. 
 
The NMR analysis confirms that all of the peptides adopt a β-hairpin structure in 
equilibrium with random-coil conformations in aqueous solution. The population ranking is 
BHKE > BHAE > BHEK > BHKA ≈ BHAA. In previous work, the authors have shown 
that a plateau of β-hairpin population was found at 40 % TFE for the BH8.10 The 
conformational shifts of the Cα protons in 40 % TFE are larger than in aqueous solution 
indicating an increase of the structured population. As in aqueous solution, peptide BHKE 
4 
 is the one with the highest population, close to 100 %. All of the peptides are more 
structured at higher pH values as shown by the downfield shift of the CαH of the two Thr 
residues. 
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Figure 3: CαH conformational shifts of the different BH-peptides. The conformational shifts of the CαH 
protons are obtained by subtracting the random-coil values.11 A: aqueous solution; B: 40 % TFE 
 
Searle and co-workers, using a model β-hairpin system of 16 residues, investigated 
energetic contributions to the stability of Glu-Lys salt bridges.12 The authors mutated two 
Ser-Lys interstrand pairs in 2a to Glu-Lys salt bridges (2b and 2c) and examined the 
energetic effects of introducing two salt bridges simultaneously at these two positions (2d). 
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2a: X2 = Lys, X6 = Ser, X11 = Lys, X15 = Ser
2b: X2 = Lys, X6 = Glu, X11 = Lys, X15 = Ser
2b: X2 = Lys, X6 = Ser, X11 = Lys, X15 = Glu
2d: X2 = Lys, X6 = Glu, X11 = Lys, X15 = Glu  
Figure 4: Schematic representation of the b-hairpin peptides β1-β4. “X” indicates the sites of the mutated 
residues with boxes representing the position of the salt bridge 
 
The analytical data show clearly that the selective introduction of an ion-pairing interaction 
at either position enhances the stability of the folded state by increasing the magnitude of 
∆δHα values. Individually, each interaction contributes 1.2-1.3 kJ/mol to stability; however, 
when introduced simultaneously, the contribution (-3.6 kJ/mol) is greater than the sum of 
the individual contributions. 
In addition to electrostatic interactions, hydrophobic interactions have been investigated. 
Cochran and co-workers used the stabilization of the β-hairpin conformation in short 
peptides by a tryptophan zipper (trpzip).13 These trpzips are minimal units of β tertiary 
structure and have the thermodynamic properties of typical folded proteins.  
 
3a trpzip1 Ser-Trp-Thr-Trp-Glu-Gly-Asn-Lys-Trp-Thr-Trp-Lys Type II´turn 
3b trpzip2 Ser-Trp-Thr-Trp-Glu-Asn-Gly-Lys-Trp-Thr-Trp-Lys Type I´turn 
3c trpzip3 Ser-Trp-Thr-Trp-Glu-DPro-Asn-Lys-Trp-Thr-Trp-Lys Type II´turn 
Table 2: Amino acid sequences of the trpzip peptides 
 
6 
 High-resolution NMR structures show the two cross-strand Trp pair`s interdigitating in a 
zipper-like motif on the surface of the folded peptide. In each case, the peptides are highly 
water-soluble, well structured, and monomeric. Trpzip2 (3b) appears to be the most stable 
peptide due to the stronger promoting turn sequence Asn-Gly, despite previous conclusions 
that the D-Pro-Asn turn is more stabilizing than Asn-Gly.14  
Based on the results of Cochran´s trpzip, a β-hairpin peptide, which functions as a 
molecular receptor for nucleotides in water, was synthesized by Butterfield and co-
workers.15 The diagonal Trp-Trp pair in the non-hydrogen-bonding sites of the β-hairpin 
peptide WKWK (4) provides a binding cleft for aromatic intercalation. 
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WKWK (4): Ac-Arg-Trp-Val-Lys-Val-Asn-Gly-Orn-Trp-Ile-Lys-Gln-NH2
4
 
Figure 5: Structure of the peptide WKWK (4) 
 
The ability of WKWK (4) to bind ATP in aqueous solution was investigated by 
fluorescence titration. A remarkable association constant for ATP in aqueous solvent of 
5800 M-1 was determined from tryptophan emission quenching. Titration of ATP into 
peptide WKWK (4) produced significant upfield shifting of aromatic protons on both Trp 
7 
 residues as well as the adenine protons of ATP, indicating that the adenine base is 
interacting with both Trp residues of WKWK (4). The selectivity of nucleotide recognition 
by WKWK (4)16 was investigated by proton NMR titrations and the affinity constants for 
WKWK binding to ATP, guanosine 5´-triphosphate (GTP), cytidine 5´-triphosphate (CTP), 
and thymidine 5´-triphosphate (dTTP) are summarized in table 3.  
 
nucleotide Kassoc, M-1 Kd, mM ∆G (error*), kcal/mol ∆0, ppm 
ATP 700 1.4 - 3.9 (0.1) - 0.12 
GTP 2200 0.45 - 4.6 (0.1) - 0.06 
dTTP 3700 0.27 - 4.9 (0.1) - 0.05 
CTP 270 3.7 - 3.3 (0.1) - 0.03 
Table 3: Affinity constants for WKWK (4) binding to nucleotide triphosphates (in 10 mM d3-acetate buffer, 
10 mM NaCl, pH 5.0 (uncorrected) at 298 K. * Errors determined from the average deviation between 2 and 4 
separate titration experiments 
 
Peptide WKWK (4) demonstrates measurable selectivity of dTTP and GTP binding. The 
order of binding affinity follows dTTP>GTP>ATP>CTP, with differences in binding 
energies spanning as much as 1.6 kcal/mol.  
The two Lys residues of WKWK (4) on the same face of the hairpin allow a favorable 
electrostatic interaction with flavin mononucleotide (FMN).17 Several analytical methods 
demonstrate that the flavin ring intercalates between the two Trp residues. The difference in 
binding affinities between FMN (Kassoc = 2200 M-1) and riboflavin (Kassoc = 310 M-1) 
indicates that electrostatic interactions of the FMN phosphate group contribute 
approximately - 1 kcal/mol to the overall FMN binding. This value is in agreement with 
electrostatic contributions to ATP recognition by WKWK (4). 
The interaction between proteins and single-stranded DNA (ssDNA) plays an important 
role in the regulation of critical biological processes such as the DNA replication and 
repair.18 Due to the remarkable association constants of WKWK (4) to nucleotides, the 
authors expected the dimer (WKWK)2 (5) as a potential receptor for ssDNA. A disulfide 
bond between N-terminal Cys side chains dimerizes WKWK. 
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Figure 6: Structure of peptide (WKWK )2 (5). The residues in bold create the nucleic acid binding site 
 
The structure of the (WKWK)2 dimer (5) creates two nucleotide binding sites which are 
expected to be well-structured due to the highly populated β-hairpin conformation of 
WKWK. The recognition of a single-stranded pentanucleotide sequence 5´-d(AAAAA)-3´ 
(dA5) was investigated, followed by the determination of sequence selectivity between dA5, 
dT5, ‘and dC5. Finally, the binding of (WKWK)2 (5) to an 11-residue single-stranded 
oligonucleotide and its corresponding duplex was investigated.  
 
Entry sequence [NaCl], 
mM 
Ka, M-1 Kd, µM ∆G (error*), 
kcal/mol 
1 5´-AAAAA-3´ 0 8 x 104 12 - 6.7 (0.1) 
2 5´-TTTTT-3´ 0 3 x 104 30 -6.1 (0.1) 
3 5´-CCCCC-3´ 0 5 x 104 20 - 6.4 (0.1) 
4 5´-CCATCGCTACC-3´ 
5´-CCATCGCTACC-3´ 
100 3 x 105 3 - 7.5 (0.1) 
5 3´-GGTAGCGATGG-5´ 100 2 x 105 5 - 7.2 (0.1) 
Table 4: affinity constants for (WKWK)2 (5) with DNA sequences in a 10 mM sodium phosphate buffer, pH 
7.0, at 298 K. * Errors determined from the average deviation between 2 and 4 separate titration experiments 
9 
 The modest selectivity for dA5 is not surprising given the ssDNA-binding proteins 
interacting with their nucleotide target in a largely independent manner.19 The stronger 
interaction with the 11-mer relative to the pentanucleotides can be attributed to an increased 
number of favorable contacts that are possible with the longer oligonucleotide. 
The growing problem of resistance to established antibiotics has stimulated intense interest 
in the development of novel antimicrobial agents with new modes of action. One emerging 
class of antibiotics is based on naturally occurring cationic peptides.20 These include the 
disulfide-bridged β-hairpin and β-sheet peptides protegrins,21 tachyplesins,22 and defensins, 
which adopt a β-hairpin-like structure.23
 
Protegrin-I
Tachyplesin-I
Polyphemusin-II
RTD-1
 
Figure 7: Naturally occurring β-hairpin antimicrobial peptides. R* = C-terminal arginine amide. 
 
The naturally occurring protegrins and tachyplesins exert a significant haemolytic activity 
against human red blood cells, a key indicator of toxicity. Based on the natural peptides 
(Figure 3), Robinson et al. synthesized new antimicrobial peptidomimetics that show potent 
and selective activity.24  
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Figure 8: β-hairpin mimetics. X = cationic and/or hydrophobic/aromatic amino acid residue, Temp. = 
template T1 or T2. 
 
Screening of a library of 12-amino acid residue mimetics (Figure 4), which contain a D-
Pro-L-Pro template (T1) or a xanthene template (T2), gave several members with activity 
against Gram-positive and Gram-negative bacteria, as well as the yeast Candida albicans 
(Table 5).  
 
Mimetic Amino acid sequence*   MIC [µg ml-1]  % Hemolysis 
  S. aureus E. coli P. aerug C. albic  
6a LRLKYRRFKYRV-T1 25 12 25 12 27 
6b LRLQYRRFQYRV-T1 12 6 12 6 27 
6c LRLEYRRFEYRV-T1 100 100 > 100 50 14 
6d LRLKKRRWKYRV-T1 12 12 6 12 1 
6e LRLKKRRWKYRV-T2 6 25 25 6 13 
6f LCLKKRRWKYCV-T1 25 6 25 12 3 
6g LRCKKRRWKCRV-T1 25 25 50 50 1 
 Protegrin I 6 3 3 6 37 
 Tachyplesin I 2 1 2 2 34 
Table 5: Assay of antibiotic and hemolytic activity. *: Amino acids in the single letter code 
 
The structure of the mimetics is different to the naturally occurring peptides that adopt a β-
hairpin-like structure. While mimetic compound 6d is largely unstructured in water, despite 
the effect of the D-Pro-L-Pro template, it clearly adopts a β-hairpin conformation in the 
11 
 presence of DPC micelles. A regular β-hairpin geometry is not present in compound 6g, 
although a short stretch of 310 helix is seen.  
 
12 
 3. Turn Mimics for Peptide Hairpin Structures 
 
Peptides showing a turn conformation are of high relevance since, in many cases, the turn 
region is responsible for biological activity. Well known examples are somatostatin25 and 
oxytocin.26 Consequently, β-turns and β-turn mimetic adopting  discrete conformations 
(“foldamers”) have become target structures in medicinal research. This section will focus 
on turn mimetics and their ability to promote a turn structure. Lubell pursued two strategies 
for generating peptide mimics: the first employs the use of biciclics to constrain a dipeptide 
unit. The second uses the steric interactions of bulky ring substituents to influence the 
geometry.27 Golebiowski and co-workers using the Ugi reaction as a key step describe the 
synthesis of a bicyclic diketopiperazine.28 This compound overlaps well with a type II β-
turn. 
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Figure 9: A bicyclic diketopiperazine β-turn mimetic 
 
Next to their ability to induce β-turns, diketopiperazines are rigid backbones of peptide 
receptors.29 Several receptors with two identical arms were prepared in order to examine 
their binding properties against a peptide library of 24,389 peptides.  
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Figure 10: Two-armed diketopiperazine receptors. 
 
The receptors were marked with the red azo dye Disperse Red 1 (DR1) which allows the 
monitoring of the peptide bonding. The following receptors were used: 
 
DR mimetic 1 (8a)  Phe-Asn(Trt)-Tyr 
DR mimetic 2 (8b)  Phe-Asn(Trt)-D-Tyr 
DR mimetic 3 (8c)  Asn(Trt)-Phe-D-Tyr 
DR mimetic 4 (8d)  Phe-Gln(Trt)-Tyr 
DR mimetic 5 (8e)  Gln(Trt)-Phe-Tyr 
 
The assays of DR mimetic 1 (8a) and DR mimetic 5 (8e) indicated a particularly high level 
of binding specificity since only 25 beads from all tested members of the library showed 
the red color of the receptor. This corresponds to a selectivity of one selected bead out of 
5000. While 8a exclusively selects peptides containing a D-His following two hydrophobic 
D-amino acids, 8e solely chooses peptides with an Asn following both a hydrophobic L- 
and D-amino acid. Affinity constants up to Ka = 1420±200 M-1 were observed. 
Most of the synthetic foldamers have homogeneous backbones, i.e. they are built from a 
single type of monomer. Oligomers of heterogeneous backbones are also important in 
conformational design. Gellman and co-workers reported an oligomer that adopts a β-
hairpin shape. The loop is composed of β-amino acids while the strands consist of α-amino 
14 
 acids.30 The loop segments made from dinipecotic acid (Nip) adopts a loop conformation in 
β-hairpins as shown in previous studies.31
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Figure 11: β-Turn hairpins bearing a nipecotic acid loop segment 
 
The data of IR and NMR analysis indicate that the heterochiral loops (9a, 9b) support 
hairpin formation while the homochiral loops (9c, 9d) do not. A homochiral dinipecotic 
acid β-peptide does not allow the formation of a 12-membered ring hydrogen bond that is 
necessary for the hairpin folding.32
To help understand the folding and stability of peptides, a negatively charged dibenzofuran-
based β-turn mimic was incorporated into the loop 1 of the PIN1 WW domain.33 These 
three-stranded β-sheet domains are found in more than 200 multidomain proteins where 
loop 1 of PIN1 plays a critical role in binding of the phosphoserine (pS) residue in the 
YSPTpSPS peptide substrate.34 The formation of the loop 1 is rate limiting for the folding 
of the PIN1 WW domain.35
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Figure 12: 4-(2-aminoethyl)-6-dibenzofuran propionic acid (10) 
 
The incorporation of the bis-anionic version of 4-(2-aminoethyl)-6-dibenzofuran propionic 
acid (10) as turn mimetic in lieu of the uncharged analogue resulted in enhanced solubility. 
The thermodynamic stability of the PIN WW domain is not perturbed significantly. 
Dipeptide isosters derived from Leu and meso-tartraic acid derivatives (6-endo-BTL (11a) 
and 6-endo-BtL (11b)) were inserted in a small peptide.36 The chair conformation of the 
six-membered ring locked in the biciclic structure, in conjunction with the endo 
configuration at C6 gives the right shape for imposing a reverse β-turn. 
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Figure 13: 6-endo-BTL (11a) and 6-endo-BtL (11b) 
 
Both turn structures were incorporated into a tetrapeptide, giving Ac-Val-Ala-6-endo-
BT(t)L-Val-Gly-OMe. The 6-endo-BTL peptide shows the turn structure as a minor 
conformer in a 1:3 ratio to an open reverse turn conformation, while the corresponding 
16 
 peptide shows a unique turn conformation. However, the 6-endo-BTL peptide, having the 
Leu side chain in axial position, is a better turn inducer since it can promote a tighter turn. 
A turn mimic derived from PLG (prolyl-glycine amide) containing a β-lactam in the turn 
area was prepared by Podlech et al.37 The substrate has a turn configuration even though no 
stabilizing central hydrogen bond is present. The so-called “open turn conformation”38 is in 
fact stabilized by a hydrogen bond between the β-lactam carbonyl group and the 
neighboring NH moiety. 
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Figure 14: Targeted peptidomimetic (12) bearing a β-lactam moiety. 
 
The resulting six-membered twist-boat-like ring is not only present in the solid state but 
also in solution in CDCl3. The stabilization is only possible because of the additional 
alkylidene group between incoming and leaving peptide strands. 
Proline substitution has been widely used to search for turns39 because Pro is frequently 
found at the i+1 position of a β-turn.40 Ishiguro et al. have synthesized (2S,4S)- and 
(2S,4R)-4-(2´-guanidinoethyl) proline as a conformational restricted arginine.41 These 
analogues were incorporated into mini atrial natruretic polypeptide (miniANP), which has 
an important turnlike conformation at Gly6-Arg7-Met8-Asp9.42 The backbones of the 
arginine analogues fit the turn because of the bent backbone of proline. Although NMR 
could not determine the overall conformation of the analogues, in each case the distance 
constraints were consistent with and converged well into a type I β-turn. MiniANP is the 
smallest analogues of ANP-related peptides.43 It contains 15 natural amino acids and binds 
selectively to natriuretic peptide receptor A (NPR-A). In biological activity measurements, 
17 
 the production of cGMP in Chinese hamster ovary cells expressing NPR-A in response to 
peptides 13a-e was measured. 
 
Peptide 
 
Biological 
avtivity 
EC50 (nmol) 
Relative biological 
activity 
EC50 (analogue)/ 
EC50 (miniANP) 
miniANP 13a 3.1 ± 0.5 1.0 
[4S-GEPro7]miniANP 13b 4.6 ± 0.4 1.5 
[4R-GEPro7]miniANP 13c 1.3 ± 0.6 0.4 
[Pro7]miniANP 13d 58.1 ± 17.2 18.7 
[Ala7]miniANP 13e 137.3 ± 11.3 44.3 
Tabelle 1: Biological activity of miniANP (13a) and analogues (13b-e) 
 
The table shows that [4S-GEPro7]miniANP (13b) and [4R-GEPro7]miniANP (13c) are as 
potent as miniANP (13a) but of 19 times lower activity than [Pro7]miniANP (13d).  
To develop a definitive approach towards the design of an I´ turn nucleated β-hairpin, 
Shamala & Balaram have investigated α-aminoisobutyric (Aib) Aib-D-Xxx nucleating 
segments.44 The incorporation of a D-residue intends to favor a formation of a type I´ β-
turn, as in the analogue D-Pro-Gly segments.45 The Aib-D-Ala segment was incorporated 
into a hexapeptide, giving Boc-Leu-Phe-Val-Aib-D-Ala-Leu-Phe-Val-OMe. This peptide 
adopts a β-hairpin structure with a type I´ β-turn at the Aib-D-Ala segment. 
Tomasini and co-workers described the synthesis and the conformational analysis of a 
small library of fully protected tetramers containing pseudoprolines.46 The general structure 
of the tetramers and the pseudoprolines is shown in figure 14. 
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Figure 15: General structure of the fully protected tetramers 
 
L-Pyroglutamic acid (L-pGlu), (4S,5R)-4-methyl-5-carboxybenzyloxazolidin-2-one (L-
Oxd), or (4R,5S)-4-methyl-5-carboxybenzyloxazolidin-2-one (D-Oxd) are used in place of 
pseudoproline. Table 6 summarizes the amino acid sequences of the investigated 
tetrapeptides. 
 
Entry Amino acid sequence 
14a Boc-Ala-L-pGlu-Gly-Ala-OBzl 
14b Boc-Val-L-pGlu-Gly-Ala-OBzl 
14c Boc-Val-L-pGlu-Aib-Ala-OBzl 
14d Boc-Val-L-Oxd-Gly-Ala-OBzl 
14e Boc-Val-D-Oxd-Gly-Ala-OBzl 
14f Boc-Val-D-Oxd-Aib-Ala-OBzl 
Table 6: Amino acid sequences of the investigated tetrapeptides (14a-f) 
 
Gly is widely found in natural reverse-turn structures while Aib tends to form helical 
structures (helycogenic).47 The molecules containing D-Oxd showed a good propensity to 
form a β-hairpin conformation. Among them, Boc-Val-D-Oxd-Gly-Ala-OBzl (14e) had a 
preferential β-turn conformation in chloroform and a preferential γ-turn conformation in 
DMSO. Its epimer, Boc-Val-L-Oxd-Gly-Ala-OBzl (14d) is less able to assume ordered 
forms in solution. 
19 
 Metzler-Nolte and co-workers prepared Di- and tertapeptides bearing a metallocene 
backbone.48 The metal was altered between Fe2+ and Co+ to change the overall charge of 
the constructs.  
 
15
16
17
 
Figure 16: Synthesis of the di- and tetrapeptides with a metallocene backbone 
 
Evidence of strong interaction was found in 15 and 16, while 17a shows no intramolecular 
hydrogen bond. In the solid state, an intramolecular hydrogen bond is formed between the 
amide NH and the ferrocene CO in 15a. If connecting atoms are counted, an 8-membered 
ring is formed. The situation for 16a is different. Two intramolecular hydrogen bonds 
N1···O6 and N3···O2 are formed. Both define 11-membered rings between O (i) and N 
(i+3). This describes 15a as a γ-turn-like and 16a as a β-turn-like structure. Similar results 
are found in chloroform solution for 16a but 15a shows now a NH···CO (ester) hydrogen 
bond. A comparison between uncharged ferrocene derivatives 15a and 16a and positively 
charged cobaltocenium derivatives 15b and 16b shows that both pairs do presumably form 
very similar structures. 
Photochromic compounds, which undergo large conformational changes when exposed to 
light, are also interesting in the field of turn mimetics. Azobenzenes are potentially well 
20 
 suited for this application. Hilvert and co-workers incorporated substituted azobenzenes in 
a 12-residue peptide, derived from GB1.49 GB1 has been shown to adopt a hairpin structure 
in aqueous solution.50
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Figure 17: Cis-trans isomerization of azobenzene and the amino acid sequence of the peptides 
 
Irradiation at the wavelength of the π→π∗ transition converts the trans (18a) into the cis 
(18b) isomer. The reverse process can be induced either thermally or by the irradiation at 
the wavelength of the n→π∗ transition. In its cis configuration, the meta-substituted 
azoebenzene mimics the dipeptide D-Pro-Gly in nucleating a stable and monomeric hairpin 
structure. In contrast, the trans configurated peptide did not adopt a unique structure.  
Short linear peptides are inherent flexible molecules, especially in aqueous solution, and so 
are often poor mimetics of the secondary structures. To circumvent this folding-problem, 
much attention has been paid to the design of templates that constrain peptide chains into 
biologically relevant secondary structures such as cyclic peptides.51 Linear synthetic 
peptides containing tandemly repeated NPNA motifs were evaluated in the late 1980s as 
potential malaria vaccine candidates.52 Such linear peptides are flexible in water, but 
presumably adopt a folded conformation in the intact protein.53 A bicyclic template, 
containing a diketopiperazine derived from Asp and (2S,3R,4R)-diaminoproline was 
incorporated in an acyclic peptide bearing the NPNA-motif.54
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Figure 18: Structure of the NPNA-motif containing mimetic 
 
NMR spectra indicate a well-defined β-hairpin conformation for (19) in DMSO solution. 
NOEs and H/D-exchange rates show a well-populated 2:2 conformation with a type I β-
turn in the Asn2-Pro3-Asn4-Ala5 (NPNA) motif in the tip of the hairpin loop. 
Amino acid 7/5 bicyclic lactams are dipeptide surrogates in angiotensin-converting enzyme 
(ACE) inhibitors.55 The 7/5 bicyclic lactam was used as external constraints for the GLDV 
motif by Young and co-workers.56  
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Figure 19: The structure of the 7/5 bicyclic lactam (20) and of the synthesized peptide (21) 
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 In agreement with X-ray crystal structure analysis and calculations, the 7/5 bicyclic lactam 
(20) was not a β-turn mimetic on its own. However, the high-resolution NMR 
spectroscopic data for the cyclic peptide (21) was consistent with a single backbone 
conformation, either type VI or type II´ β-turn properties. 
The effects of chirality and side-chain interactions on the formation of a type II´ β-turn 
were studied by Wishart et al.57 The appealing β-hairpin model is based on gramicidin S 
(GS). GS is a cyclic, amphiphatic decapeptide composed of two evenly spaced type II´ β-
turn connected by an antiparallel β-sheet.58 For this study, a 14-residue cyclic analogue of 
GS was selected bearing different amino acids in the i+1 and i+2 positions in both turns. 
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Figure 20: Amino acids at position i+1 and i+2 in both turn 1 and turn 2. 
 
Heterochirality is an essential requirement for type II´ β-turn conformation supporting 
Rose´s “equatorial-axial rule”.59 Gly-Gly and Sar-Sar analogues are not able to adopt or 
stabilize a type II´ β-turn. The content of β-sheet formation and proper side-chain 
interactions accounts for ≈ 10 % type II´ β-turn stabilization. Analogues with L-Pro at 
position i+2 and/or D-Pro at position i+1 have a predisposition to form a β-turn. 
Furthermore, D-Pro (i+1), pipecolic acid (Pip), and 3,4-dehydroproline (Dhp) act as 
excellent type II´ β-turn promoters and lead to 20 % type II´ β-turn stability. 
23 
 4. Peptide Hairpin Structure Mimetics 
 
β-Strands are usually found hydrogen bonded at least in pairs, forming β-sheet structures in 
proteins. Isolated β-strands are not common. In the former sections, we focused on natural 
amino acids as (anti-)parallel strands connected by a β-turn. This chapter describes peptide 
mimetics incorporated into a hairpin structure.60
In immune defense, the major histocompatability complex (MHC) proteins selectively bind 
the extended β-strand conformation of peptides. The peptides derive from intracellular 
process of viral, bacterial, and endogenous proteins.61 This type of recognition has 
implications in leukaemia, inflammatory, and neurological diseases.62 A series of 
pathological processes is associated with the formation of a β-sheet structure and protein 
aggregation in the form of β-amyloid deposition. Alzheimer´s disease as well as 
Creutzfeld-Jakob disease and BSE are connected with β-sheet aggregation.63 For these 
reasons alone, small molecules that mimic β-strands are of great interest in medicinal 
applications. 
Over the past decade, Nowick and co-wokers investigated the β-sheet structure and 
developed useful peptidomimetic blocks that mimic protein β-proteins. The core is 5-
amino-2-methoxybenzoic acid. This aromatic system contains an intramolecular hydrogen 
bond between the oxygen atom of the methoxy group to the lone pair of the nitrogen atom 
of an amide bond making the receptor more rigid.  
An artificial β-sheet with either β-strand mimics either along the upper or the lower edge 
forming a double stranded turn was described in the last decade.64 In further studies, a triply 
templated artificial β-sheet is reported. 
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Figure 21: Nowick´s double (22, 23) and triple stranded (24) artificial β-sheet structures 
 
The NOE and coupling constant data of (24) indicate that the component peptide and the 
strand mimics adopt a β-sheet tlike conformation in chloroform. The folded structure is 
only observed in a non-compeptitive solvent such as chloroform. It is lost in methanol, a 
competitive solvent. The upper and lower strand mimics induces a β-sheet structure on an 
attached peptide strand.65 The new amino acid, Orn(iPrCO-Hao) (25), was introduced, 
consisting of an ornithine residue (Orn) with the β-strand-mimicking amino acid Hao.66
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Figure 22: Structure of Orn(iPrCO-Hao) (25) 
 
The Orn side chain allows the Hao oxalamide carbonyl group to form a 10-membered ring 
with the amino group of a connected peptide, forming a β-turn in a β-hairpin. The 
Orn(iPrCO-Hao) amino acid (25) works as a splint that helps to enforce a β-sheet like 
structure. The triple stranded artificial β-sheet (24) depicted in figure 21 shows both the 
upper and the lower sheet in an antiparallel binding motif. Replacing the lower artificial 
sheet by a α-peptide strand (Phe-Ile) leads to a combined parallel and anti- β-sheet (26).67
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Figure 23: A triple stranded β-sheet with mixed parallel and antiparallel β-sheets 
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 The Hao template forms a pattern of hydrogen bonds similar to that of an antiparallel β-
sheet with the middle peptide strand while the middle peptide strand forms a pattern of 
hydrogen bonds similar to that of a parallel β-sheet with the bottom peptide. The β-strand 
mimic may be viewed as acting in conjunction with the triurea template to form a “corner 
bracket”. This leads to a stabilized β-sheet structure (26) in both of the attached peptide 
strands. Nowick´s artificial β-strand mimetic was also used for the investigation of 
sequence-selective recognition of peptide strands across non-hydrogen-bonded rings.68 
Therefore, Orn(iPrCO-Hao) (25) was attached to a peptide. Two residues, Thr and Val, 
were replaced in all possible orders at position R1 and R4. The residues R2 (Phe) and R3 
(Ile) were not changed. 
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Figure 24: Structure of the investigated molecules (27a-d) 
 
Entry R1 R2 R3 R4
27a Thr Phe Ile Val 
27b Val Phe Ile Thr 
27c Thr Phe Ile Thr 
27d Val Phe Ile Val 
Table 7: Sequence of the investigated molecules (27a-d) 
 
It was expected that Thr would preferentially pair with Thr and Val with Val, through self-
complementary non-covalent interactions that occur frequently in the non-hydrogen-bonded 
rings of antiparallel β-sheets.69 The investigation was carried out by 1H-NMR spectroscopic 
27 
 studies. The analysis revealed a strong preference for Thr-Val (27a) and Val-Thr (27b) to 
form a heterodimer, while Thr-Thr (27c) and Val-Val (27d) remain as homodimers. These 
results confirm the hypothesis that pairing of like residues is preferred. 
Koenig and co-workers used structurally similar compounds. First, methoxypyrrole amino 
acids (MOPAS) and a peptide strand were connected by the D-Pro-Gly turn fragment.70
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Figure 25: Monomer (28) and dimer MOPAS receptors (29) connected to peptide strands 
 
It was reported earlier that 5-(aminomethyl)pyrrole-2-carboxylic acid can be considered as 
a constrained surrogate of Gly-∆Ala.71 The replacement of the methyl group by a methoxy 
substituent allows the oxygen atom to form an intramolecular hydrogen bond to the amide 
proton of a second MOPAS unit. This should keep the pyrrole rings in one plane making 
the receptor more rigid. The turn structure was proven by 1H-NMR investigation and by X-
ray structure analysis of the monomer MOPAS turn (28). In further studies, a pyrimidine 
ring substitutes the pyrrole.72 As shown by the systems of Nowick, a hydrazine unit is 
necessary for the right pattern of geometry of the pyrimidine hydrazine acids (PHA) to 
build up extended artificial β-strands. It also allows the formation of an intramolecular 
hydrogen bond to the lone pair of the nitrogen atom of the pyrimidine ring. This was 
confirmed by the analysis of temperature dependent 1H-NMR spectra. 
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Figure 26: Monomer (30) and dimer PHA receptors (31) connected to peptide strands 
 
The PHA receptors are not only UV active but show also emission around 420 nm in non-
protic solvents after irradiation at 380 nm. The emission intensity decreased upon peptide 
binding and signaled the binding event.  
In this connection with heteroaromatic peptide mimetics, the intensive studies of sequence-
selective DNA recognition are to be mentioned. Based on the natural dDNA binding 
peptides of distamycin73 and netropsin,74 Dervan and co-workers developed the art of 
polyamide technology, using N-methylpyrazole (Py) and N-methylimidazole (Im) 
covalently linked side-by-side and in a specific manner.75 We cannot discuss the work in 
detail here, but is covered in recent reviews.76
Fluorescence labeling has become also a general technique for studying the intermolecular 
accumulation and localization of exogenously administered materials.77 Phosphotyrosyl 
(pTyr) mimetic-containing Grb2 SH2 domain binding antagonists are known as anticancer 
therapeutics typified by naphthylpropylamide analogues (32).78 Burke Jr. and co-workers 
have used these results and modified a potential anticancer drug (33) to monitor cellular 
distribution studies of this class of inhibitors.79 The environmentally sensitive 
nitrobenzoxadiazole (NBD) serves as fluorophore by replacing the naphthyl function. 
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Figure 27: Structures of the parent compounds with a naphthylpropylamide ligand (left) and a 
nitrobenzoxadiazole ligand (NBD) (right) 
 
The binding affinities of the two compounds were determined using an ELISA-based 
competition assay. Although modeling studies suggest that the level of bonding interactions 
afforded by the NBD ring system may not be as great as those provided by the naphthyl 
ring, the binding affinities are similar. 
Cyclic peptides and peptide mimetics are of great interest in medicinal applications because 
of their rigid shape. Starting from a combinatorial approach, Burgess and co-workers 
discovered a lead structure of a small macrocyclic molecule that potentates the effect of 
nerve growth factor (NGF) via interactions with its high affinity transmembrane tyrosine 
kinase receptor (TrkA).80
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Figure 28: Structure of the synthesized macrocycles (34a-d) 
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 All compounds consist of three natural amino acids (Glu-Lys-Ser) connected by 2-hydroxy-
5-nitro-benzoic acid derivatives. However, there are conformational differences among 
(34a-d), NMR experiments and molecular simulations indicate that all compounds can 
access a turn conformation, close to type I.  
The type VI β-turn involving a cis imide bond N-terminal to a L-Pro residue situated at the 
i+2 position plays a significant role in protein folding. It has a profound influence on the 
recognition process involving protein-ligand interaction.81 Derived from the tetrapeptide N-
cinnamoyl-Val-Pro-Phe-Leu-methyl ester (35), Iqbal and co-workers synthesized a novel 
cis-Pro cyclic peptide (36) via ring closing metathesis adopting a type VI β-turn.82
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Figure 29: Synthesis of the desired cyclic peptide (36). 
 
The open peptide (35) exists in a 310 helical structure.83 The conformation of the cyclic 
peptide (36) depends on the solvent. The solution NMR studies indicate that the major 
conformer adopts a type VIa β-turn in chloroform, but a type VIb β-turn in DMSO. 
β-Peptide foldamers stabilize helical conformation in organic solvents.84 Hairpin designs 
have been used to stabilize antiparallel β-peptide sheets.85 Gellman and co-workers report 
examples of these two concepts.86 Two β-tetrapeptides were connected by (R)-nipecotic-
acid-(3S,4R)-4-aminopiperidine-3-carboxylic acid (Nip-APiC) and both enentiomeric forms 
of β2-valine-β3-lysine. 
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Figure 30: Six antiparallel hairpins with different reverse turn side chain arrangements 
 
The compounds differ in the arrangement of the side chains. All of the large side chain 
groups are either oriented above (arrangement A) or below (arrangement B) the plane of the 
amide group. While each pair in of the arrangements differs from the turn segment, the two 
peptides differ from one another in the juxtaposition of the side chains. In methanol 
solution, (37) and (38) adopt at least a partial population of an expected hairpin 
conformation. The change from S- to R-configuration (37a↔37b, 38a↔38b) has no 
influence on the hairpin population. The arrangements A and B are both tolerated in 
antiparallel β-peptide sheets. Finally, pairing of large side chains on neighboring strands 
does not sterically disallow the hairpin formation. No distinct conformations were observed 
for (39a) and (39b). 
Non-peptidic β-strand complements could also provide a basis for disrupting protein-
protein interactions that depend on the recognition of peptide segments in an extended 
conformation.87 Gellman and co-workers introduced hydrogen bonding complementarity 
between a secondary sulfonamide and a α-amino acid residue.88
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Figure 31: The two point hydrogen-bonded interaction between a secondary sulfonamide group and the C=O 
and N-H of a single peptide residue 
 
Compound (40) is the first molecule for which a double hydrogen-bonding pattern of the 
shown type has been characterized. Both, IR and NMR data confirm the turn structure. 
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 5. Conclusions 
 
In summary, we report herein the recent publications in the field of small peptides adopting 
a hairpin conformation. These peptides are of great interest due to their biological activity 
and medicinal applications. Peptide mimetics based on β-turns are important, as many 
peptides are required to adopt such a conformation while effecting biological response. The 
article describes the different factors leading to stabilization or destabilization of the 
peptides´ conformation and activity. Nearby natural peptides, we focus on mimetics 
incorporated either in the turn region, the peptide strand, or both of them. These pseudo 
amino acids consist mainly of (heteroaromatic) cycles, metallogenic centers, and inorganic 
units. The combination of naturally active peptides adopting one conformation as a lead 
structure and combinatorial chemistry as a tool is supposed to be a promising method 
resulting in new peptide mimetics. In the ongoing research of biological and medicinal 
active compounds mediating Alzheimer, AIDS, and cancer, these compounds might help 
understanding and treating the diseases. 
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B. Main Part 
 
1. Synthesis of Substituted Pyrimidine Hydrazine Acids (PHA)  
and their Use in Peptide Recognition*
 
1.1 Introduction 
 
Interactions between peptide β-sheets are of importance for protein quaternary structure 
formation, protein-protein interaction, and protein aggregation. They are involved in 
important biological processes and the development of diseases - ranging from cancer 
and AIDS, to anthrax and Alzheimer´s.1,2 Small synthetic molecules that mimic surface 
epitopes on proteins are a potential source of novel ligands for use in drug and vaccine 
design.3 Over the last years peptidomimetics have attracted interest from both organic 
and medicinal chemists. In the biological, chemical, and pharmaceutical areas, they 
offer advantages over physiologically active peptides, which as active substances are 
crucial for the organism and may lead to severe side effects.4 There is much current 
interest in the preparation of peptides and peptidomimetics with a well-defined 
conformation.5 These conformationally constrained peptides are useful to probe protein 
folding and to mimic peptide structures.  
Since 1992, Nowick et al. have reported the development of peptidomimetic templates, 
which have been termed molecular scaffolds.6 These templates have oligourea structure 
and reassemble, in some ways, β-turns. Early in 1996, Nowick described an artificial 
antiparallel β-sheet (1), in which a 5-amino-2-methoxybenzamide β-strand mimic (2) 
and a diurea molecular scaffold stabilize a β-sheet structure in an attached peptide 
strand (Scheme 1).7
 
 
                                                 
* The results of this chapter have been published: S. Miltschitzky, V. Michlova, S. Stadlbauer, and B. 
Koenig, Heterocycles 2005, in press. 
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Scheme 1: Nowick´s artificial antiparallel β-sheet (1) and β-strand mimic (2) 
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1.2 Results and Discussions 
 
We report in this paper the synthesis of substituted pyrimidine-hydrazine-acids (PHA), 
and their inter- and intramolecular peptide binding properties as determined by NMR 
spectra and emission changes.  
We envisioned 6-hydrazinopyrimidine-4-carboxylic acids as a building block for 
extended β-strand mimics. Molecular modelling calculations on force field level 
(MMFF, program package Spartan)8 were carried out to explore the conformational 
preferences of PHA. The calculations show that oligomers of PHA adopt a linear 
conformation required to be complementary to peptide β-sheets.  
The hydrazine provides the right pattern of hydrogen bond donor and acceptor geometry 
complementary to extended peptide β-sheets and allows the formation of an 
intramolecular hydrogen bond. This should keep the pyrimidine ring of PHA 
oligoamides in a planar arrangement.  
 
Scheme 2: Low energy conformation of a PHA dimmer as calculated by force field method 
 
Starting material for PHA derivatives is the commercial available orotic acid (3). The 
acid is converted into the ester with methanol according to a literature procedure,9 
followed by a halogenation with POCl39 or POBr3, respectively. The substitution of a 
halogen atom by Boc- or Cbz-monoprotected hydrazine takes place selectively in 6-
position. The yields of the substitution reaction are typically between 60 and 95 %. 
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Scheme 3: Synthesis of the PHA parent structure 
 
The selective substitution of the chlorine and bromine was investigated by Yamanaka et 
al in detail.10 Computational and experimental studies both showed a dependency on the 
substituent in 4-position. Acceptors, such as the methyl ester guide substitution in 6-
position, while a methoxy groups yields selective substitution in 2-position. The X-Ray 
structure analysis of 6a and 6b and the HMBC spectrum of 6a confirm the expected 
substitution pattern. 
 
 
 
Scheme 4: Structures of 6a (left) and 6b (right) in the crystal 
 
The HMBC spectra of an 8 mM solution in deuterated DMSO at room temperature of 
6a shows a sharp cross peak between the protons on hydrazine nitrogen NH2 and on 
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carbon CH1, supporting the structure of the expected compound. The double set of 
signals arises from the cis- and trans-isomers of the Boc protecting group.11
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Scheme 5: HMBC-spectrum of 6a in deuterated DMSO. 
 
However, the X-ray structure of 6a does not show the assumed intramolecular hydrogen 
bond of the proton on hydrazine nitrogen and the pyrimidin nitrogen. The temperature 
dependence of the 1H NMR chemical shift of the NH2 proton (-5.15 ppb/K) in 10 mmol 
solution CDCl3 reflects its state of hydrogen bonding. 
The course of the subsequent substitution in 2-position with N-nucleophiles depends on 
the halogen atom. Chlorine substitution occurs only when activated with DMAP in situ. 
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Scheme 6: Proposed mechanism of the substitution of 2-chlorine atoms by N-nucleophiles 
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The DMAP displaces the chlorine atom as a nucleophile forming the charged 
intermediate 7. The amine attacks in the subsequent step the more electrophilic carbon 
C2 under basic conditions. The amine is nucleophile and base, but an excess of 
10 equivalents is used. In case of NEt3 as an auxiliary base, still 5 equivalents of the 
nucleophile are required. Although the second step of the reaction releases the DMAP, 
stoichiometric amounts are required to achieve good yields. The highest yields were 
obtained in the presence of 1.2 equivalents of DMAP, 2 equivalents of NEt3 and 
8 equivalents of amine (see Experimental). The bromine derivative is, as expected, more 
reactive than the chlorine substituted compound. No activation or addition of base is 
required for the substitution. In the presence of DMAP and NEt3 however, complete 
conversion requires a 5-fold excess of amine. Best yields were obtained by using 
2 equivalents of NEt3 and a 10-fold excess of amine (see Experimental). Table 1 
summarizes the different compounds either derived from 6a (method A) or 6c (method 
B). In general, the more nucleophilic secondary amines give higher yields than primary 
amines. The hydrazine protecting group (PG) does not influence the yield of the 
substitution reaction. 
 
PHA Amine   PG    Method Yield (corrected*) [%] 
8a HNEt2 Boc A 42 
8a HNEt2 Boc B 74 
8b HNEt2 Cbz B 80 
8c H2NBu Boc B 13 (26) 
* Yield of the reaction adjust to conversion in brackets 
Table 1: Synthesized derivatives (8) 
 
To avoid a side reaction by aminolysis of the ester, 4 was converted into the butylamide 
(9) according to a literature procedure12 followed by bromination and subsequent 
substitution in 6- and 2-position with Boc-protected hydrazine and amines. The amidic 
hydrogen atom allows the formation of another intramolecular hydrogen bond to the 
pyrimidine nitrogen. Table 2 summarizes the results of the Br-substitution in 2-position 
of compound (11) with several amines.  
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Scheme 7: Synthesis of compounds (12) 
 
 
Entry Amine Yield (corrected*) [%] 
12a H2NBu 68 
12b HNEt2 82 
12c Morpholine 67 
12d 18-aza-crown-6 56 
12e 2-(2-Methoxy-ethoxy)-ethylamine 33 (68) 
* Reaction yield adjust to conversion given in brackets 
Table 2: Synthesized derivatives (12) 
 
A more extended peptide (15) was prepared to show the complementary structure and 
binding affinity of PHA oligomers to peptide β-sheet structures. Cleaving off the ester 
and the Boc-group of 8a under basic and acidic conditions gives the acid (13) and amine 
(14), respectively. A coupling of (13) and (14) under standard peptide coupling 
conditions yields dipeptide (15) in moderate yield.13
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Scheme 8: Synthesis of dipeptide (15) 
 
All synthesized PHA derivatives appear as mixtures of cis- and trans-isomers of the 
carbamate protecting groups in the 1H NMR spectra. The pyrimidine ring and the 
hydrazine protons do not show tautomerisation. Compounds (8, 12 and 15) emit around 
420 nm when irradiated at 330 nm. The halogenated compounds (5, 6, 10, and 11) have 
no luminescence. The emission intensity of solutions of the compounds decreases from 
less polar (e.g. CHCl3) to polar aprotic solvents (e.g. MeCN). Polar protic solvents, such 
as H2O, quench the emission completely. The intensity of emission changes with 
hydrogen bonds to PHA. Therefore, fluorescence titration is a tool to monitor the 
binding process between PHA and β-sheet peptides in aprotic solvents. 
The mono PHA (8a) provides three binding sites as acceptor-donor-acceptor (ADA) 
motif, while bis PHA (15) can form up to five (ADADA) intermolecular hydrogen 
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bonds with a complementary binding partner. Top and bottom face of an N- and C-
terminal protected tripeptide differ in their hydrogen bond donor and acceptor pattern. 
While the top face can form four hydrogen bonds (DADA), the bottom face has only 
three (ADA). An N- and C-terminally protected tetrapeptide offers five hydrogen 
binding sites (ADADA) at the top face and four (DADA) on the bottom face. 
The binding affinities of the PHA derivatives (8a) and (15) to small peptides of natural 
amino acids were determined by 1H NMR spectra and fluorescence titrations in CDCl3 
and CHCl3. Binding constants were determined by non-linear fitting of chemical 
induced shifts (CIS) of several protons14 in the NMR spectrum and of the decrease of 
emission intensity. Self-associations of the peptides and the PHA (8a K11 = 17 L/mol, 
15 K11 = 28 L/mol) were determined independently and were taken into account. 
Emission intensities corrected for dilution during the titration are used. The 
stoichiometry of the complexes was determined according to Job´s method of 
continuous variations.15 Table 3 summarizes the results of our binding studies. 
 
Entry PHA Peptide Stoichiometry Ka 
[L/mol]a
1 8a Ac-Phe-Val-Leu-OMe 1:1 101 
2 15 Boc-Phe-Ala-Val-Leu-
OMe 
1:1 78 
3 15 Boc-Phe-Gly-Val-Leu-
OMe 
2:1 2742 
15381 
aAll binding constants have errors of approx. ± 10 %. 
Table 3: Ka values determined from NMR and fluorescence titrations in CDCl3 and CHCl3
 
The affinity of 8a to the tripeptide is 101 L/mol. Figure 3 shows the CIS of the acetyl 
singlet during titration. By formation of three cooperative hydrogen bonds with PHA 8a 
the binding of the peptide´s top face should be favoured (see Figure 1). 
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Figure 1: A 1:1 complex between 8a and Ac-Phe-Val-Leu-OMe 
 
The binding affinity determined for (15) to the tetrapeptide Boc-Phe-Ala-Val-Leu-OMe 
is in the same order of magnitude as the binding of (8a) to a tripeptide, although an 
additional hydrogen bond formation should be possible between (15) and the 
tetrapeptide. Figure 2 summarizes the possible 1:1 binding motifs between (15) and 
Boc-Phe-Ala-Val-Leu-OMe. 
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Figure 2: Possible 1:1 complexes between 15 and Boc-Phe-Ala-Val-Leu-OMe 
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For steric reasons, the binding motifs containing Boc protecting group on different ends 
might be favoured. The observed CIS and the calculated binding affinity result from an 
average value of the experiment. The different aggregates are presumably in a fast 
dynamic equilibrium and NMR cannot distinguish between them. All efforts to co-
crystallize (8a) and (15) with a peptide giving a picture of the binding motif failed so 
far. 
Figures 3 and 5 illustrate that a plateau in CIS or a minimum of emission is reached 
after the addition of 1 equivalent of the peptide to a solution of PHA. The 1H NMR 
Job´s plot of 8a and Ac-Phe-Val-Leu-OMe (Figure 4) shows a maximum at x = 0.5, 
confirming a 1:1 binding motif.  
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Figure 3: NMR titration curve (up) and fluorescence titration curve (below) of Ac-Phe-Val-Leu-OMe 
with compound (8a) in CDCl3, c0 = 10 mmol/L, observing CIS of the acetyl hydrogen resonance and the 
emission intensity at 423 nm (excitation at 330 nm) 
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Figure 4: 1H NMR job-plot of 8a and Ac-Phe-Val-Leu-OMe 
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Figure 5: NMR titration curve of Boc-Phe-Ala-Val-Leu-OMe with compound 15 in CDCl3, 
c0 = 6.0 mmol/L, monitoring CIS of the pyrimidine hydrogen resonance. 
 
The titration of (15) with Boc-Phe-Gly-Val-Leu-OMe gives a different picture. A slight 
chance in the peptide sequence from Ala to Gly in position 2 leads to a significant 
increase of the binding affinity and change of the aggregate stoichiometry. The NMR 
spectra titration curve indicates two subsequent binding processes. 
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Figure 6: NMR spectra titration curve (above; CIS of the methyl ester group) and emission Job´s plot 
analysis (below; emission intensity at 423 nm,excitation at 330 nm)) of Ac-Phe-Val-Leu-OMe with 
compound (15) in CDCl3, c0 = 9.5 mmol/L. 
 
The first part of the NMR titration curve is identical in shape to the titrations of (8a) 
with the tripeptide Boc-Phe-Val-Leu-OMe or (15) with the tetrapeptide Boc-Phe-Ala-
Val-Leu-OMe, respectively. Addition of one equivalent 15 to Boc-Phe-Gly-Val-Leu-
OMe saturates the CIS. Addition of a second equivalent of 15 leads to a further CIS of 
the methoxy resonance signal. For the first binding process an affinity constant of 
K11 = 2742 L/mol is derived, while the subsequent binding with K12 of 15381 L/mol 
indicates a highly cooperative assembly process. We cannot provide a structure for the 
complex assembly, but the exchange of alanine for glycine in the tripeptide sequence 
allows almost free rotation around the C-C and the C-N bond in the glycine residue.16  
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To avoid higher aggregates and arrive at a more defined PHA – peptide interaction a 
short β-turn fragment incorporating PHA was prepared. Scheme 9 shows the synthesis. 
Extension of Gellman´s β-turn fragment Gly-D-Pro17 by H-Phe-Leu-Val-OMe required 
1.1 equivalents of EDC and HOBt and 2 equivalents of Huenig´s Base. The product 
precipitates from DMF solution after the addition of water. Lithium salt (14) and the 
deprotected pentapeptide couple to (16) in moderate yields. 
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Scheme 9: Synthesis of the β-turn fragment (16) 
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Figure 7: Emission spectra of (8a) and (16) in a 8 mM solution in acetonitrile 
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 Figure 7 shows the emission intensity of equally concentrated solutions of (8a) and (16) 
(8 mM) in acetonitrile. The significant decreased emission intensity of (16) in 
comparison to (8a) indicates an intramolecular binding process of PHA and peptide. 
NMR spectra in 10 mM deuterated DMSO solution show only one conformer for (16) 
in solution. Analysis of the observed intramolecular NOE contacts in deuterated DMSO 
clearly confirm a β-turn structure as depicted in figure 8.  
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Figure 8: NOE contacts found in the analysis of compound (16) 
 
ROESY experiments revealed numerous short-range and long-range NOEs. The NOE 
contact between the pyrimidine proton and the Val-i-Pr-residue indicates a folded 
conformation. Due to signal overlap and broad NH signals no further NOE contacts of 
PHA and peptide are observable.18
A more extended β-turn fragment was prepared incorporating dipeptide (15). The β-turn 
fragment Gly-D-Pro was extended by H-Phe-Leu-Phe-Ala-NH2 and coupling of the 
deprotected hexapeptide with the lithium carboxylate (17) gave (18) in good yield. 
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Scheme 10: Synthesis of the β-turn fragment (18) 
 
Figure 9 shows the analysis of the intramolecular NOE contacts of compound (18) in 
deuterated DMSO solution. The NOE contacts between the N-terminal PHA unit and 
the C-terminal amino acid residue indicate that the interaction of heterocycles and 
peptide chain propagates the turn. The proton on the hydrazine of the terminal PHA unit 
shows a contact to the methyl group and the Cα proton of alanine to the CH2 group of 
the phenylalanine. In both cases, signal overlap prohibits distinction of the diasterotopic 
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protons of the CH2 group in the phenylalanine and leucine side chain. The NOE contact 
of a PHA proton and the glycine amide proton confirms the turn structure. Overall, 
eight NOE contacts support a solution structure of 18 as shown in Figure 9. 
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Figure 9: NOE contacts found in the analysis of compound (18) 
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1.3 Conclusions 
 
We have reported the synthesis of substituted pyrimidine-hydrazine-acids (PHA) from 
orotic acid. Standard peptide coupling procedures couple or incorporate the heterocyclic 
hydrazine acids into peptides of natural amino acids. Their geometry of hydrogen bond 
acceptor and donor sites make them suitable for complementary interaction with peptide 
β-sheets. An interesting feature is their luminescence in non-polar solvents, which 
changes upon peptide binding. PHA´s are simple dipeptide mimics, with a build in 
luminescence chemosensor monitoring the local polarity of the environment and 
interaction with adjacent peptide chains. 
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1.4 Experimental 
 
General Methods: Melting points were determined on a Tottoli micromelting point 
apparatus and are uncorrected. 1H-NMR spectra were recorded on a Bruker Avance 300 
NMR spectrometer at 300 K. Chemical shifts (δ) are reported in ppm downfield from 
internal TMS. Emission spectra were recorded on a Cary Eclipse spectrophotometer. 
Thin layer chromatographic (TLC) analyses were performed on silica gel 60 F-254 with 
a 0.2 mm layer thickness. Preparative chromatography columns were packed with silica 
gel Geduran SI 60. Mass spectra were recorded on a Finnigan MAT TSQ 7000 (ESI) 
and on a Finnigan MAT 95 (HRMS). 
 
X-Ray Structures: Crystallographic data for the structures (6a) and (6b) have been 
deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication numbers CCDC 267816 & 267817. Copies of the data can be obtained, free 
of charge, on application to CDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: 
+44(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk]. 
 
1H-NMR and Emission Titrations: A solution of the PHA molecule (c = 15 mmol/L) 
was added in portions via a microsyringe to a solution of a peptide (c = 1 mmol/L). 
Volume and concentration changes were taken into account for the analysis of the 
binding event.14  
 
Job´s Plot: Equimolar solutions (0.1 mM) of PHA molecule and peptide were prepared 
and mixed in various amounts. Emission spectra of the mixtures were recorded, and the 
emission intensities were analyzed by Job´s method modified for emission results.15  
 
General procedure for the substitution of a halogen atom by a protected hydrazine 
(GP1): To a solution of the halogenated pyrimidine (1 mmol) in DMF (1 mL/mmol) 
was added triethylamine (1.1 mmol), followed by a solution of the protected hydrazine 
(1.1 mmol) in DMF (2 mL/mmol). The solution was stirred at 60 °C until complete 
conversion of the pyrimidine (12-24 h). The reaction mixture was allowed to cool to rt, 
diluted with water, and extracted with ethyl acetate. The organic phases were dried over 
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Na2SO4, evaporated, and then concentrated under reduced pressure. If necessary, the 
residue was purified by column chromatography (mixtures of hexanes and ethyl acetate) 
to afford the products. 
 
General procedure for the substitution of a halogen atom by an amine (GP2): To a 
solution of the brominated pyrimidine (1 mmol) in DMF (2 mL/mmol) was added the 
amine (10 mmol). The solution was stirred at 60 °C until complete conversion of the 
pyrimidine was observed (18-36 h). The reaction mixture was allowed to cool to rt, 
diluted with ethyl acetate, and washed with brine. The organic phases were dried over 
Na2SO4, evaporated, concentrated under reduced pressure and purified by column 
chromatography (mixtures of hexanes and ethyl acetate) to afford the products. 
 
General procedure for the peptide synthesis (GP3): A solution of Boc-AA-OH 
(1.0 mmol), H-AA-R·X (R = OMe, NH2, X = TFA, HCl) (1.0 mmol), EDC (1.1 mmol), 
HOBt (1.1 mmol) and Huenig´s base (2.5 mmol) in DMF (1 mL/mmol) was stirred at rt 
until complete conversion was observed (10-24 h). The reaction mixture was allowed to 
cool to 0 °C and treated with water. The precipitate was filtered off and washed with 
water affording the desired peptide. The crude product was used without further 
purification. 
 
General procedure for cleavage of the Boc-protecting group by Et2O·HCl (GP4): 
The Boc-protected amino acid (1 mmol) was dissolved in Et2O·HCl (2 mL/mmol) at 
0 °C. The reaction mixture was allowed to warm to rt and stirred for 30 min. The 
precipitate was filtered off and washed with Et2O affording the deprotected amino acid. 
The crude product was used without further purification. 
 
General procedure for cleavage of the Boc-protecting group by TFA (GP5): The 
Boc-protected amino acid (1 mmol) was dissolved in a 20 % solution of TFA in CH2Cl2 
(2 mL/mmol). The reaction mixture was stirred at rt for 2 h. The solvent was removed 
under reduced pressure. The crude product was used without further purification. 
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X-Ray appendix: 
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Crystal data and structure refinement for compound 6a: 
 
Identification code    B132 
Empirical formula    C11H15ClN4O4  
Formula weight    302.72 
Temperature     173(1) K 
Wavelength     0.71073 
Crystal system, space group   Monoclinic, P2(1)c 
Unit cell dimensions    a = 10.5874(8) Å α = 90° 
      b = 25.3603(19) Å β = 94.871(9)° 
      c = 10.9279(8) Å γ = 90° 
Volume     2923.5(4) Å3  
Z, calculated density    8, 1.376 Mg/m3
Absorption coefficient   0.280 mm-1  
F(000)      1264 
Crystal size     0.24·0.20·0.03 mm 
θ-range for data collection   2.04 to 25.20° 
Index ranges     -12<=h<=12, -30<=k<=30, -13<=l<=13 
Reflection collected/unique   20704 / 4750 [Rint = 0.0822] 
Refinement method    Full-matrix least-squares on F2  
Data/restraints/parameters   4750 / 0 / 373 
Goodness-of-fit on F2    0.764 
Final R indices [I>2σ(I)]   R1 = 0.0398, wR2 = 0.0694 
R indices (all data)    R1 = 0.1054, wR2 = 0.0809 
Largest diff. peak and hole   0.181 and -0.149 e. Å-3  
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Crystal data and structure refinement for compound 6a: 
 
Identification code    C123 
Empirical formula    C14H13ClN4O4  
Formula weight    336.73 
Temperature     173(1) K 
Wavelength     0.71073 
Crystal system, space group   Trclinic, P -1 
Unit cell dimensions    a = 7.5068(6) Å α = 86.402(11)° 
      b = 8.0366(7) Å β = 89.652(10)° 
      c = 13.7126(12) Å γ = 68.834(10)° 
Volume     769.82(13) Å3  
Z, calculated density    2, 1.453 Mg/m3
Absorption coefficient   0.274 mm-1  
F(000)      348 
Crystal size     0.28·0.20·0.06 mm 
θ-range for data collection   2.72 to 25.81° 
Index ranges     -9<=h<=9, -9<=k<=9, -16<=l<=16 
Reflection collected/unique   10185 / 2758 [Rint = 0.0500] 
Refinement method    Full-matrix least-squares on F2  
Data/restraints/parameters   2758 / 0 / 239 
Goodness-of-fit on F2    1.055 
Final R indices [I>2σ(I)]   R1 = 0.0535, wR2 = 0.1261 
R indices (all data)    R1 = 0.0696, wR2 = 0.1311 
Largest diff. peak and hole   0.375 and -0.190 e. Å-3  
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Synthesis of the peptides: 
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Boc-Phe-Val-Leu-OMe: H-Val-Leu-OMe·TFA (200 mg, 0.56 mmol) was allowed to 
react with Boc-Phe-OH (70 mg, 0.56 mmol), EDC (109 µL, 96 mg, 0.62 mmol), HOBt 
(83 mg, 0.62 mmol) and Huenig´s Base (240 µL, 181 mg, 1.40 mmol) following GP3 to 
yield Boc-Phe-Val-Leu-OMe (258 mg, 0.53 mmol, 94 %) as a colorless powder. 
mp.: 151 °C, 1H-NMR (CDCl3, 600 MHz): δ = 0.87-0.94 ppm (m, 12 H; HSQC: CH3 
Leu, CH3 Val), 1.40 (s, 9 H; HSQC: Boc-CH3), 1.54-1.59 (m, 1 H; HMBC: CHs Leu), 
1.61-1.69 (m, 2 H; HMBC: CH2 Leu), 2.10-2.19 (m, 1 H; COSY: CHs Val), 3.05 (dd, 
3J = 7.2 Hz, 3J = 13.7 Hz, 1 H; HMBC: CH2 Phe), 3.11 (dd, 3J = 6.2 Hz, 3J = 14.0 Hz, 
1 H; HMBC: CH2 Phe), 3.72 (s, 3 H; HSQC: OCH3), 4.27 (t, 3J = 7.2 Hz, 1 H; COSY: 
CH Val), 4.39 (bs, 1 H; COSY: CH Phe), 4.55-4.59 (m, 1 H; HMBC: CH Leu), 5.05 
(bs, 1 H; COSY: NH Phe), 6.48 (bs, 1 H; COSY: NH Leu), 6.63 (d, 3J = 8.6 Hz, 1 H; 
COSY: NH Val), 7.19-7.29 (m, 5 H; HSQC: Ar-H). 13C-NMR (CDCl3, 150 MHz): 
δ = 17.8 ppm (+; HSQC: CH3 Leu, CH3 Val), 19.0 (+; HSQC: CH3 Leu, CH3 Val), 21.8 
(+; HSQC: CH3 Leu, CH3 Val), 22.8 (+; HSQC: CH3 Leu, CH3 Val), 24.8 (+; HSQC: 
CHs Leu), 28.2 (+; HSQC: Boc-CH3), 30.8 (+; HSQC: CHs Val), 37.8 (-; HMBC: CH2 
Phe), 41.2 (-; HSQC. CH2 Leu), 50.8 (+; HSQC: CH Leu), 52.2 (+; HSQC: OCH3), 55.9 
(+; HSQC: CH Phe), 58.5 (+; HSQC: CH Val), 80.3 (Cquat; HMBC: Boc), 127.0 (+; 
HSQC: Ar-H), 128.7 (+; HSQC: Ar-H), 129.3 (+; HSQC: Ar-H), 136.5 (Cquat; HMBC: 
Ar), 155.5 (Cquat; HMBC: C=O Boc), 170.5 (Cquat; HMBC: C=O Val), 171.4 (Cquat; 
HMBC: C=O Phe), 173.0 (Cquat; HMBC: C=O Leu). MS (ESI, MeOH): m/z 
(%) = 1005.7 [2M+Na+] (8), 1000.7 [2M+NH4+] (4), 983.7 [2M+H+] (2), 509.3 
[M+NH4+] (30), 492.3 [MH+] (100), 436.1 [MH+-C4H8] (18). 
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H-Phe-Val-Leu-OMe·HCl: Boc-Phe-Val-Leu-OMe (80 mg, 0.16 mmol) was allowed 
to react with Et2O·HCl following GP4 to afford H-Phe-Val-Leu-OMe·HCl (68 mg, 
0.16 mmol, 98 %) as a colorless powder. 
mp.: 188 °C. IR (KBr disk): 3319cm-1, 3031, 2959, 1743, 1646, 1545, 1458, 1374, 
1212, 1159, 1077. 1H-NMR (DMSO-[D6], 300 MHz): δ = 0.85-0.93 ppm (m, 12 H, 
CH3 Leu, CH3 Val), 1.45-1.68 (m, 3 H, CH2 Leu, CHs Leu), 1.91-2.03 (m, 1 H, CHs 
Val), .2.95 (dd, 3J = 7.0 Hz, 3J = 14.0 Hz, 1 H, CH2 Phe), 3.10 (dd, 3J = 5.5 Hz, 
3J = 14.0 Hz, 1 H, CH2 Phe), 3.60 (s, 3 H, OCH3), 4.21-4.32 (m, 3 H, CH Phe, CH Val, 
CH Leu), 7.22-7.31 (m, 5 H, Ar-H), 8.22 (bs, 2 H, NH), 8.49 (d, 3J = 7.4 Hz, 1 H, NH), 
8.68 (d, 8.9 Hz, 1 H, NH). 13C-NMR (DMSO-[D6], 75 MHz): δ = 18.3 ppm (+, CH3 
Val), 18.9 (+, CH3 Val), 21.1 (+, CH3 Leu), 22.7 (+, CH3 Leu), 24.1 (+, CHs Leu), 30.0 
(+, CHs Val), 30.6 (-, CH2 Phe), 39.3 (-, CH2 Leu), 50.1 (+, CH Phe), 51.7 (+, CH Leu), 
52.8 (+, OCH3), 57.6 (+, CH Val), 126.9 (+, Ar-H), 128.2 (+, Ar-H), 129.5 (+, Ar-H), 
134.7 (Cquat, Ar), 167.6 (Cquat), 170.5 (Cquat), 172.6 (Cquat). MS (ESI, MeOH + 
10 mmol/l NH4Ac): m/z (%) = 783.6 [2M+H+] (14), 392.1 [MH+] (100). 
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Boc-D-Pro-Gly-Phe-Val-Leu-OMe: H-Phe-Val-Leu-OMe·HCl (471 mg, 1.10 mmol) 
was allowed to react with Boc-D-Pro-Gly-OH (299 mg, 1.10 mmol), EDC (214 µL, 
188 mg, 1.21 mmol), HOBt (164 mg, 1.21 mmol) and Huenig´s Base (471 µL, 355 mg, 
2.75 mmol) following GP3 to yield Boc-D-Pro-Gly-Phe-Val-Leu-OMe (612 mg, 
0.95 mmol, 86 %) as a colorless powder. 
mp.: > 210 °C (decomp). IR (KBr disk): 3292cm-1, 3069, 2963, 1743, 1641, 1532, 1394, 
1207, 1162, 744, 691. 1H-NMR (CDCl3, 600 MHz): δ = 0.88-0.96 ppm (m, 12 H: 
HSQC: CH3 Leu, CH3 Val), 1.45-1.48 (m, 9 H; HSQC: Boc-CH3), 1.52-1.63 (m, 3 H; 
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COSY: CHs Leu, CH2 Leu), 1.67-1.70 (m, 1 H; COSY: CHs Val), 1.96-1.99 (m, 2 H; 
COSY: CH2 Pro), 2.12-2.15 (m, 2 H; COSY: CH2 Pro), 2.96-3.01 (m, 2 H; HSQC: CH2 
Phe), 3.98-4.03 (m, 2 H; HSQC: CH2 Gly), 3.36-3.42 (m, 2 H; COSY: CδH2 Pro), 3.70 
(s, 3 H; HSQC: OCH3), 4.21-4.27 (m, 1 H; COSY: CH Pro), 4.55-4.58 (m, 1 H; COSY: 
CH Leu), 4.62-4.67 (m, 1 H; COSY: CH Val), 5.04-5.06 (m, 1 H; COSY: CH Phe), 
7.09-7.27 (m, 5 H; HSQC: Ar-H), 7.35-7.40 (m, 1 H, NH), 7.55-7.60 (m, 1 H, NH), 
7.75 (bs, 1 H, NH), 8.08 (bs, 1 H, NH). 13C-NMR (CDCl3, 150 MHz): δ = 18.1 ppm (+; 
HSQC: CH3 Val), 18.6 (+; HSQC: CH3 Val), 21.9 (+; HSQC: CH3 Leu), 22.8 (+; 
HSQC: CH3 Leu), 23.8 (+; HSQC: CHs Leu), 28.5 (+; HSQC: Boc-CH3), 29.7 (+; 
HSQC: CHs Val), 31.1 (-; HSQC: CH2 Pro), 32.1 (-; HSQC: CH2 Pro), 39.8 (-; HSQC: 
CH2 Phe), 40.5 (-; HSQC: CH2 Leu), 43.2 (-; HSQC: CH2 Gly), 47.3 (-; HSQC: CδH2 
Pro), 50.7 (+; HSQC: CH Leu), 52.1 (+; HSQC: OCH3), 55.2 (+; HSQC: CH Phe), 58.3 
(+; HSQC: CH Val), 60.3 (+; HSQC: CH Pro), 80.1 (Cquat, Boc), 126.8 (+; HSQC: Ar-
H), 128.4 (+; HSQC: Ar-H), 129.3 (+; HSQC: Ar-H), 137.0 (Cquat, Ar), 155.3 (Cquat, 
C=O Boc), 162.5 (Cquat), 169.0 (Cquat), 170.5 (Cquat), 170.8 (Cquat), 173.1 (Cquat). UV 
(CH3OH): λmax (lg ε) = 258 nm (3.503), 281 (3.397), 310 (3.501). MS (ESI, MeOH + 
10 mmol/l NH4Ac): m/z (%) = 1313.9 [2M+Na+] (3), 668.4 [M+Na+] (42), 663.5 
[M+NH4+] (63), 646.5 [MH+] (100). Anal. Calcd. for C33H51N5O8: C: 61.4; H: 8.0; N: 
10.8; O: 19.8; Found: C: 61.5; H: 7.5; N: 11.2. 
 
N
H
N
H
N
H
O
O
O
OMe
Ph
O
N
H
O
N
HHCl.
 
H-D-Pro-Gly-Phe-Val-Leu-OMe·HCl: Boc-D-Pro-Gly-Phe-Val-Leu-OMe (250 mg, 
0.39 mmol) was allowed to react with Et2O·HCl following GP4 to afford H-D-Pro-Gly-
Phe-Val-Leu-OMe·HCl (225 mg, 0.39 mmol, 99 %) as a colorless powder. 
mp.: > 210 °C (decomp). IR (KBr disk): 3332cm-1, 3281, 3054, 2955, 1744, 1640, 1531, 
1439, 1374, 1238. 1H-NMR (DMSO-[D6], 300 MHz): δ = 0.83-0.91 ppm (m, 12 H, 
CH3 Leu, CH3 Val), 1.41-1.64 (m, 3 H, CHs Leu, CH2 Leu), 1.72-1.88 (m, 3 H, CHs 
Val, CH2 Pro), 1.92-2.03 (m, 1 H, CH2 Pro), 2.19-2.28 (m, 1 H, CH2 Pro), 2.70-2.79 (m, 
1 H, CH2 Phe), 2.89-3.04 (m, 1 H, CH2 Phe), 3.59 (s, 3 H, OCH3), 3.65 (dd, 3J = 5.6 Hz, 
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3J = 16.9 Hz, 1 H, CH2 Gly), 3.83 (dd, 3J = 5.9 Hz, 3J = 16.9 Hz, 1 H, CH2 Gly), 4.15-
4.31 (m, 3 H), 4.57-4.67 (m, 3 H), 7.13-7.24 (m, 5 H, Ar-H), 8.16 (d, 3J = 8.8 Hz, 1 H, 
NH), 8.23 (d, 3J = 8.2 Hz, 1 H, NH), 8.41 (d, 3J = 7.1 Hz, 1 H, NH), 8.46-8.54 (m, 1 H, 
NH) 8.77 (d, 3J = 5.6 Hz, 1 H, NH Gly), 10.01-10.10 (m, 1 H, NH). 13C-NMR (DMSO-
[D6], 75 MHz): δ = 18.2 ppm (+, CH3 Val), 19.0 (+, CH3 Val), 21.1 (+, CH3 Leu), 22.7 
(+, CH3 Leu), 23.4 (-, CH2 Leu), 24.1 (+, CHs Leu) 29.5 (-, CH2 Pro), 30.6 (+, CHs Val), 
37.4 (-, CH2 Pro), 39.4 (-, CH2 Phe), 39.9 (-, CδH2 Pro), 45.4 (-, CH2 Gly), 50.1 (+, CH 
Leu), 51.6 (+, OCH3), 53.6 (+, CH Phe), 57.4 (+, CH Val), 58.5 (+, CH Pro), 126.1 (+, 
Ar-H), 127.8 (+, Ar-H), 129.2 (+, Ar-H), 137.6 (Cquat, Ar), 167.7 (Cquat), 168.3 (Cquat), 
170.6 (Cquat), 171.0 (Cquat), 172.6 (Cquat). UV (CH3OH): λmax (lg ε) = 259 nm (3.733), 
286 (3.453). MS (ESI, H2O/MeOH/AcN): m/z (%) = 1091.8 [2M+H+] (22), 546.3 
[MH+] (100). 
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Boc-Phe-Leu-Phe-Ala-NH2: H-Phe-Ala-NH2·HCl (176 mg, 0.50 mmol) was allowed 
to react with Boc-Phe-Leu-OH (189 mg, 0.50 mmol), EDC (97 µL, 85 mg, 0.55 mmol), 
HOBt (74 mg, 0.55 mmol) and Huenig´s Base (214 µL, 162 mg, 1.25 mmol) following 
GP3 to yield Boc-Phe-Leu-Phe-Ala-NH2 (239 mg 0.40 mmol, 82 %) as a colorless 
powder. 
mp.: 223 °C. IR (KBr disk): 3292 cm-1, 3064, 2962, 2373, 2168, 1644, 1525, 1455, 
1367, 1251, 1169, 1026, 856, 741. 1H-NMR (DMSO-[D6], 400 MHz): δ = 0.82 ppm (d, 
3J = 6.5 Hz, 3 H; HSQC: CH3 Leu), 0.86 (d, 3J = 6.6 Hz, 3 H; HSQC: CH3 Leu), 1.20 
(d, 3J = 7.1 Hz, 3 H; HSQC: CH3 Ala), 1.29 (s, 9 H; HSQC: Boc-CH3), 1.38-1.45 (m, 
2 H; COSY:, CH2 Leu), 1.53-1.61 (m, 1 H: COSY: CHs Leu), 2.67-2.73 (m, 1 H; 
HMBC: CH2 Phe), 2.80-2.92 (m, 2 H: HMBC: CH2 Phe), 3.05 (dd, 3J = 4.8 Hz, 
3J = 14.0 Hz, 1 H: HMBC: CH2 Phe), 4.12-4.23 (m, 2 H: COSY: CH Ala, CH Phe), 4.30 
(q, 3J = 7.6 Hz, 1 H; COSY: CH Leu), 4.50-4.55 (m, 1 H; HMBC: CH Phe), 6.91 (d, 
3J = 8.7 Hz, 1 H; COSY: NH Ala), 7.00 (bs, 1 H; HSQC: NH2), 7.15-7.20 (m, 1 H; 
HSQC: NH2), 7.23-7.27 (m, 10 H; HSQC: Ar-H), 7.89 (d, 3J = 8.3 Hz, 1 H; COSY: NH 
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Phe), 7.94 (d, 3J = 7.5 Hz, 1 H; COSY: NH Leu), 8.00 (d, 3J = 8.0 Hz, 1 H; COSY: NH 
Phe). 13C-NMR (DMSO-[D6], 100 MHz): δ = 18.3 ppm (+; HSQC: CH3 Ala), 21.6 (+; 
HSQC: CH3 Leu), 23.0 (+; HSQC: CH3 Leu), 23.8 (+, HSQC: CHs Leu), 28.0 (+; 
HSQC: Boc-CH3), 37.1 (-; HSQC: 2 CH2 Phe), 41.0 (-; HMBC: CH2 Leu), 47.9 (+; 
HMBC: CH Ala), 50.9 (+; HSQC: CH Leu), 53.5 (+; HSQC: CH Phe), 55.5 (+; HSQC: 
CH Phe), 77.9 (Cquat; HMBC: Boc), 126.1 (+; HSQC: Ar-H), 126.2 (+; HSQC: Ar-H), 
127.8 (+; HSQC: Ar-H), 127.9 (+; HSQC: Ar-H), 129.1 (+; HSQC: Ar-H), 137.5 (Cquart; 
HMBC: Ar), 138.2 (Cquat; HMBC: Ar), 155.1 (Cquat; HMBC: C=O Boc), 170.2 (Cquat; 
HMBC: C=O Leu), 171.4 (Cquat; HMBC: C=O Phe), 171.7 (Cquat; HMBC: C=O Phe), 
173.8 (Cquat; HMBC: C=O Ala). UV (CH3OH): λmax (lg ε) = 253 nm (3.825), 258 
(3.862), 264 (3.768). MS (ESI, DCM/MeOH + 10 % NH4Ac): m/z (%) = 613.4 
[M+NH4+] (47), 596.3 [MH+] (100). 
 
NH2
N
H
N
H
O
O
O
N
H
O
NH2
Ph Ph
TFA.
 
H-Phe-Leu-Phe-Ala-NH2·TFA: Boc-Phe-Leu-Phe-Ala-NH2 (250 mg, 0.39 mmol) was 
allowed to react with 20 % TFA in CH2Cl2 following GP5 to afford H-Phe-Leu-Phe-
Ala-NH2·TFA (203 mg, 0.33 mmol, 99 %) as a colorless powder. 
mp.: 225 °C. IR (KBr disk): 3269cm-1, 3082, 2955, 1636, 1544, 1456, 1180, 1032, 800. 
1H-NMR (DMSO-[D6], 300 MHz): δ = 0.82-0.91 ppm (m, 6 H, CH3 Leu), 1.20 (d, 
3J = 7.0 Hz, 3 H, CH3 Ala), 1.34-1.47 (m, 2 H, CH2 Leu), 1.51-1.65 (m, 1 H, CHs Leu), 
2.75-2.88 (m, 2 H, CH2 Phe), 2.92-3.11 (m, 2 H, CH2 Phe), 3.96-4.07 (m, 1 H CH Phe), 
4.12-4.23 (m, 1 H, CH Ala), 4.32-4.42 (m, 1 H, CH Leu), 4.50-4.60 (m, 1 H, CH Phe), 
7.04 (bs, 1 H, NH), 7.11-7.36 (m, 10 H, Ar-H), 7.98-8.21 (m, 4 H, NH), 8.26 (d, 
3J = 8.0 Hz, 1 H, NH), 8.60 (d, 3J = 8.3 Hz, 1 H, NH). 13C-NMR (DMSO-[D6], 
75 MHz): δ = 18.3 ppm (+, CH3 Ala), 21.6 (+, CH3 Leu), 22.9 (+, CH3 Leu), 23.9 (+, 
CHs Leu), 36.9 (-, CH2 Phe), 37.0 (-, CH2 Phe), 41.1 (-, CH2 Leu), 47.9 (+, Ala), 50.9 
(+, CH Leu), 53.0 (+, CH Phe), 53.6 (+, CH Phe), 126.1 (+, Ar-H), 127.0 (+, Ar-H), 
127.9 (+, Ar-H), 128.4 (+, Ar-H), 129.0 (+, Ar-H), 129.4 (+, Ar-H), 134.7 (Cquat, Ar), 
137.7 (Cquat, Ar), 167.5 (Cquat), 170.2 (Cquat), 171.2 (Cquat), 173.8 (Cquat). UV (CH3OH): 
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λmax (lg ε) = 252 nm (3.698), 258 (3.738), 264 (3.649). MS (ESI, H2O/AcN): m/z 
(%) = 596.3 [MH+] (100). 
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Boc-D-Pro-Gly-Phe-Leu-Phe-Ala-NH2: H-Phe-Leu-Phe-Ala-NH2·HCl (179 mg, 
0.29 mmol) was allowed to react with Boc-D-Pro-Gly-OH (215 mg, 0.29 mmol), EDC 
(56 µL, 50 mg, 0.32 mmol), HOBt (43 mg, 0.32 mmol) and Huenig´s Base (124 µL, 
94 mg, 0.73 mmol) following GP3 to yield Boc-D-Pro-Gly-Phe-Leu-Phe-Ala-NH2 
(138 mg 0.18 mmol, 61 %) as a colorless powder. 
mp.: 228 °C. IR (KBr disk): 3269cm-1, 3084, 2953, 1635, 1544, 1459, 1184, 1030. 1H-
NMR (DMSO-[D6], 300 MHz): δ = 0.80 ppm (d, 3J = 6.2 Hz, 3 H; HSQC: CH3 Leu), 
0.85 (d, 3J = 6.4 Hz, 3 H; HSQC: CH3 Leu), 1.20 (d, 3J = 7.0 Hz, 3 H; HSQC: CH3 Ala), 
1.24-1.44 (m, 11 H; HSQC: Boc-CH3; COSY: CH2 Leu), 1.45-1.59 (m, 1 H, COSY: 
CHs Leu), 1.61-2.13 (m, 4 H; COSY: CH2 Pro), 2.63-3.13 (m, 4 H; HMBC: CH2 Phe), 
3.16-3.29 (m, 2 H; HSQC: CH2 Pro), 3.42-3.61 (m, 1 H; HMBC. CH Phe), 3.64-3.86 
(m, 1 H; HMBC: CH Phe), 4.00-4.29 (m, 3 H; HMBC: CH Pro, CH Ala, CH Leu), 
4.39-4.62 (m, 2 H; HMBC: CH2 Gly), 7.03 (s, 1 H, NH), 7.08-7.30 (m, 11 H; HMBC: 
Ar-H; NH), 7.76-8.04 (m, 3 H, NH), 8.16 (d, 3J = 8.2 Hz, 1 H, NH), 8.33-8.40 (m, 1 H, 
NH). 13C-NMR (DMSO-[D6], 100 MHz): δ = 18.2 ppm (+; HSQC: CH3 Ala), 21.6 (+; 
HSQC: CH3 Leu), 22.8 (+; HSQC. CH3 Leu), 23.4 (-; HSQC. CH2 Pro), 24.0 (+; 
HSQC: CHs Leu), 27.9 (+; HSQC: Boc-CH3), 36.8 (-; HSQC. CH2 Phe), 37.0 (-; HSQC: 
CH2 Phe), 40.5 (-; HSQC: CH2 Leu), 42.2 (-; HSQC: CH2 Gly), 46.5 (-; HSQC: CH2 
Pro), 47.9 (+; HSQC: CH Ala), 51.2 (+; HMBC: CH Leu), 53.4 (+; HMBC: CH Phe), 
53.6 (+; HMBC: CH Phe), 59.4 (+; HMBC: CH Pro), 78.6 (Cquat; HMBC: Boc), 126.1 
(+; HSQC: Ar-H), 127.9 (+; HSQC: Ar-H), 128.0 (+; HSQC: Ar-H), 128.9 (+; HSQC: 
Ar-H), 129.1 (+; HSQC: Ar-H), 137.6 (Cquat; HMBC: Ar), 137.8 (Cquat; HMBC: Ar), 
153.5 (Cquat; HMBC: C=O Boc), 168.5 (Cquat; HMBC: C=O Phe), 170.1 (Cquat; HMBC: 
C=O Gly), 170.7 (Cquat; HMBC: C=O Pro), 171.6 (Cquat; HMBC: C=O Leu), 172.8 
(Cquat; HMBC: C=O Phe), 173.8 (Cquat; HMBC: C=O Ala). UV (CH3OH): 
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λmax (lg ε) = 257 nm (3.488), 281 (3.367), 310 (3.492). MS (ESI, MeOH + 10 mmol/l 
NH4Ac): m/z (%) = 772.4 [M+Na+] (37), 750.4 [MH+] (100). 
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D-Pro-Gly-Phe-Leu-Phe-Ala-NH2.TFA: Boc-D-Pro-GlyPhe-Leu-Phe-Ala-NH2 
(100 mg, 0.0.13 mmol) was allowed to react with 20 % TFA in CH2Cl2 following GP5 
to afford H—D-Pro-Gly-Phe-Leu-Phe-Ala-NH2·TFA (98 mg, 0.13 mmol, 99 %) as a 
colorless powder. 
mp.: 224 °C. IR (KBr disk): 3753cm-1, 3423, 3067, 2955, 2376, 2249, 1656, 1528, 
1447, 1178, 801. 1H-NMR (DMSO-[D6], 300 MHz): δ = 0.76 ppm (d, 3J = 6.3 Hz, CH3 
Leu), 0.81 (d, 3J = 6.4 Hz, CH3 Leu), 1.15 (d, 3J = 7.0 Hz, CH3 Ala), 1.29-1.39 (m, 2 H, 
CH2 Leu), 1.40-1.54 (m, 1 H, CHs Leu), 1.66-1.88 (m, 3 H, CH2 Pro), 2.13-2.26 (m, 
1 H, CH2 Pro), 2.63 (dd, 3J = 10.0 Hz, 3J = 13.8 Hz, 1 H, CH2 Phe), 2.76 (dd, 
3J = 9.1 Hz, 3J = 13.9 Hz, 1 H, CH2 Phe), 2.86-2.95 (m, 1 H, CH2 Phe), 2.96-3.05 (m, 
2 H, CH2 Phe), 3.07-3.21 (m, 2 H, CH2 Pro), 3.58 (dd, 3J = 5.3 Hz, 3J = 16.8 Hz, CH2 
Gly), 3.79 (dd, 3J = 5.8 Hz, 3J = 16.8 Hz, CH2 Gly), 4.06-4.28 (m, 3 H, CH Ala, CH 
Leu, CH Pro), 4.42-4.55 (m, 2 H, CH Phe), 6.99 (bs, 1 H, NH), 7.17-7.28 (m, 11 H, Ar-
H, NH), 7.90-8.01 (m, 2 H, NH), 8.14 (d, 3J = 8.2 Hz, 1 H, NH), 8.47 (bs, 1 H, NH), 
8.58-8.67 (m, 1 H, NH), 9.31 (bs, 1 H, NH). 13C-NMR (DMSO-[D6], 75 MHz): 
δ = 18.3 ppm (+, CH3), 21.6 (+, CH3), 22.9 (+; CH3), 23.4 (-), 24.0 (+, CH), 29.4 (-), 
37.1 (-), 37.5 (-), 40.7 (-), 41.6 (-), 45.6 (-), 47.9 (+, CH), 51.0 (+, CH), 53.3 (+), 53.4 
(+), 58.7 (+, CH), 126.1 (+, Ar-H), 127.9 (+, Ar-H), 129.1 (+, Ar-H), 137.5 (Cquat, Ar), 
137.6 (Cquat, Ar), 167.6 (Cquat), 168.2 (Cquat), 170.2 (Cquat), 170.6 (Cquat), 171.6 (Cquat), 
173.8 (Cquat). UV (CH3OH): λmax (lg ε) = 253 nm (3.858), 258 (3.878), 264 (3.828). MS 
(ESI, H2O/AcN): m/z (%) = 672.5 [M+Na+] (54), 650.5 [MH+] (100). 
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Synthesis of new compounds: 
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2,6-Dibromopyrimidine-4-carboxylic acid methyl ester (5b): Orotic acid methyl 
ester (4) (0.4 g, 2.35 mmol) was dissolved in acetonitrile (5 mL) and POBr3 (3.37 g, 
11.8 mmol) was added. The reaction mixture was stirred for 3 h under reflux. The 
resulting yellow solution was allowed to cool to rt, poured into 20 ml of crushed ice 
water, and extracted with ethyl acetate. The combined extracts were dried over Mg2SO4, 
and evaporated off. The residue was recrystallized from ethyl acetate/hexanes (3:1) to 
give 5b as brown crystalline needles (541 mg, 78 %). 
mp: > 185 °C (decomp). IR (KBr disk): 3116 cm-1, 3069, 1729, 1549, 1517, 1439, 1314, 
1233, 1103, 957, 784, 730. 1H-NMR (DMSO-d6): δ = 3.94 ppm (s, 3 H, OCH3), 8.33 (s, 
1 H, PHA-H). 13C-NMR (DMSO-d6): δ = 53.4 ppm (+; HMBC: OCH3), 124.8 (+; 
HMBC: PHA-H), 150.8 (Cquat), 155.0 (Cquat), 157.0 (Cquat), 161.8 (Cquat; HMBC: -CO-
OCH3). UV (MeCN): λmax (log ε) = 283 nm (4.664). MS m/z (%): 313.9 [M+NH4+] 
(100), 296.9 [MH+] (15). 
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Methyl 6-(N'-tert-butoxycarbonylhydrazino)-2-chloro-pyrimidine-4-carboxylate 
(6a): Compound (5a) (1.32 g, 6.38 mmol) was allowed to react with triethylamine 
(1.06 mL, 0.78 g, 7.73 mmol) and Boc-hydrazine (1.02 g, 7.73 mmol) following GP1 
(hexanes/ethyl acetate 2:1, Rf = 0.30) to yield 6a (1.17 g, 60 %) as a colorless powder. 
mp: 151-152 °C. IR (KBr disk): 3264 cm-1, 3230, 3109, 2982, 1735, 1609, 1446, 1263, 
1159, 993, 754. 1H-NMR (CDCl3): δ = 1.39-1.41 ppm (m, 9 H, Boc-CH3), 3.85 (s, 3 H, 
O-CH3), 6.61 (s, 1 H, NH), 7.33 (s, 1 H, PHA-H), 7.77 (br, 1 H, NH). 13C-NMR 
(CDCl3): δ = 28.1 ppm (+; HMQC: Boc-CH3), 53.4 (+; HMQC: OCH3), 82.8 (Cquat; 
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HMBC: Boc), 102.1 (+; HMQC: PHA-H); 155.1 (Cquat), 156.6 (Cquat), 160.5 (Cquat), 
163.8 (Cquat; HMBC: C=O ester), 168.0 (Cquat). UV/VIS (MeCN): λmax (log ε) = 244 nm 
(4.860), 301 (4.517). MS m/z (%): 622.1 [2M+NH4+] (1), 605.2 [2M+H+] (2), 303.2 
[MH+] (100), 247.1 [MH+-C4H8] (8), 203.1 [MH+-Boc] (2). Anal. Calcd for 
C11H15N4O4Cl: C: 43.6; H: 5.0; N: 18.5; Found: C: 43.9; H: 5.0; N: 17.9. 
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Methyl 6-(N'-benzyloxycarbonylhydrazino)-2-chloro-pyrimidine-4-carboxylate 
(6b): Compound (5a) (228 mg, 1.10 mmol) was allowed to react with triethylamine 
(128 µL, 122 mg, 1.21 mmol) and Cbz-hydrazine (201 mg, 1.21 mmol) following GP1 
(hexanes/ethyl acetate 3:2, Rf = 0.25) to yield 6a (280 mg, 75 %) as a colorless powder. 
mp: 94-96 °C. IR (KBr disk): 3264 cm-1, 3116, 2956, 1729, 1597, 1561, 1443, 1267, 
1203, 978, 754. 1H-NMR (CDCl3): δ = 3.98 ppm (s, 3 H, O-CH3), 5.21 (s, 2 H, CH2-
Ar), 6.78 (br s, 1 H, N-H), 7.31-7.60 (m, 7 H, 5 Ar-H + PHA-H + N-H). 13C-NMR 
(CDCl3): δ = 53.3 ppm(+; HMQC: OCH3), 68.4 (-; HMQC: CH2 Bzl), 102.2 (+; 
HMQC: PHA-H), 128.3 (+; HMQC: Ar-H), 128.7 (+; HMQC: Ar-H), 135.0 (Cquat, Ar), 
156.1 (Cquat), 156.7 (Cquat), 160.6 (Cquat), 163.6 (Cquat; HMBC: C=O ester), 168.2 (Cquat). 
UV/VIS (MeCN): λmax (log ε) = 234 nm (4.689), 300 (4.360). MS m/z (%): 337.1 
[MH+] (100), 228.9 [MH+-PhCH2OH] (7), 202.9 [MH+-Cbz] (22), 188.1 [MH+-Cbz-
NH] (29). Anal. Calcd for C14H13N4O4Cl: C: 49.9; H: 3.9; N: 16.6; Found: C: 49.8; H: 
4.2; N: 16.5. 
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Methyl 2-bromo-6-(N'-tert-butoxycarbonylhydrazino)pyrimidine-4-carboxylate 
(6c): Compound (5b) (164 mg, 0.55 mmol) was allowed to react with triethylamine 
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(91 µL, 87 mg, 0.66 mmol) and Boc-hydrazine (87 mg, 0.66 mmol) following GP1 
(hexanes/ethyl acetate 1:1, Rf = 0.54) to yield 6a (123 mg, 64 %) as a colorless powder. 
mp: 227-228 °C. IR (KBr disk): 3228 cm-1, 3105, 2981, 1734, 1603, 1445, 1259, 1159, 
752. 1H-NMR (DMSO-d6, 363 K): δ = 1.44 ppm (s, 9 H, Boc-CH3), 3.89 (s, 3 H, 
OCH3), 7.36 (s, 1 H), 8.92 (bs, 1 H), 9.71 (s, 1 H). 13C-NMR (DMSO-d6): δ = 28.2 ppm 
(+; HMQC: Boc-CH3), 53.5 (+; HMQC: OCH3), 83.0 (Cquat; HMBC: Boc), 102.7 (+; 
HMQC: PHA-H), 152.1 (Cquat), 155.0 (Cquat; HMBC: C=O Boc), 156.3 (Cquat), 163.7 
(Cquat; HMBC: C=O ester), 167.1 (Cquat). UV (MeCN): λmax (log ε) = 235 nm (4.973), 
303 (4.654). MS m/z (%): 340.0 [MH+] (100). HRMS Calcd for C11H15BrN4O4: 
346.0277; Found: 346.0275±0.0002. 
 
N N
O
MeO
Br
N
H
N
H
Cbz
 
Methyl 6-(N'-benzyloxycarbonylhydrazino)-2-bromo-pyrimidine-4-carboxylate 
(6d): Compound (5b) (836 mg, 2.83 mmol) was allowed to react with triethylamine 
(470 µL, 343 mg, 3.39 mmol) and Cbz-hydrazine (563 mg, 3.39 mmol) following GP1 
(ethyl acetate/hexanes 2:3, Rf = 0.22) to yield 6a (839 mg, 78 %) as a colorless powder. 
mp: 94-95 °C. IR (KBr disk): 3354 cm-1, 3270, 2958, 2930, 1721, 1691, 1591, 1512, 
1376, 1287, 1211, 1121, 995, 968, 773, 743, 695. 1H-NMR (CDCl3): δ = 3.92 ppm (s, 
3 H, OCH3), 5.16 (s, 2 H, CH2), 7.05-7.58 (m, 7 H, Ar-H, PHA-H, NH), 8.60 (br s, 1 H, 
NH). 13C-NMR (CDCl3): δ = 53.5 ppm (+, OCH3), 68.4 (-, CH2), 102.4 (+, PHA-H), 
127.3 (+, Ar-H), 127.7 (+, Ar-H), 134.1 (Cquat, Ar), 150.8 (Cquat), 155.2 (Cquat, C=O 
Cbz), 162.5 (Cquat), 162.6 (Cquat), 165.8 (Cquat). UV (MeCN): λmax (log ε) = 301 nm 
(4.644). MS m/z (%): 380.9 [MH+] (100). Anal. Calcd for C14H13BrN4O4: C: 44.1; H: 
3.4; Br: 21.0; N: 14.7; O: 16.8; Found: C: 44.6; H: 3.4; N: 14.9. 
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Methyl 6-(N'-tert-butoxycarbonylhydrazino)-2-diethylaminopyrimidine-4-
carboxylate (8a): Method A: A solution of (6a) (117 mg, 0.39 mmol), DMAP (59 mg, 
0.48 mmol) and diethylamine (80 µL, 57 mg, 0.78 mmol) in DMF (6 mL) is stirred for 
1 d at 40 °C. The red solution is diluted with ethyl acetate (8 mL) and washed with brine 
(2x15 mL). The organic extract is dried over MgSO4, evaporated under reduced 
pressure and the residue purified by column chromatography (hexanes/ethyl acetate 3:1, 
Rf = 0.22) to afford 8a (55 mg, 42 %) as a colorless powder. 
Method B: A solution of 6c (200 mg, 0.58 mmol) and diethylamine (299 µL, 212 mg, 
2.90 mmol) in DMF (4 mL) is stirred for 8 h at 80 °C. The solvent is evaporated and the 
crude product purified by column chromatography (hexanes/ethyl acetate 3:1, Rf = 0.22) 
to afford 8a (146 mg, 74 %). 
mp: 176-177 °C. IR (KBr disk): 3237 cm-1, 2967, 2933, 1732, 1668, 1601, 1531, 1368, 
1253, 1161. 1H-NMR (DMSO-d6): δ = 1.09 ppm (t, 3J = 6.9 Hz, 6 H, CH3), 1.25-152 
(m, 9 H, Boc-CH3), 3.54 (q, 3J = 6.9 Hz, 4 H, CH2), 3.81 (s, 3 H, OCH3), 6.32 (s, 1 H, 
PHA-H), 8.48-9.17 (m, 2 H, N-H). 13C-NMR (DMSO-d6): δ = 13.1 ppm (+, CH3), 27.9 
(+, Boc-CH3), 40.7 (-, CH2), 52.2 (+, OCH3), 78.8 (Cquat, Boc), 93.5 (+, PHA-H), 155.2 
(Cquat), 155.6 (Cquat), 160.6 (Cquat), 164.3 (Cquat), 165.5 (Cquat). UV (MeCN): λmax (log ε): 
243 (5.316) nm, 329 (4.660). MS m/z (%): 701.5 [2MNa+] (6), 340.0 [MH+] (100) 
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Methyl 6-(N'-benzyloxycarbonylhydrazino)-2-diethylaminopyrimidine-4-
carboxylate (8b): To a solution of 6d (270 mg, 0.71 mmol) in DMF (5 mL) was added 
diethylamine (366 µL, 260 mg, 3.55 mmol). The reaction mixture was stirred for 16 h at 
70 °C. The solution was diluted with ethyl acetate (7 mL) and washed with brine 
(2x10 mL). The organic phase washed dried over MgSO4, evaporated under reduced 
pressure and purified by column chromatography (hexanes/ethyl acetate 3:2, Rf = 0.40) 
affording 8b (212 mg, 80 %). 
mp: 174-177 °C. IR (KBr disk): 3262 cm-1, 2955, 1783, 1596, 1499, 1443, 1263, 1196, 
976, 748. 1H-NMR (CDCl3): δ = 1.12 ppm (t, 3J = 7.0 Hz, 6 H, NCH2CH3), 3.58 (q, 
75 
3J = 6.6 Hz, 4 H, NCH2CH3), 3.89 (s, 3 H, OCH3), 5.18 (s, 2 H, CH2 Cbz), 6.51-6.72 
(m, 3 H, PHA-H, NH), 7.22-7.38 (m, 5 H, Ar-H). 13C-NMR (CDCl3): δ = 13.1 ppm (+, 
NCH2CH3), 41.6 (-, NCH2CH3), 52.7 (+, OCH3), 67.9 (-, CH2 Cbz), 92.1 (+, PHA-H), 
128.3 (+, Ar-H), 128.5 (+, Ar-H), 128.6 (+, Ar-H), 135.5 (Cquat, Ar), 156.0 (Cquat, C=O 
Cbz), 156.8 (Cquat), 161.1 (Cquat), 165.6 (Cquat), 166.0 (Cquat). UV (MeCN): 
λmax (log ε) = 246 nm (5.289), 341 (4.579). MS m/z (%): 374.0 [MH+] (100). 
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Methyl 6-(N'-tert-butoxycarbonylhydrazino)-2-butylaminopyrimidine-4-
carboxylate (8c): To a stirred solution of (6c) (100 mg, 0.29 mmol) in DMF (3 mL) 
was added butyl amine (71 µL, 53 mg, 0.72 mmol) and the reaction mixture was stirred 
for 18 h at 65 °C. The solution was diluted with ethyl acetate (5 mL) and washed with 
brine (3x8 mL). The organic extract was dried over Na2SO4, evaporated off and purified 
by column chromatography (hexanes/ethyl acetate 3:2, Rf = 0.14) to afford 8c (13 mg, 
13 %) as colorless powder and unreacted 6c (49 mg, 0.14 mmol). 
mp: 110-112 °C. IR (KBr disk): 3337 cm-1, 2959, 2873, 1735, 1591, 1542, 1439, 1368, 
1249, 1160, 1102, 778. 1H-NMR (CDCl3): δ = 0.92 ppm (t, 3J = 7.2 Hz, CH3), 1.24-1.58 
(13 H, Boc-CH3, CH3CH2, CH3CH2CH2), 3.36 (q, 3J = 6.4 Hz, 2 H, CH2NH), 3.93 (s, 
3 H, OCH3), 5.34 (br s, 1 H, NH), 6.55 (s, 1 H, NH), 6.65 (s, 1 H, PHA-H), 6.76 (br s, 
1 H, NH). 13C-NMR (DMSO-d6): δ = 13.8 ppm (+, CH3), 20.1 (-, CH3CH2), 28.2 (+, 
Boc-CH3), 31.6 (-, CH3CH2), 36.9 (-, CH3CH2CH2), 53.0 (+, OCH3), 82.0 (Cquat, Boc), 
93.2 (+, PHA-H), 155.6 (Cquat, 2 C), 162.4 (Cquat), 165.5 (Cquat), 166.7 (Cquat). UV 
(MeCN): λmax (log ε) = 244 (5.213) nm, 323 (4.552). MS m/z (%): 340.1 [MH+] (100). 
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2,6-Dibromopyrimidine-4-carboxylic acid butylamide (10): Orotic acid butylamide 
(9) (1.65 g, 5.76 mmol) and POBr3 (7.74 g, 28.8 mmol) were suspended in acetonitrile 
(15 mL). The reaction mixture was stirred for 3.5 h at 65 °C. The clear solution was 
allowed to cool to rt and poured on crushed ice (20 mL) and water (10 mL) and 
extracted with ethyl acetate (3x45 mL). The organic extract was washed with sat. 
NaHCO3 solution and dried over Na2SO4, evaporated off affording 10 (466 mg, 72 %) 
in analytical pure form.mp: > 175 °C (decomp). IR (KBr disk): 3010 cm-1, 2987, 2979, 
1650, 1636, 1225, 675. 1H-NMR (DMSO-d6): δ = 0.88 ppm (t, 3 H; 3J = 7.4 Hz, CH3), 
1.18-1.36 (m, 2 H, CH3-CH2), 1.40-1.57 (m, 2 H, CH2-CH2-NH), 3.27 (q, 2 H, 
3J = 6.7 Hz, CH2-NH), 8.21 (s, 1 H, PHA-H), 9.02 (t, 1 H, 3J = 6.8 Hz, N-H). 13C-NMR 
(DMSO-d6): δ = 13.5 ppm (+, CH3), 19.4 (-, CH3-CH2), 30.8 (-, CH2-CH2-NH), 38.8 (-, 
CH2-NH), 122.4 (+, PHA-H), 146.6 (Cquat), 150.1 (Cquat), 154.7 (Cquat), 160.1 (Cquat). 
UV (MeCN): λmax (log ε) = 276 nm (4.774). MS m/z (%): 333.7 [M+H+] (100). 
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2-Bromo-6-[N'-(tert-butoxyhydroxymethyl)hydrazino]pyrimidine-4-carboxylic 
acid butylamide (11): (10) (350 mg, 1.04 mmol) was allowed to react with 
triethylamine (173 µL, 127 mg, 1.25 mmol) and Boc-hydrazine (165 mg, 1.25 mmol) 
following GP1 (ethyl acetate/hexanes 3:5, Rf = 0.18) to yield 11 (331 mg, 82 %) as a 
colorless powder. 
mp: 161-163 °C. IR (KBr disk): 3339 cm-1, 3227, 2974, 2932, 1725, 1651, 1593, 1526, 
1392, 1272, 1254, 1165. 1H-NMR (CDCl3): δ = 0.95 ppm (t, 3 H, 3J = 7.3 Hz; HSQC: 
CH3), 1.36-1.45 (m, 2 H; ROESY: CH3CH2), 1.47 (s, 9 3.43 (q, 2 H, 3J = 6.7 Hz, CH2-
NH), 6.79 (s, 1 H; ROESY: 1NH), 7.46 (s, 1 H; HSQC: PHA-H), 7.62 (bs, 1 H; 
ROESY: 2NH), 7.77 (t, 3J = 5.8 Hz, 1 H; HMBC: NHCO). 13C-NMR (DMSO-d6): δ: 
13.7 ppm (+; HSQC: CH3), 20.1 (-; HSQC: CH3CH2), 28.2 (+; HSQC: Boc-CH3), 31.5 
(-; HSQC: CH3CH2CH2), 39.4 (-; HSQC: CH2NH), 82.7 (Cquat; HMBC: Boc), 99.6 (+; 
HSQC: PHA-H), 150.8 (Cquat), 154.8 (Cquat; HMBC: C=O Boc), 161.7 (Cquat), 167.3 
(Cquat). UV (MeCN): λmax (log ε) = 240 nm (5.227), 295 (4.709). MS m/z (%): 388.0 
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[MH+] (88), 331.9 [MH+ - C4H8] (100). Anal. Calcd for C14H22BrN5O3: C. 43.3; H: 5.7; 
N: 18.0; O: 12.4; Br: 20.6; Found: C: 43.6; H: 5.6; N: 17.9. 
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6-[N'-(tert-Butoxyhydroxymethyl)hydrazino]-2-butylaminopyrimidine-4-
carboxylic acid butyl-amide (12a): (11) (142 mg, 0.36 mmol) was allowed to react 
with butylamine (357 µL, 263 mg, 3.60 mmol) following GP2 (ethyl acetate/hexanes 
1:1, Rf = 0.37) to give 12a (93 mg, 68 %) as a yellow solid. 
mp: 184-186 °C. IR (KBr disk): 3372 cm-1, 3213, 2962, 1735, 1665, 1589, 1528, 1460, 
1367, 1250, 1161, 1015, 771. 1H-NMR (CDCl3): δ = 0.73-0.97 ppm (m, 6 H, 2 CH3), 
1.32-1.66 (m, 17 H, Boc-CH3, 4 CH2), 3.32-3.45 (m, 4 H, 2 CH2NH), 5.14 (br s, 1 H, 
NH), 6.73 (br s, 1 H, NH), 6.80 (s, 1 H, PHA-H), 7.09 (br s, 1 H, NH), 7.89 (br s, 1 H, 
NHCO). 13C-NMR (CDCl3): δ = 13.8 ppm (+, CH3), 13.9 (+, CH3), 20.0 (-), 20.1 (-) 
28.2 (+, Boc-CH3), 31.6 (-), 31.7 (-), 39.0 (-), 41.2 (-), 88.9 (Cquat, Boc), 91.0 (+, PHA-
H), 155.7 (Cquat), 156.0 (Cquat), 161.3 (Cquat), 161.4 (Cquat), 163.8 (Cquat), 164.1 (Cquat). 
UV (MeOH): λmax (log ε) = 236 nm (5.197), 328 (4.460). MS m/z (%): 381.1 [MH+] 
(100). 
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6-[N'-(tert-Butoxy-hydroxy-methyl)-hydrazino]-2-diethylamino-pyrimidine-4-
carboxylic acid butylamide (12b): To a solution of (11) (242 mg, 0.62 mmol) in DMF 
(3 mL) was added diethylamine (312 µL, 228 mg, 3.12 mg) and the solution was stirred 
for 16 h at 70 °C. The solution was diluted with ethyl acetate (10 mL) and washed with 
brine (2x20 mL). The organic extract was dried over MgSO4 and evaporated off. The 
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residue was purified by column chromatography (hexanes/ethyl acetate 1:2, Rf = 0.33) 
to afford 12b (200 mg, 82 %). 
mp: 165-167 °C. IR (KBr disk): 3226cm-1, 2967, 2933, 1732, 1668, 1601, 1531, 1368, 
1253, 1161. 1H-NMR (CDCl3): δ = 0.95 ppm (t, 3J = 7.3 Hz, 3 H, CH3 Bu), 1.17 (t, 
3J = 7.0 Hz, 6 H, CH3 Et), 1.30-1.73 (m, 13 H, Boc-CH3, CH3CH2, CH3CH2CH2), 3.41 
(q, 3J = 6.7 Hz, CH2NHCO), 3.57 (q, 3J = 7.0 Hz, CH2 Et), 6.68-6.77 (m, 2 H, NH), 6.91 
(s, 1 H, PHA-H), 7.88 (br s, 1 H, NHCO). 13C-NMR (CDCl3): δ = 13.5 ppm (+, CH3 
Bu), 13.6 (+, CH3 Et), 19.4 (-, CH3CH2), 27.9 (+, Boc-CH3), 31.0 (-, CH3CH2CH2), 38.2 
(-, CH2 Et), 38.5 (-, CH2 Et), 40.7 (-, CH2NHCO), 80.2 (Cquat, Boc), 98.3 (+, PHA-H), 
155.6 (Cquat, C=O Boc), 158.6 (Cquat), 161.3 (Cquat), 163.5 (Cquat), 167.2 (Cquat). UV 
(MeCN): λmax (log ε) = 243 nm (5.316), 330 (4.645). MS m/z (%): 783.6 [2M+Na+] (4), 
761.7 [2M+H+], 381.0 [M+H+] (100), 324.9 [MH+-C4H8] (32), 280.8 [MH+-Boc] (48). 
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tert-Butyl N'-(6-butylcarbamoyl-2-morpholin-4-ylpyrimidin-4-yl)hydrazine 
carboxylate (12c): Compound (11) (100 mg, 0.26 mmol) was allowed to react with 
1,4,7,10,13-pentaoxa-16-aza-cyclo-octa-decane (225 µL, 225 mg, 2.58 mmol) following 
GP2 (ethyl acetate/hexanes 1:1, Rf = 0.24) to give 12c (68 mg, 0.17 mmol, 66 %) as a 
colourless, hygroscopic solid. 
mp: 167-170 °C. IR (KBr disk): 3356 cm-1, 3290, 3197, 2691, 1724, 1659, 1558, 1523, 
1447, 1361, 1254, 1161, 1104, 1002, 875. 1H-NMR (CDCl3): δ = 0.95 ppm (t, 
3J = 7.3 Hz, 3 H, CH3), 1.23-1.64 (m, 13 H, Boc-CH3, CH3CH2, CH3CH2CH2), 3.41 (dd, 
3J = 7.1 Hz, 3J = 13.4 Hz, 2 H, CH2NHCO), 3.75 (br s, 8 H, CH2 morpholine), 6.61-6.82 
(m, 3 H, PHA-H, 2 NH), 7.79 (t, 3J = 5.6 Hz). 13C-NMR (CDCl3): δ = 13.8 ppm (+, 
CH3), 20.2 (-, CH3CH2), 28.2 (+, Boc-CH3), 31.7 (-, CH3CH2CH2), 39.1 (-, CH2NHCO), 
44.3 (-, CH2 morpholine), 66.8 (-, CH2 morpholine), 81.8 (Cquat, Boc), 91.2 (+, PHA-H), 
155.8 (Cquat, C=O Boc), 157.4 (Cquat), 160.7 (Cquat), 163.8 (Cquat), 166.7 (Cquat). UV 
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(MeOH): λmax (log ε) = 242 nm (5.449), 328 (4.680). MS m/z (%): 395.1 [MH+] (100), 
296.8 [MH+-Boc] (52). HRMS Calcd for C18H30N6O4: 394.2329; Found: 
394.2330±0.0004. Anal. Calcd for C18H30N6O4: C: 54.8; H: 7.7; N: 21.3; O: 16.2; 
Found: C: 54.8; H: 7.5; N: 21.5. 
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tert-Butyl N'-[6-butylcarbamoyl-2-(1,4,7,10,13-pentaoxa-16-azacyclooctadec-16-
yl)pyrimidin-4-yl]hydrazine carboxylate (12d): Compound (11) (145 mg, 0.37 mmol) 
and triethylamine (154 µL, 112 mg, 1.11 mmol) were dissolved in DMF (3 mL) and 
1,4,7,10,13-pentaoxa-16-aza-cyclooctadecane (292 mg, 1.11 mmol) was added. The 
resulting solution was stirred for 36 h at 65 °C, diluted with ethyl acetate (5 mL) and 
washed with brine (2x10 mL). The organic extract was dried over MgSO4, evaporated 
off and purified by column chromatography (ethyl acetate, Rf = 0.17) to afford 12d 
(118 mg, 56 %). 
mp: > 180 °C (decomp). IR (CH2Cl2): 3110 cm-1, 2979, 1665, 1571, 1259, 902, 886. 1H-
NMR (CDCl3): δ = 0.87 ppm (t, 3J = 7.3 Hz, 3 H, CH3), 1.21-1.72 (m, 13 H, Boc-CH3, 2 
CH2), 3.32 (q, 3J = 6.8 Hz, 2 H, CH2NHCO), 3.41-3.94 (m, 24 H, CH2 crown ether), 
6.39-6.99 (m, 3 H, PHA-H, 2 NH), 7.84 (t, 3J = 5.6 Hz, 1 H, NHCO). 13C-NMR 
(CDCl3): δ = 13.8 ppm (+, CH3), 20.1 (-, CH3CH2), 28.2 (+, Boc-CH3), 39.0 (-, 
CH3CH2CH2), 48.8 (-, CH2NHCO), 69.5 (-, CH2 crown ether), 70.7 (-, CH2 crown 
ether), 70.8 (-, CH2 crown ether), 81.6 (Cquat, Boc), 90.1 (+, PHA-H), 155.8 (Cquat, Boc 
C=O), 157.4 (Cquat), 160.4 (Cquat), 164.1 (Cquat), 166.6 (Cquat). UV (MeCN): 
λmax (log ε) = 244 nm (5.255), 331 (4.578). MS m/z (%): 609.3 [M+K+] (12), 593.3 
[M+Na+] (10), 571.4 [MH+] (100). HRMS Calcd for C26H46N6O8: 570.3377; Found: 
570.3379±0.0004. 
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tert-Butyl N'-{6-butylcarbamoyl-2-[2-(2-methoxyethoxy)ethylamino]pyrimidin-4-
yl}-hydrazine carboxylate (12e): Compound (11) (110 mg, 0.28 mmol) was allowed to 
react with 2-(2-methoxy-ethoxy)ethylamine (361 µL, 334 mg, 2.80 mmol) following 
GP2 (ethyl acetate, Rf = 0.16) to give 12e (33 mg, 28 %) as a colourless powder and 
unreacted 11 (51 mg, 0.13 mmol). 
mp: 88-89 °C. IR (KBr disk): 3436 cm-1, 3376, 3242, 2963, 1730, 1670, 1590, 1569, 
1522, 1440, 1257, 1149, 1091, 802. 1H-NMR (CDCl3): δ = 0.95 ppm (t, 3J = 7.3 Hz, 
3 H, CH3), 1.36-1.46 (m, 11 H, Boc-CH3, 2 CH2), 1.53-1.63 (m, 2 H, CH2), 3.36-3.43 
(m, 5 H, OCH3, CH2), 3.55-3.65 (m, 8 H, 4 CH2), 5.55 (br s, 1 H, NH), 6.74-6.81 (m, 
2 H, PHA-H, NH), 7.00 (br s, 1 H, NH), 7.86 (br s, 1 H, NH). 13C-NMR (CDCl3): 
δ = 12.8 ppm (+, CH3 Bu), 19.1 (-), 27.2 (+, Boc-CH3), 30.6 (-), 38.1 (-), 40.1 (-), 58.0 
(+, OCH3), 69.0 (-), 69.3 (-), 70.9 (-), 80.8 (Cquat, Boc), 90.3 (+, PHA-H), 154.6 (Cquat, 
C=O Boc), 158.6 (Cquat), 160.2 (Cquat), 162.7 (Cquat), 166.1 (Cquat). UV (MeOH): 
λmax (log ε) = 242 nm (4.758). MS m/z (%): 427.1 [MH+] (100), 853.6 [2M+H+] (8). 
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Methyl 2-diethylamino-6-hydrazinopyrimidin-4-carboxylate bishydrochloride 
(13): Compound (8a) (53 mg, 0.16 mmol) is dissolved in ether saturated with HCl 
(2 mL) at 0 °C and stirred for 15 min. Removal of the solvent under reduced pressure 
gives 13 in quantitative yield (50 mg). The product is used without further purification. 
mp: > 185 °C (decomp). IR (KBr disk): 3446 cm-1, 2887, 1744, 1643, 1591, 1521, 1449, 
1337, 1254, 1182, 1058. 1H-NMR (DMSO-d6): δ = 1.14 ppm (t, 3J = 6.9 Hz, 6 H, CH3), 
3.64 (q, 3J = 6.9 Hz, 4 H, CH2), 3.86 (s, 3 H, OCH3), 6.56 (s, 1 H, PHAt-H), 10.55 (br s, 
5 H, NH). MS m/z (%): 240.0 [MH+] (100). 
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Lithium 6-(N'-tert-butoxycarbonylhydrazino)-2-diethylaminopyrimidine-4-
carboxylate (14): To a solution of (8a) (108 mg, 0.32 mmol) in a 4:1 mixture of 
acetone/water (6 mL) was added LiOH·2H2O (13.4 mg, 0.32 mmol). The reaction 
mixture was stirred for 6 h at rt. The solvents are removed under reduced pressure to 
afford 14 (100 mg, 94 %) in almost quantitative yield. The salt is used without further 
purification. 
mp: > 185 °C (decomp). IR (KBr disk): 3298 cm-1, 2974, 1725, 1589, 1520, 1420, 1362, 
1247, 1164, 1077, 859, 784. 1H-NMR (DMSO-d6): δ = 1.06 ppm (t, 3J = 6.9 Hz, 6 H, 
CH3), 1.42 (s, 9 H, Boc-CH3), 3.51 (q, 3J = 6.9 Hz, 4 H, CH2), 6.33 (s, 1 H, PHA-H), 
8.68 (bs, 1 H, NH), 8.95 (bs, 1 H, NH). 13C-NMR (DMSO-d6): δ = 13.8 ppm (+, CH3), 
29.5 (+, Boc-CH3), 40.6 (-, CH2), 78.9 (Cquat, Boc), 90.4 (+, PHA-H), 155.7 (Cquat, C=O 
Boc), 160.4 (Cquat), 166.9 (Cquat), 167.7 (Cquat), 174.6 (Cquat, C=O carboxylate). MS m/z 
(%): 326.0 [M-H+] (100). 
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Methyl 6-{N'-[6-(N'-tert-butoxycarbonylhydrazino)-2-diethylaminopyrimidine-4-
carbonyl]-hydrazino}-2-diethylamino-pyrimidine-4-carboxylate (15): Lithium salt 
(14) (198 mg, 0.35 mmol), hydrazine dihydrochloride (13) (109 mg, 0.35 mmol), HOAt 
(57 mg, 0.42 mmol), HATU (160 mg, 0.42 mmol), and Huenig´s Base (238 µL, 
181 mg, 1.40 mmol) are dissolved in dichloromethane (5 mL). The solution is stirred for 
30 h at rt. The solvent is removed under reduced pressure and the yellow residue 
purified by column chromatography (ethyl acetate/hexanes 3:1, Rf = 0.68) to afford 15 
(78 mg, 40 %) as a colorless powder. 
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mp: 154-156 °C. IR (KBr disk): 3257 cm-1, 3388, 2974, 1720, 1604, 1583, 1548, 1474, 
1435, 1130, 1259, 1165, 1122. 1H-NMR (DMSO-d6): δ = 0.81-1.22 ppm (m, 12 H, 4 
CH3), 1.28-1.54 (m, 9 H, Boc-CH3), 3.34-3.78 (m, 8 H, 4 CH2), 3.80 (s, 3 H, OCH3), 
6.15-6.70 (m, 4 H, 2 N-H, 2 PHA-H), 8.50-10.2 (m, br s, 2 H, N-H). 13C-NMR (DMSO-
d6): δ = 12.7 ppm (+, CH3), 13.1 (+, CH3), 28.0 (+, Boc-CH3), 40.8 (-, CH2), 52.2 (+, 
OCH3), 85.8 (Cquart, Boc), 121.6 (+, PHA-H), 129.5 (+, PHA-H), 152.3 (Cquat, C=O 
Boc), 160.5 (Cquat, C=O), 165.4 (Cquat, C=O); further signals could not be labelled. UV 
(MeCN): λmax (log ε) = 211 nm (5.483), 245 (5.519), 346 (4.933). MS m/z (%): 547.4 
[MH+] (100). HRMS Calcd for C24H38N10O5: 546.3027; Found: 546.3026±0.0004. 
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Methyl 2-(2-{2-[2-({1-[6-(N'-tert-butoxycarbonylhydrazino)-2-
diethylaminopyrimidine-4-carbonyl]-pyrrolidine-2-carbonyl}amino)acetylamino]-
3-phenylpropionylamino}-4-methylpentanoyl-amino)-3-methyl-butyrate (16): 
Compound (14) (75 mg, 0.23 mmol), H-D-Pro-Gly-Phe-Val-Leu-OMe (131 mg, 
0.23 mmol), EDC (45 µL, 39 mg, 0.25 mmol), HOBt (34 mg, 0.25 mmol), and Huenig´s 
Base (75 µL, 57 mg, 0.46 mmol) were dissolved in DMF (3 mL). The reaction mixture 
was stirred for 18 h at rt. At 0 °C, water (5 mL) was added to precipitate 16 (99 mg, 
52 %) in analytical pure form. 
MP: 121 °C. IR (KBr disk): 3349cm-1, 3024, 2995, 1754, 1670, 1591, 1364, 1275, 1161, 
913, 898. 1H-NMR (DMSO-d6): δ = 0.74-0.95 ppm (m, 12 H; HSQC: CH3 Leu, CH3 
Val), 1.04-1.18 (m, 6 H; HSQC: CH3 PHA), 1.34-1.45 (m, 9 H; HSQC: Boc-CH3), 
1.46-1.53 (m, 1 H; COSY: CHs Val), 1.54-1.70 (m, 2 H; COSY: CH2 Pro), 1.75-1.85 
(m, 2 H; COSY CH2 Pro), 1.86-2.01 (m, 2 H; COSY: CH2 Leu), 2.02-2.16 (m, 1 H; 
COSY: CHs Leu), 2.70-2.89 (m, 1 H; HMBC: CH2 Phe), 2.94-3.08 (m, 1 H; HMBC: 
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CH2 Phe), 3.41-3.81 (m, 11 H; COSY: CδH2 Pro, CH2 PHA; HSQC: OCH3, CH2 Gly), 
4.12-4.22 (m, 1 H; COSY: CH Pro), 4.24-4.33 (m, 1 H; COSY: CH Val), 4.38-4.47 (m, 
1 H; COSY: CH Leu), 4.51-4.71 (m, 1 H; COSY: CH Phe), 5.99-6.24 (m, 1 H; HSQC: 
PHA-H), 7.10-7.29 (m, 5 H; HSQC: Ar-H), 7.79-7.91 (m, 1 H, NH), 7.92-8.00 (m, 1 H; 
NH), 8.04-8.11 (m, 1 H; NH), 8.14-8.24 (m, 1 H; NH), 8.30-8.38 (m, 1 H; NH), 8.45-
8.55 (m, 1 H; NH). 13C-NMR (DMSO-d6): δ = 13.5 ppm (+; HMQC: CH3 PHA), 18.5 
(+; HMQC: CH3 Leu), 18.7 (+; HMQC: CH3 Leu), 19.5 (+; HMQC: CH3 Val), 21.7 (+; 
HMQC: CH3 Val), 23.2 (-; HSQC: CH2 Pro), 24.6 (+; HSQC: CHs Leu), 28.5 (+; 
HMQC: Boc-CH3), 28.6 (+; HMQC; Boc-CH3), 29.6 (-; HSQC: CH2Pro), 31.1 (+; 
HSQC: CHs Val), 40.2 (-; HSQC: CH2 PHA), 40.7 (-; HSQC: CH2 Leu), 41.8 (-; 
HSQC: CH2 Pro), 42.5 (-; HSQC: CH2 Gly), 50.7 (-; HSQC: CH2 Phe), 52.2 (+; HSQC: 
OCH3), 54.4 (+; HSQC: CH Val), 58.2 (+; HMBC: CH Phe), 60.7 (+; HSQC: CH Pro), 
62.5 (+; HSQC: CH Leu), 79.4 (Cquart; HMBC: Boc), 116.7 (+; HSQC: PHA-H), 126.7 
(+; HSQC: Ar-H), 128.5 (+; HSQC: Ar-H), 129.7 (+; HSQC: Ar-H), 138.2 (Cquart; 
HMBC: Ar), 156.8 (Cquart; HMBC: C=O Boc), 167.5 (Cquart), 168.4 (Cquart; HMBC: C=O 
Gly), 168.5 (Cquart; HMBC: CHet-NEt2), 169.3 (Cquart), 170.6 (Cquart; HMBC: C=O Phe), 
170.7 (Cquart; HMBC: C=O Pro), 172.5 (Cquart; HMBC: C=O Leu), 172.7 (Cquart; HMBC: 
C=O Val). UV (MeOH): λmax (log ε): 330 nm (6.961). MS m/z (%): 853.6 [MH+] (100). 
HRMS Calcd for C42H65N10O9+: 853.4936; Found: 853.4926±0.0006. 
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Lithium 6-{N'-[6-(N'-tert-butoxycarbonylhydrazino)-2-methylpyrimidine-4-
carbonyl]-hydrazino}-2-methylpyrimidine-4-carboxylate (17): To a solution of (15) 
(216 mg, 0.50 mmol) in a 4:1 mixture of acetone/water (8 mL) was added LiOH·2H2O 
(20.6 mg, 0.50 mmol). The reaction mixture was stirred for 14 h under reflux. The 
solvents are removed under reduced pressure to afford 17 (202 mg, 95 %) in almost 
quantitative yield. The salt is used without further purification. 
mp: 185 °C (decomp). IR (KBr disk): 3332 cm-1, 2977, 1725, 1588, 1524, 1360, 1247, 
1167. 1H-NMR (DMSO-d6): δ = 0.96-1.11 ppm (m, 12 H, CH3), 1.44 (s, 9 H, Boc-CH3), 
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3.38-3.55 (m, 8 H, CH2), 6.39 (s, 1 H, PHA-H), 6.89 (s, 1 H, PHA-H), 8.24 (br s, 1 H, 
NH), 8.68 (br s, 1 H, NH), 8.87 (br s, 1 H, NH), 8.95 (br s, 1 H, NH). 13C-NMR 
(DMSO-d6): δ = 13.6 ppm (+, CH3), 13.8 (+, CH3), 29.5 (+, Boc-CH3), 40.2 (-, CH2), 
40.6 (-, CH2), 78.5 (Cquat, Boc), 90.4 (+, PHA-H), 98.7 (+, PHA-H), 155.7 (Cquat, C=O 
Boc), 160.4 (Cquat), 160.9 (Cquat), 164.7 (Cquat), 165.4 (Cquat), 166.9 (Cquat), 167.7 (Cquat), 
169.6 (Cquat), 174.8 (Cquat, C=O carboxylate). MS m/z (%): 419.1 [M-H+] (100). 
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Turn structure (18): Compound (17) (43 mg, 0.10 mmol), D-Pro-Gly-Phe-Leu-Phe-
Ala-NH2.TFA (73 mg, 0.10 mmol), EDC (54 µL, 47 mg, 0.30 mmol), HOBt (41 mg, 
0.30 mmol), and Huenig´s Base (65 µL, 50 mg, 0.40 mmol) were dissolved in DMF 
(4 mL). The reaction mixture was stirred for 15 h at rt. At 0 °C, water (5 mL) was added 
to precipitate 18 (87 mg, 75 %) in analytical pure form. 
mp: 118 °C. IR (KBr disk): 3321 cm-1, 2961, 2297, 1728, 1662, 1576, 1531, 1456, 
1373, 1272, 1161, 1125, 1074, 779, 703. 1H-NMR (DMSO-d6, 290 K): δ = 0.61-
0.64 ppm (m, 3 H; COSY: CH3 Leu), 0.72-0.76 (m, 3 H; COSY: CH3 Leu), 0.90-1.14 
(m, 18 H; COSY: CH3 PHA), 1.21 (d, 3J = 7.05 Hz, 3 H; COSY: CH3 Ala), 1.25-1.33 
(m, 3 H; COSY: CH2 Leu, CHs Leu), 1.35-1.44 (m, 13 H; HMBC: Boc-CH3; COSY: 
2xCH2 Pro), 1.76-1.87 (m, 1 H; COSY: CH2 Pro), 2.06-2.13 (m, 1 H; COSY: CH2 Pro), 
2.75-2.85 (m, 1 H; NOESY: CH2 Phe), 2.89-2.98 (m, 1 H; NOESY: CH2 Phe), 3.02-
3.10 (m, 2 H; NOESY: CH2 Phe), 3.27-3.68 (m, 8 H; COSY: CH2 PHA), 3.70-3.83 (m, 
2 H; COSY: CH2 Gly), 4.06-4.20 (m, 2 H; COSY: CH Leu, CH Ala), 4.35-4.55 (m, 
3 H; COSY: CH Pro; NOESY: CH Phe, CH Phe), 6.29 (s, 1 H: HMBC: PHA-H), 6.99-
7.37 (m, 13 H; HMBC: Ar-H, PHA-NH, Ala-NH2), 7.70 (d, 3J = 7.8 Hz, 1 H; COSY: 
NH Phe), 7.74-7.82 (m, 1 H; COSY: NH Ala), 7.85 (d, 3J = 7.4 Hz, 1 H; NOESY: PHA-
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NH), 7.88-7.96 (m, 1 H; COSY: NH Phe), 7.97-8.00 (m, 1 H; COSY: NH Leu), 8.14-
8.17 (m, 1 H; NOESY: PHA-NH), 8.93 (bs, 1 H; NOESY: PHA-NHNH), 10.09 (s, 1 H; 
NOESY: PHA-NHNH). 13C-NMR (DMSO-d6): δ = 15.7 ppm (+; HMQC: CH3 Ala) 
17.4 (+; HMQC: CH3 Leu), 18.9 (+; HMQC: CH3 Leu), 22.0 (+; HMQC: CH3 PHA), 
24.0 (-; HMQC: CH2 Pro), 27.8 (-; HMQC: CH2 Pro), 29.8 (+; HMBC: CHs Leu), 31.2 
(+; HMQC: Boc-CH3), 33.7 (-; HMQC: CH2 Pro), 36.7 (-; HMQC: CH2 Phe), 37.4 (-; 
HMQC: CH2 Phe), 39.4 (-; HMBC: CH2 Leu), 47.4 (-; HMQC: CH2 Gly), 50.1 (+; 
HMQC: CH Pro), 51.3 (-; HMQC: CH2 PHA) 53.5 (+; HMQC: CH Phe), 57.4 (+; 
HMBC: CH Leu), 57.7 (+; HMQC: CH Ala), 60.3 (+; HMQC: CH Phe), 79.7 (Cquat; 
HMBC: Boc), 126.0 (+; HMBC: Ar-H), 127.7 (+; HMBC: Ar-H), 128.1 (+; HMBC: Ar-
H), 129.1 (+; HMBC: Ar-H), 130.7 (+; HMBC: Ar-H), 137.3 (Cquat; HMBC: Ar), 137.5 
(Cquat; HMBC: Ar). Further signals are not detectable. UV (MeOH): 
λmax (log ε) = 245 nm (3.275), 346 (1.730). UV (MeOH): λmax (lg ε): 245 nm (3.275), 
346 nm (1.730). MS m/z (%): 1186.8 [M+Na+] (30), 1164.7 [MH+] (80), 583.1 [M+2H+] 
(100). HRMS Calcd for C57H82N17O10+: 1164.6431; Found: 1164.6436±0.0005. 
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2. Substituted Pyrimidine Hydrazine Acid (PHA) Oligoamides and 
their Binding Affinity to Peptides and Proteins 
 
2.1. Introduction 
 
Although peptides play an essential role in wide-ranging biological processes their use 
as biological probes and therapeutic agents has been complicated by poor receptor 
selectivity, poor water solubility, low binding affinities, or unfavorable absorption 
properties.1 The design of high affinity and constrained peptidomimetics has therefore 
been studied intensively in the fields of medicinal chemistry and molecular recognition. 
The synthesis of small artificial receptors that mimic the interactions of ligands with 
binding sites in proteins has been an ongoing goal in recent research.2 We recently 
reported the synthesis and properties of a luminescent benzo crown ether with a pendant 
copper imidodiacetic acid complex, which coordinates with high affinity to His.3  
 
 
Figure 1: Proposed mode of binding of a luminescent crown ether and H-Lys-HisOMe 
 
Sequence specific synthetic peptide receptors are model systems for biologically 
relevant peptide-protein interactions and may find applications in the area of biosensors, 
therapeutics, and catalysis.4
Substituted pyrimidine hydrazine acids (PHA) are peptidomimetics, which were 
recently reported.5 Their geometry of hydrogen bond acceptor and donor sites make 
them suitable for complementary interaction with peptide β-sheets.6
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Figure 2: General binding motif of substituted PHA to peptides β-sheets 
 
Binding affinities between oligoamides and small peptides were measured by 1H-NMR 
and fluorescence titration in chloroform. Assuming a 1:1 stoichiometry affinity 
constants of 103 M-1 were derived from the titration data. Unfortunately, no indicative 
data about the binding motif geometry could be obtained. The spectroscopic properties 
of the synthesized PHA receptors are interesting for analytical applications. After 
excitation at 330 nm emission around 420 nm occurs, depending on the polarity of the 
solvent. An important method used in biological applications to probe interactions is the 
Forster type fluorescence resonance energy transfer (FRET).7 This approach implies 
that the investigated samples carry two fluorophores, one acting as an acceptor (A) and 
the other one as donor (D). When a long-range energy transfer occurs (D*→A), one can 
evaluate the energy transfer efficiency depending on the interprobe distance. This tool 
has been used previously to investigate the conformations of amyloid aggregations,8 
determining the structural features of ordered peptides in solution,9 and visualizing the 
binding process of a metal-complex to a Trp residue.10 The natural amino acids Phe, 
Tyr, and Trp show emission around 285 (excitation at 255 nm) 305 (270), and 350 nm 
(280). If the binding of PHA receptors occurs in proximity to a Trp residue, a FRET 
signal should be observed. 
 
90 
2.2. Synthesis of Highly Water Soluble PHA Receptors 
 
The previously synthesized PHA receptors have poor water solubility and dimerisation 
using standard peptide coupling conditions gives low coupling yields prohibiting the 
preparation of extended structures. Therefore, a new generation of PHA was prepared 
bearing ethylene glycol chains to increase water solubility. According to a literature 
known procedure, bis-[2-(2-methoxy-ethoxy)-ethyl]-amine 4 was synthesized in three 
steps and 80 % overall yield.11 2-(2-Methoxy-ethoxy)-ethanol is tosylated first, treated 
with benzylamine, and finally deprotected with Pd/C and H2 to give the desired amine 
4. 
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Figure 3: Synthesis of bis-[2-(2-methoxy-ethoxy)-ethyl]-amine 4 
 
Amine 4 was used for the substitution of the bromine atom of compound 5 to yield the 
water soluble compound 6 in high yields. 
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Figure 4: Synthesis of the hydrophilic PHA receptor 6 
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The extension of water soluble PHA receptor strands was possible by regioselective 
bromine substitution reaction. PHA 6 was converted quantitatively into the 
corresponding hydrazide 7. This hydrazide is used as a nucleophile substituting a 
bromine atome of 8 regioselective in 4-position. The subsequent substitution of the 
bromine in 2-position with amine 6 yields PHA receptor 10, which is highly water 
soluble. 
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Figure 5: Synthesis of the PHA receptor 10 
 
Starting from 6, compound 10 was synthesized in three steps and 51 % overall yield. 
This method can be used for the synthesis of the PHA trimer (11) and PHA tetramer 
(12). Compound 16 is converted in the corresponding hydrazide with hydrazine hydrate 
first, alkylated with heterocycle 8, and finally treated with amine 6 yielding 11 in 
overall 44 %. Repeating these three steps starting from the trimer 11 leads to the 
tetramer 12 in 9 % overall yield.  
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Figure 6: Synthesis of highly water soluble PHA receptors 11 and 12 
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2.3. Spectroscopic Investigation of the Substituted PHA Receptors 
 
The emission quantum yields of the PHAs were measured in different solvents with 
chinine bisulfate as reference. The effect of solvent on emission is similar for all 
compounds showing decreasing quantum yields with higher polarity. Electron donating 
groups in position 2, such as secondary (17) and tertiary amines (13, 15, 19) increase 
the emission quantum yield. Acceptors, such as chlorine (18) and bromine (5) decrease 
the emission quantum yield. Table 1 summarizes the results. 
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Figure 7: Investigated PHA compounds 
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Entry CHCl3 MeCN MeOH 
5 1.0   
13 10.0 2.1  
15 8.1 2.1 0.9 
16 6.6 5.2 2.0 
17 2.8 2.8 2.3 
18 1.0   
19 20.7   
Table 1: Relative quantum yields of PHAs in %. Chinine bisulfate was used as standard; concentration: 
4·10-5 M 
 
Compound 19 shows the highest quantum yield due to the aromatic Trp side chain, 
which acts as an antenna chromophore (vide infra). Additional PHA units do not 
increase the quantum yield of the system. The dimeric PHA receptor 15 shows a 
quantum yield of 8 % in CHCl3, which is similar to the monomeric molecule 13 with 
10 %.  
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Figure 8: Emission spectra of substituted PHA 13 (R = NEt2) in a 12 mM solution of different solvents 
(excitation at 330 nm) 
 
Solvent polarity effects, beside emission intensity, effect the maximum emission 
wavelength. The substituted PHA 13 exhibits an emission maximum at 437±1 nm in 
CHCl3, which gradually red-shifts with increasing solvent polarity. The emission 
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intensity decreases in the presence of water in MeCN solution. Similar results are 
obtained in the case of the water soluble PHA receptor 11. The emission intensity is 
decreased with an increased polarity of the solvent and is red shifted. 
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Figure 9: Emission spectra of substituted PHA 11 in a 1·10-5 M solution of CHCl3 (circle) and H2O 
(dotted) 
 
The PHA chromophore can be sensitized by Trp. Excitation of a mixture of Fmoc-
Trp(Boc)-OH (1.21 mM) and 14 (1.54 mM, 0 to 0.15 equivalents) in MeCN at 
wavelengths of 280 nm results in a emission of the PHA around 320 nm. The emission 
of Fmoc-Trp(Boc)-OH at 320 nm is quenched in the presence of PHA receptor 81 
resulting from a FRET process. 
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Figure 10: FRET experiment with a 1.21 mM solution of Fmoc-Trp(Boc)-OH and 14 (1.54 mM, 0 to 0.15 
equivalents) in MeCN 
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Figure 11: Stern-Volmer plot of a 1.21 mM solution of Fmoc-Trp(Boc)-OH and 14 (1.54 mM, 0 to 0.15 
equivalents) in MeCN 
 
PHA 14 reveals as a compound quenching the emission of Trp rather strong. A 
quenching constant of 21.5·103 L/mol can be determined from the slope of the 
corresponding Stern-Volmer plot of a mixture of Fmoc-Trp(Boc)-OH and 14 (1.54 mM, 
0 to 0.15 equivalents) in MeCN (figure 11). 
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2.4. Binding Affinities of PHA Receptors to Tetradecapeptide Somatostatin in 
Different solvents 
 
For medicinal and biological applications the binding effectiveness of artificial 
receptors on biological active compounds is of interest. Therefore, the binding of PHA 
receptors to the tetradecapeptide somatostatin (SRIF)12 was investigated. The peptide is 
a potent regulator of multiple biological functions. In clinical studies this substance was 
shown to suppress the release of growth hormone (GH) secretion from the anterior 
pituitary.13 It inhibits the secretion of glucagon and insulin14 as well as gastrin.15 For our 
experiments we used commercial available ampoules of Curamed® containing SRIF-x-
acetate. The amino acid sequence and the secondary structure of SRIF are shown below. 
 
Thr-Phe-Thr-Ser-Cys-OH
Phe-Phe-Asn-Lys-Cys-Gly-Ala-H
Lys
Trp S
S
 
Figure 12: Secondary structure and amino acid sequence of SRIF 
 
Structure-activity-relations have shown that amino acid residues Phe7, Trp8, Lys9, and 
Thr10, which compromise a β-turn, are necessary for biological activity, with residues 
Trp8 and Lys9 being crucial.16 Selective interactions between the Trp8 and a synthetic 
receptor might influence its activity. The titration to determine the binding of 14 to 
SRIF was monitored spectroscopically. At different ratios of both compounds, the 
sample is excited at 281 nm and the quenching of the Trp emission is recorded. In 
addition at each titration point, the PHA moiety is excited at 320 nm to monitor its 
spectroscopic change upon peptide binding. Figure 3 summarizes the titration results. 
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Figure 13: Fluorescence titration of a 7.4·10-5 M solution of SRIF in MeCN with PHA receptor 14 
 
The fluorescence titration of SRIF with PHA receptor 14 in MeCN shows an increase of 
emission intensity of 14 with an increase of the receptor concentration if either excited 
at either 281 nm or 320 nm. Saturation is observed in the presence of approximately 
7 equivalents. Simultaneously the emission (excitation at 281 nm) is quenched with 
increasing amounts of PHA added, reaching saturation after the addition of 
8 equivalents. of PHA. This indicates clearly an intramolecular FRET process between 
the peptides Trp and the binding PHA compound.17
The calculation of a binding affinity constant requires the assumption of a specific 
stoichiometry. In the following, binding affinity constants were calculated by non-linear 
fitting of the emission intensity of Trp8 and 14.18 Assuming a 1:1 binding motif, an 
apparent affinity constant of 3.4·103±0.2 L/mol is derived from the Trp quenching 
curve. As SRIF contains only one Trp, the observed FRET requires donor and acceptor 
in close proximity (less than 10 Å),19 and the affinity of the PHA is moderate, the 1:1 
motif is likely and its assumption is justified. Job plot20 contribute the expected 1:1 
stoichiometry. 
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Figure 14: Job plot of SRIF and 14 (c = 1.5·10-4 mol/L) 
 
Next, the PHA-SRIF binding process was studied in buffered water using compounds 
10 and 11, which are soluble under physiological conditions. A 0.01 M phosphate 
buffer (PBS, pH 7.2) was used as solvent. The fluorescence titration of 10 and SRIF is 
shown in the next figure 15. Trp8 is selectively excited at 280 nm. 
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Figure 15: Fluorescence titration of a 2.3·10-5 M solution of SRIF in 0.01 M PBS with PHA receptor 10 
(excitation at 280 nm) 
 
The wide range of emission maxima of Trp residues in proteins is attributed to 
differences in the microenvironment and its effect on the excited indole ring of Trp. For 
example, a fluorescence red shift occurs as the microenvironment surrounding Trp 
residues changes from nonpolar to polar.21 At low concentrations of 10, SRIF exhibits 
an emission maximum at 358 ± 1 nm. It gradually red shifts with increasing 
100 
concentration of 10, and finally levels off at 393 ± 1 nm. This indicates the Trp8 
exposure to the receptor and its hydrophilic ethylene glycol chains. The emission curve 
of Trp8 is overlapping with the PHA emission around 451 nm. The increase of the 
emission intensity of 10 at 452 nm is shown by the excitation at 392 nm. 
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Figure 16: Fluorescence titration of a 2.3·10-5 M solution of SRIF in 0.01 M PBS with PHA receptor 10 
(excitation at 392 nm) 
 
The relative enhancement of the emission intensity is lower than in the case of PHA 
receptor 14 and the binding experiment in MeCN. The phosphate buffer solution 
suppresses the emission due to a possible protonation of 10.  
Similar results are obtained for the binding affinity of the trimer 11 to SRIF under the 
same conditions. The emission maximum of SRIF is red-shifted with higher 
concentrations of 11 (358→395 nm, data not shown). The quenching of Trp8 with 
increasing amounts of PHA receptors 10 and 11 together with their initial slopes is 
shown in figure 15. The initial slope of 11 (2.62·106 M-1) is more than twice the one of 
10 (1.22·106 M-1). This indicates a higher affinity constant due the more extended 
geometry and additional hydrogen bonds of 11.22
The emission changes of PHA in the presence of the peptide are similar to the effects in 
MeCN, but less pronounced. Quenching of the Trp emission indicates an energy 
transfer to the PHA, but emission of this chromophore is not effective in the protic 
solvent (see above). Direct excitation of PHA (at 392 nm) leads to a small, but 
detectable emission in the presence of the peptide. Binding to the peptide may lead to 
101 
small polarity changes in the PHA environment becoming less polar and increasing the 
emission intensity. 
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Figure 17: Fluorescence titration of a 2.3·10-5 M solution of SRIF in 0.1 M PBS with PHA receptor 10 
(circle) and 11 (dotted), initial slopes are dashed 
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2.5. Binding Affinities of Highly Water Soluble PHA Receptors to Concanavalin A 
under Physiological Conditions 
 
Next, the investigation were extended to the interaction of PHA receptors 10 and 11 to a 
larger protein bearing several β-sheets and Trp. Concanavalin A (ConA) is a lectin 
isolated from jack beans.23 It is the best known member of legume lectins because of its 
numerous biological applications as probing normal and tumor cell membrane 
structures and studying glycosylation mutants of transformed cells.24The three-
dimensional structure of the lectin at 1.75 Å resolution has been determined by X-ray 
diffraction analysis,25 and was further refined at 1.2 Å.26 The lectin monomer (figure 
18) features a ‘jelly roll’ fold architecture. It is made up largely of three antiparallel β-
sheets: a six-stranded nearly flat ‘back’ sheet, a seven-stranded concave ‘front’ sheet 
and a five-stranded sheet forming a ‘roof’ over the two. 
 
 
Figure 18: X-ray structure of ConA monomer displayed in flat ribbon style; sticks: Trp 
 
The lectin dimer is termed the ‘canonical dimer’, which is characterized by a large 12-
stranded β-sheet resulting from the antiparallel side-by-side alignment of the two six-
stranded back sheets (figure 19). Two such canonical dimmers associate with the center 
parts of their back sheets in a perpendicular manner forming the tetramer. 
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 Figure 19: X-ray structure of ConA dimer displayed in flat ribbon style; sticks: Trp 
 
Depending on the concentration of denaturating urea one can affect a specific structure 
of ConA.27 The denaturation equilibrium displays a three-state mechanism involving a 
structured monomeric state (2.7 M urea) between native tetrameric and unfolded 
monomeric state (> 8 M urea). In addition, ConA was denaturated in the presence of 
Trypsin following a modified method of Burger and Noonan28 to eliminate most 
structural elements of the peptide. Depending on the state, ConA has several extended 
β-sheets. With increasing concentration of urea or in the presence of Trypsin, the 
number of β-sheet regions is decreased leading to an unfolded peptide strand. When 
enzymatically digested, ConA remains with almost no distinct secondary and tertiary 
structure. The CD spectra indicate clearly the states of structure under different 
conditions. 
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Figure 20: Far-UV CD spectra of ConA (2 µM) at 25 °C in PBS in the presence of 2.7 M urea (dotted), 
8 M urea (line), and tripsin (circle) 
 
The native tetramer (data not shown) and the dissociated monomer in 2.7 M urea show 
the characteristics of β-sheet structures. Both spectra are different from that in 8 M urea 
and from tripsinized ConA. ConA denaturated by 8 M urea may still have some 
extended β-sheet substructures, while these are clearly eliminated in the case of 
tripsinized ConA.  
First, we investigated the affinity of the PHA dimer 10 to ConA in PBS. As shown in 
figures 19 and 20, ConA has eight Trp per monomer located both on the surface and in 
the core of the peptide. They can be excited at 280 nm and show emission around 
340 nm in PBS. A series of titration experiments were carried out in the presence of 
different concentrations of urea and after tripsin digestion of ConA. Due to the extended 
β-sheet structures of ConA, which are potential binding sites for PHA, no clear 
evidence of the binding motif and the stoichiometry of PHA receptors to ConA can be 
derived from the titration data. Therefore, the Trp emission data were analyzed 
graphically and the initial slope of Trp emission quenching, which depends on the 
efficiency of energy transfer from Trp to PHA, correlates to the ability of the PHA 
compound to bind to the peptide. 
The Trp emission maximum is only slightly red shifted from 332±1 to 340±1 nm. Even 
at high concentrations of 10 (100 µM, 50 equivalents), an emission of Trp is still 
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detectable. Some of the proteins Trp units are shielded inside by the peptide structure 
and are not accessible by PHA binding to the surface exposed β-sheet structures. 
Therefore, their emission is not quenched.  
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Figure 21: Fluorescence titration of a 2 µM solution of ConA in 0 M urea (circle), 2.7 M urea (square), 
8 M urea (triangle), and tripsinized (cross) with 10 
 
Going from the native protein state to the monomeric structure and to the denaturated 
structures, leads to distinct differences in the PHAs efficiency to quench the Trp 
emission. Table 3 summarizes the initial slopes derived from the Trp titration curve and 
the shifts of the emission maximum. 
 
 initial slope 
[-M-1/106] 
shift emission 
max. [nm] 
∆ shift emission max 
[nm] 
ConA (2 µM) native 2.81 332 → 340 8 
ConA (2 µM) + 2.7 M urea 1.99 341 → 387 46 
ConA (2 µM) + 8 M urea 1.16 349 → 383 34 
ConA (2 µM) + tripsin 1.23 349 → 393 44 
SRIF (22 µM) 1.22 359 → 403 44 
Table 2: Initial slopes and red-shift of Trp emission maximum of a peptide solution in PBS with PHA 
receptor 10 
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The ability of PHA 10 to quench the Trp emission and likewise its binding affinity to 
ConA depends on the secondary and tertiary structure of the peptide. ConA has 
extended β-sheets in its native state. In the presence of 2.7 M urea, the resulting 
monomeric protein offers a smaller number of suitable binding motifs which leads to a 
decreased binding affinity. When ConA is either denaturated with 8 M urea or treated 
with tripsin, the affinity is diminished by a factor of 3. Table 3 also contains the slope of 
the titration curve of 10 and SRIF. Similar values are obtained for the binding of 10 to 
SRIF and denaturated ConA. This indicates a diminished binding affinity due to 
unfolded or more unstructured peptide. The initial slope of Trp emission quenching in 
denatured and digested ConA is comparable to the value obtained with SRIF. This 
indicates that the higher Trp emission quenching and binding affinity of PHA for native 
and partly denatured ConA is an effect of the secondary and tertiary protein structure. In 
its unfolded and unstructured state, the affinity of PHA to the protein is comparable to a 
small peptide without distinct structure. 
The emission maximum is red-shifted in all titrations. The shift is small for 10 and 
native ConA due to the shielded Trp inside the protein, which are not accessible by the 
PHA. A shift of 40 nm during the titration is observed for all the other experiments with 
small but significant differences. The emission levels off around 390 nm indicating a 
hydrophilic microenvironment of Trp. In contrast to native ConA, the fluorescence of 
Trp decreased gradually to almost negligible intensity at high concentrations of 10.  
Due to the extended binding motif of PHA trimer 11, a higher binding affinity was 
expected. The Trp emission quenching was again analyzed graphically and the initial 
slope of the titration curves was determined as an indicator. Figure 22 shows the relative 
change of emission of Trp (excitation at 280 nm) as a function of PHA 11 
concentration. 
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Figure 22: Fluorescence titration of a 2 µM solution of ConA in 0 M urea (diamond), 2.7 M urea 
(triangle), 8 M urea (circle), and tripsinized (+) with 11 
 
The binding affinity of 11 to ConA in the native state shows the steepest initial slope 
(-3.09·106 M-1) of all the binding experiments. Table 4 summarizes the results. 
 
 initial slope 
[-M-1/106] 
shift emission 
max. [nm] 
∆ shift emission max 
[nm] 
ConA (2 µM) native 3.09 336 → 347 11 
ConA (2 µM) + 2.7 M urea 2.95 339 → 383 44 
ConA (2 µM) + 8 M urea 1.96 349 → 387 38 
ConA (2 µM) + tripsin 2.76 346 → 391 45 
SRIF (22 µM) 2.62 359 → 401 42 
Table 3: Initial slopes and red-shift of Trp emission maximum of a peptide solution in PBS with PHA 
receptor 11 
 
The initial slope decreases with an increase of unfolded and unstructured peptide. ConA 
in the presence of 8 M urea shows the lowest binding affinity. The slopes for tripsinized 
ConA (-2.76·106 M-1) and SRIF (-2.62·106 M-1) are similar, but somewhat steeper than 
ConA denaturated by urea (-1.96·106 M-1), which is surprising because structural 
differences are expected to be small.  
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The red-shift of the Trp emission maxima is again small for 11 and the native ConA. A 
shift of 40 nm is observed in the titration in all the other experiments with small 
differences. The emission wavelength shift shows the increasing exposure of the Trp to 
the hydrophilic environment upon denaturation. While in the titration of 11 with native 
ConA the fluorescence of Trp is quenched only partly, an almost quantitative quenching 
with increasing concentration of 11 is observed with the denatured protein. 
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2.6. Conclusions 
 
The emission intensity of PHA chromophores strongly depends on solvent polarity and 
PHA excitation is possibly by direct light absorption (at 382 nm) or a FRET process 
utilizing the Trp emission. PHA oligomers mimic a peptide structure in β-sheet 
conformation and therefore interaction with peptide β -sheet structures was expected. 
Previous investigations confirmed this for non polar solvents (CDCl3) and small 
peptides. With a newly established synthetic route water-soluble PHAs became 
available, which were extended to di-, tri- and tetramers. Although the emission 
intensity of the water soluble PHAs is significantly diminished in polar solvents, they 
are suitable molecular sensors probing protein structure. In the presence of the Trp 
containing tetradecapeptide somatostatin a FRET from the peptides Trp to the bound 
PHA is observed. At the same time, binding to the peptide leads to an increase in PHA 
emission intensity if excited directly at 382 nm, most likely due to a less polar 
microenvironment in the proximity of the peptide. Using the protein ConA in different 
denaturated and even digested structural states, significant differences in the PHA 
receptor Trp quenching and likewise binding ability were observed. The native or only 
partially denaturated protein, possessing extended and surface exposed β-sheet 
structures, show higher PHA affinity than the completely denaturated or digested 
protein. The protein binding affinity of the PHA, indicated by its ability to quench the 
proteins Trp emission, changes with the proteins secondary and tertiary structure. 
Extended β-sheet structures, complementary to the PHA structure, lead to higher 
affinities. PHA receptors can therefore be envisaged as fluorescent molecular probes for 
the determination of the extent of protein β-sheet structures. 
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2.7. Experimental Part 
 
General Methods: 
Melting points were determined on a Tottoli micromelting point apparatus and are 
uncorrected. 1H-NMR spectra were recorded on a Bruker Avance 300 NMR 
spectrometer at 300 K. Chemical shifts (δ) are reported in ppm downfield from internal 
TMS. Emission spectra were recorded on a Cary Eclipse spectrophotometer. Thin layer 
chromatographic (TLC) analyses were performed on silica gel 60 F-254 with a 0.2 mm 
layer thickness. Preparative chromatography columns were packed with silica gel 
Geduran SI 60. Mass spectra were recorded on a Finnigan MAT TSQ 7000 (ESI) and 
on a Finnigan MAT 95 (HRMS). Elemental analyses were carried out by the 
microanalytical laboratory University of Regensburg. Commercially available reagents 
were used as received. Organic extracts were dried over anhydrous Na2SO4 and 
concentrated in vacuo.  
 
Emission Titrations:  
A solution of the PHA molecule (c = 0.5 mmol/L) was added in portions by a 
microsyringe to a solution of a peptide (c = 2 µmol/L) and PHA (c = 0.1 mmol/L). 
Volume and concentration changes were taken into account for the analysis of the 
binding event. 
 
Far-UV circular dichroism (CD): 
Far-UV circular dichroism (CD) spectra were measured on a JASCO J-720 
spectropolarimeter purged with N2, and equipped with a constant temperature cell 
holder. The buffer used during measurement was PBS (pH 7.2). The spectra were 
measured at 25 °C in 1-mm-pathlength cell using a scan speed of 20 nm/min with a 
response time of 2 s, and averaged over ten scans to eliminate signal noise. The data are 
represented as the mean residue ellipticity [θ], which is defined as [θ] = 100·θobs/(c·l), 
where θobs is the observed ellipticity in degrees, l is the length of the light path in 
centimeters, and c is the concentration in moles of residue per liter.  
 
 
111 
Protein denaturation with urea: 
The denaturation experiments in urea were carried out in 0.01 M PBS (pH 7.2) at 25 °C. 
For each denaturation experiment, a known amount of PBS was mixed with a fixed 
amount of the protein stock solution and varying amounts of the concentrated 
denaturant. The mixture was incubated at 25 °C for 18 h to ensure that the equilibrium 
was achieved.  
 
Protein denaturation with trypsin: 
11 mg ConA was dissolved in 1 ml 0.01 M PBS (pH 7.2). 40 µl of 2.5 % trypsin was 
added, and the solution was incubated at 37 °C for 12 h. 
 
Synthesis of new cmpounds: 
Compounds 5, 13, 16, 17, 18, and 19 were synthesized following a literature procedure.5 
The following compounds were synthesized in a cooperation with Dr. Li during his post 
doc at the University of Regensburg based on preliminary studies. 
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2-{Bis-[2-(2-methoxy-ethoxy)-ethyl]-amino}-6-(N'-tert-butoxycarbonyl-hydrazino)-
pyrimidine-4-carboxylic acid methyl ester (6): A solution of 5 (1.4 g, 4.09 mmol), 4 
(1.8 g, 8.20 mmol), and NEt3 (621 mg, 6.15 mmol) in DMF (20 mL) was stirred at 60ºC 
for 12 h. After the solvent was removed in vacuum, the residue was dissolved in EtOAc. 
The organic phase was washed with water, brine, and dried over Na2SO4. Upon removal 
of the solvent at reduced pressure, the crude produce was purified by column 
chromatography (CH2Cl2/MeOH 1:50, Rf = 0.3) to afford compound 6 as a yellow oil 
(1.25 g, 3.27 mmol, 80 %). 300 mg of 5 were recovered.  
IR (CHCl3): 3300 cm-1, 3012, 2933, 1734, 1590, 1520, 1251, 1216, 1099, 756, 667. 1H 
NMR (CDCl3): δ = 1.44 ppm (s, 9 H, Boc- CH3), 3.35 (s, 6 H, OCH3), 3.48-3.51 (m, 4 
H, CH2), 3.57-3.63 (m, 8 H, CH2), 3.79 (s, 4 H, CH2), 3.86 (s, 3 H, COOCH3), 6.56 (s, 1 
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H, Het-H), 6.70 (s, 2 H, NH). 13C NMR (CDCl3): δ = 28.2 ppm, 48.0, 52.6, 59.0, 69.1, 
70.2, 72.0, 81.7, 92.8, 155.8, 161.4, 166.3. UV (MeCN): λmax (log ε) = 336 nm (4.647) 
MS (ESI, MeOH + 10mmol/l NH4Ac): m/z (%) = 488.4 [MH+] (100). Anal. Calcd. for 
C21H37N5O8: C: 51.4; H: 7.7; N: 14.4; Found: C: 51.1; H: 7.3; N: 14.2. 
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N'-(2-{Bis-[2-(2-methoxy-ethoxy)-ethyl]-amino}-6-hydrazinocarbonyl-pyrimidin-4-
yl)-hydrazinecarboxylic acid tert-butyl ester (7): A solution of 6 (1.50 g, 3.07 mmol) 
and NH2NH2·H2O (938 mg, 18.4 mmol) in methanol was refluxed for 1 h. After 
removal of the solvent and excess hydrazine in vacuum, the crude product 7 was 
isolated quantitative yields (1.49 g, 3.05 mmol) and could be used in the next step 
directly.  
IR (CHCl3): 3019 cm-1, 1734, 1592, 1507, 1216, 1158, 758, 669.1H NMR (CDCl3): 
δ = 1.43 ppm (s, 9 H, Boc- CH3), 3.34 (s, 6 H, OCH3), 3.49-3.51 (m, 4 H, CH2), 3.55-
3.62 (m, 8 H, CH2), 3.73-3.75 (m, 4 H, CH2), 4.06 (s, 2 H, NH2), 6.69 (s, 1 H, Het-H), 
6.91 (s, 2 H, NH), 8.85 (s, 1 H, NH). 13C NMR (CDCl3): δ = 28.2 ppm, 48.4, 59.1, 69.2, 
70.3, 72.0, 81.6, 90.4, 155.9, 160.4, 164.3. UV (MeCN): λmax (log ε) = 328 (4.751). MS 
(ESI, MeOH + 10mmol/l NH4Ac): m/z (%) = 488.3[MH+] (100). Anal. Calcd. for 
C20H37N7O7: C: 49.3; H: 7.7; N: 20.1; Found: C: 48.9; H: 7.5; N: 20.1. 
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6-{N'-[2-{Bis-[2-(2-methoxy-ethoxy)-ethyl]-amino}-6-(N'-tert-butoxycarbonyl-
hydrazino)-pyrimidine-4-carbonyl]-hydrazino}-2-bromo-pyrimidine-4-carboxylic 
acid methyl ester (9): A mixture of 7 (1.50 g, 3.07 mmol), 8 (996 mg, 3.38 mmol), and 
NEt3 (372 mg, 3.68 mmol) in DMF (15 mL) was stirred at 70ºC for 14 h. After the 
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solvent was removed in vacuum, the residue was dissolved in EtOAc. The organic 
phase was washed with water, brine, and dried over sodium sulfate. Upon removal of 
the solvent in reduced pressure, the crude produce was purified by column 
chromatography (CH2Cl2/MeOH 1:40, Rf = 0.25) to afford compound 9 as a yellow oil 
(1.06 g, 1.69 mmol, 55 %). 150mg of 7 was recovered.  
IR (CHCl3): 3019 cm-1, 1724, 1601, 1479, 1216, 1115, 770, 668. 1H NMR (CDCl3): 
δ = 1.43 ppm (s, 9 H, Boc- CH3), 3.32-3.36 (m, 6 H, OCH3), 3.52 (m, 4 H, CH2), 3.61-
3.67 (m, 6 H, CH2), 3.82 (s, 6 H, CH2), 3.97 (s, 3 H, COOCH3), 6.80 (s, 1 H, Het-H), 
6.76 (s, 1 H, Het-H), 11.06 (s, 2 H, NH). 13C NMR (CDCl3): δ = 28.3 ppm, 48.2, 53.6, 
59.1, 61.6, 69.6, 70.2, 70.5, 72.0, 81.7, 152.5, 156.1, 158.7, 160.5, 164.4. UV (MeCN): 
λmax (log ε) = 330 (5.163). MS (ESI, MeOH + 10mmol/l NH4Ac): m/z (%) = 704.3 
[MH+] (100). Anal. Calcd. for C26H40BrN9O9: C: 44.5; H: 5.7; N: 17.9; Found: C: 44.2; 
H: 5.6; N: 18.3. 
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2-{Bis-[2-(2-methoxy-ethoxy)-ethyl]-amino}-6-{N'-[2-{bis-[2-(2-methoxy-ethoxy)-
ethyl]-amino}-6-(N'-tert-butoxycarbonyl-hydrazino)-pyrimidine-4-carbonyl]-
hydrazino}-pyrimidine-4-carboxylic acid methyl ester (10): A solution of 4 (1.00 g, 
1.42 mmol), 4 (470 mg, 2.13 mmol), and NEt3 (172 mg, 1.70 mmol) in DMF (10 mL) 
was stirred at 82ºC for 14 h. After the solvent was removed in vacuum, the crude 
product was purified by column chromatography (CH2Cl2/MeOH 1:35, Rf = 0.30) to 
afford compound 10 as a yellow oil (968 mg, 1.21 mmol, 85 %). 50mg of 9 was 
recovered.  
IR (CHCl3): 3288 cm-1, 3018, 2892, 1734, 1576, 1521, 1249, 1216, 1099, 757, 668. 1H 
NMR (CDCl3): δ = 1.42 ppm (s, 9 H, Boc- CH3), 3.32-3.35 (m, 12 H, OCH3), 3.46-3.48 
(m, 10 H, CH2), 3.56-3.63 (m, 14 H, CH2), 3.77-3.79 (m, 8 H, CH2), 3.83 (s, 3 H, 
COOCH3), 6.62 (s, 1 H, Het-H), 6.74 (s, 1 H, Het-H), 7.50 (s, 2 H, NH), 9.68 (s, 1 H, 
NH). 13C NMR (CDCl3): δ = 28.2 ppm, 48.1, 48.4, 52.6, 59.0, 69.1, 69.2, 70.2, 71.9, 
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81.5, 93.4, 155.5, 156.0, 160.5, 161.4, 166.0. UV (MeCN): λmax (log ε) = 338 (5.204). 
MS (ESI, MeOH + 10mmol/l NH4Ac): m/z (%) = 843.6 [MH+] (100), 422.3 [M+2H+] 
(31), 394.3 [M+2H+-C4H8] (10). 
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N'-{2-{Bis-[2-(2-methoxy-ethoxy)-ethyl]-amino}-6-[N'-(2-{bis-[2-(2-methoxy-
ethoxy)-ethyl]-amino}-6-hydrazinocarbonyl-pyrimidin-4-yl)-hydrazinocarbonyl]-
pyrimidin-4-yl}-hydrazinecarboxylic acid tert-butyl ester (11a): A solution of 10 
(500 mg, 0.59 mmol) and NH2NH2·H2O (180 mg, 3.54 mmol) in methanol (10 mL) was 
refluxed for 1 h. After removal of the solvent and excess hydrazine in vacuum, the 
crude product 11a could be used in the next step directly. 
IR (CHCl3): 3019 cm-1, 1590, 1216, 759, 669. 1H NMR (CDCl3): δ = 1.41 ppm (s, 9 H, 
Boc-CH3), 3.33 (s, 12 H, OCH3), 3.49-3.51 (m, 10 H, CH2), 3.58-3.67 (m, 14 H, CH2), 
3.79-3.81 (m, 8 H, CH2), 4.11 (s, 2 H, NH2), 6.95-7.06 (m,3 H, Het-H), 8.20 (s, 1 H, 
NH), 8.89 (s, 1 H, NH), 10.36 (s, 2 H, NH). 13C NMR (CDCl3): δ = 28.2 ppm, 48.6, 
59.1, 69.3, 70.4, 72.0, 90.4, 156.1, 160.2, 160.5, 164.6. UV (MeCN): λmax (log ε) = 333 
(5.016). MS (ESI, MeOH + 10mmol/l NH4Ac): m/z (%) = 843.6 [MH]+ (100). Anal. 
Calcd. for C35H62N12O12: C: 49.9; H: 7.4; N: 19.9; Found: C: 49.3; H: 7.1; N: 20.0. 
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PHA compound 11b: A mixture of 10 (1.00 g, 1.19 mmol), 8 (385 mg, 1.31 mmol), and 
NEt3 (144 mg, 1.43 mmol) in DMF (15 mL) was stirred at 75-80ºC for 20 h. After the 
solvent was removed in vacuum, the residue was purified by column chromatography 
(CH2Cl2/MeOH 1:35, Rf = 0.20) to afford compound 11b as a yellow oil (507 mg, 
0.54 mmol, 45 %).100 mg of 11a was recovered. 
IR (CHCl3): 3019 cm-1, 1477, 1216, 758, 669. 1H NMR (CDCl3): δ = 1.39-1.44 ppm (m, 
9 H, Boc-CH3), 3.31-3.36 (m, 12 H, OCH3), 3.51-3.58 (m, 14 H, CH2), 3.67-3.69 (m, 8 
H, CH2), 3.83-3.93 (m, 8 H, CH2), 4.00 (s, 3 H, CH3), 6.94 (s, 2 H, Het-H), 7.49 (s, 1 H, 
NH), 7.96 (s, 1 H, NH), 10.47 (s, 1 H, NH), 10.69 (s, 1 H, NH), 11.34 (s, 1 H, NH). 13C 
NMR (CDCl3): δ = 28.2 ppm, 46.0, 48.5, 49.1, 53.7, 59.1, 69.5, 70.5, 72.0, 81.4, 94.1, 
105.9, 152.6, 152.9, 156.0, 157.2, 157.7, 160.5, 164.9. UV (MeCN): λmax (log ε) = 330 
(5.260). MS (ESI, MeOH + 10mmol/l NH4Ac): m/z (%) = 1059.6 [MH]+ (100). Anal. 
Calcd. for C41H65BrN14O14: C: 46.6; H: 6.2; N: 18.5; Found: C: 46.0; H. 6.4; N. 19.2. 
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PHA compound 11: 
A solution of 11b (500 mg, 0.47 mmol), 4 (156 mg, 0.71 mmol), and NEt3 (57 mg, 
0.56 mmol) in DMF (10 mL) was stirred at 85ºC for 18 h. After the solvent was 
removed in vacuum, the crude produce was purified by column chromatography 
(CH2Cl2/MeOH 1:30, Rf = 0.20) to afford compound 11 as a yellow oil (390 mg, 
0.38 mmol, 80 %). 40 mg of 11b was recovered. 
IR (CHCl3): 3019 cm-1, 1577, 1474, 1216, 758, 669. 1H NMR (CDCl3): δ = 1.42 ppm (s, 
9 H, Boc-CH3), 3.32-3.34 (m, 18 H, OCH3), 3.48-3.69 (m, 36 H, CH2), 3.84-3.90 (m, 16 
H, CH2, CH3), 6.98 (s, 3 H, Het-H), 7.44 (s, 1 H, NH), 10.52 (s, 5 H, NH).13C NMR 
(CDCl3): δ = 28.2 ppm, 48.2, 48.6, 52.8, 59.0, 69.5, 70.5, 72.0, 81.4, 156.1, 160.5, 
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161.3. UV (MeCN): λmax (log ε) = 338 (6.332). MS (ESI, MeOH + 10mmol/l NH4Ac): 
m/z (%) = 1199.0 [MH]+ (100), 600[MH2]2+(28). 
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PHA compound 12a: A solution of 11 (200 mg, 0.16 mmol) and NH2NH2·H2O (50 mg, 
1.01 mmol) in methanol (5 mL) was refluxed for 1 h. After removal of the solvent and 
excess hydrazine in vacuum, the crude product 12a could be used in the next step 
directly. 
IR (CHCl3): 3019 cm-1, 1577, 1474, 1216, 758, 669. 1H NMR (CDCl3): δ = 1.41 ppm (s, 
9 H, Boc-CH3), 3.32-3.35 (m, 18 H, OCH3), 3.48-3.57 (m, 24 H, CH2), 3.69-3.70 (m, 12 
H, CH2), 3.84-3.87 (m, 12 H, CH2), 7.18 (s, 1 H, Het-H), 7.35 (s, 1 H, Het-H), 7.57 (s, 1 
H, Het-H), 8.89 (s, 2 H, NH), 10.61 (s, 4 H, NH). 13C NMR (CDCl3): δ = 28.2, 48.5, 
48.6, 59.0, 59.1, 69.5, 70.5, 72.0, 81.1, 159.2, 160.3, 160.6. UV (MeCN): 
λmax (log ε) = 337 (5.229). MS (ESI, DCM/MeOH + 10mmol/l NH4Ac): m/z (%) = 
1199.0 [MH]+ (33), 600.0 [M+2H+] (100). Anal. Calcd. for C50H87N17O17: C: 50.1; H: 
7.3; N: 19.9; Found: C: 49.6; H: 7.5; N: 19.9.  
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PHA compound 12b: A mixture of 12a (200 mg, 0.16 mmol), 8 (54 mg, 0.18 mmol), 
NEt3 (25 mg, 0.25 mmol) in DMF (7 mL) was stirred at 80-83 ºC for 20 hrs. After the 
solvent was removed in vacuum, the residue was purified by column chromatography 
(CH2Cl2/EtOAc/MeOH 10:10:1, Rf = 0.20) to afford compound 12b as a yellow solid 
(63 mg, 30.0%).20 mg of 12a was recovered. 
IR (CHCl3): 3019 cm-1, 1577, 1476, 1216, 758, 669. 1H NMR (CDCl3): δ = 1.41 (s, 9 H, 
Boc-CH3), 3.33-3.35 (m, 18 H, OCH3), 3.46-3.49 (m, 22 H, CH2), 3.70-3.72 (m, 12 H, 
CH2), 3.86-3.92 (m, 14 H, CH2), 4.02 (s, 3H, OCH3), 6.98 (s, 1 H, Het-H), 7.55 (s, 1 H, 
Het-H), 7.61 (s, 1 H, Het-H), 8.02 (s, 1 H, Het-H), 10.52 (s, 2 H, NH), 10.68 (s, 2 H, 
NH), 11.48 (s, 1 H, NH). 13C NMR (CDCl3): δ = 28.2 ppm, 48.6, 53.7, 59.0, 59.0, 69.6, 
70.5, 72.0, 81.4, 94.0, 152.6, 152.8, 153.6, 160.6, 165.0. UV (MeCN): λmax (log ε) = 333 
(5.370). MS (ESI, DCM/MeOH + 10mmol/l NH4Ac): m/z (%) = 1415.0 [MH]+ (13), 
708.2 [M+2H+] (100). Anal. Calcd. for C56H90BrN19O19: C: 47.6; H: 6.4; N: 18.8; 
Found: C: 47.4; H: 6.5; N: 18.9.  
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PHA compound 12: 
A solution of 12b (63 mg, 0.044 mmol), 4 (15 mg, 0.067 mmol), NEt3 (7 mg, 
0.066 mmol) in DMF (4 mL) was stirred at 85ºC for 20 hrs. After the solvent was 
removed in vacuum, the crude produce was purified by column chromatography 
(CH2Cl2/EtOAc/MeOH 10:10:1, Rf = 0.25) to afford compound 12 as a yellow solid (42 
mg, 70%). 8 mg of 12b was recovered. 
IR (CHCl3): 3019 cm-1, 1776, 1545, 1473, 1216, 1101, 758. 1H NMR (CDCl3): 
δ = 1.41 ppm (s, 9 H, Boc-CH3), 3.31-3.34 (m, 24 H, CH2, OCH3), 3.47-3.49 (m, 16 H, 
CH2), 3.57-3.58 (m, 16 H, CH2), 3.69-3.72 (m, 16 H, CH2), 3.87-3.91 (m, 19 H, CH2, 
OCH3), 6.68 (s, 1 H, Het-H), 7.32 (s, 1 H, Het-H), 7.59 (s, 2 H, Het-H), 10.62 (s, 4 H, 
NH). 13C NMR (CDCl3): δ = 28.2 ppm, 48.6, 59.0, 69.6, 70.5, 72.0, 81.2, 94.2, 165.6. 
UV (MeCN): λmax (log ε) = 338 (5.336). MS (ESI, MeOH + 10mmol/l NH4Ac):  
m/z (%) = 1554.1 [MH]+ (6), 777.7 [M+2H+] (100). Calcd. for C66H112N20O23: C: 51.0; 
H: 7.3; N: 18.0; Found: C: 50.8; H: 7.6; N: 18.0.  
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3. Molecular Recognition of His with NTA-Ligands 
 
3.1. Introduction 
 
Molecular recognition is based on the reversible interactions of ions or molecules. It is 
thus the chemistry of non-covalent bonds such as hydrogen bonds, electrostatic or van 
der Waals interactions.1 The strength of hydrogen bonds and electrostatic interactions 
decrease rapidly as the polarity of the surrounding solvent increases.2 However, the 
recognition of substrates such as peptides, hormones, or carbohydrates under 
physiological conditions is of great importance for medicinal applications and the 
design of biosensors. 
We currently investigate the interactions of synthetic receptors on peptide β-strands in 
organic solvents and buffered solutions.3 Oligomers of these receptors must adopt a 
linear conformation to be complementary to extended β-sheets. We focused on 
substituted pyrrols and pyrimidines. 
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Figure 1: Synthetic receptors MOPAS (left) and PHA (right) and their assumed binding motif to a peptide 
strand 
 
These heterocyclic peptide mimics bind peptides via hydrogen bonds. The binding of 
methoxypyrrole amino acid (MOPAS) and pyrimidine hydrazine acid (PHA) to peptides 
was investigated by 1H-NMR and fluorescence titration. The chemical induced shift 
(CIS) of separated proton signals and the relative change of the emission maximum of 
the pyrimidine were measured. Binding affinities in chloroform and phosphate buffer 
(pH 7.2) of approx 1·103 M-1 were derived from these data assuming a 1:1 binding 
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motif. The binding of the heterocyclic peptide mimics is weak due to a limited number 
of hydrogen bonds. Self-assoziation of the peptides and mimics complicate the data 
evaluation and decrease efficiency. A combination of hydrogen bonding with strong 
ionic interaction and reversible metal to ligand coordination may allow intramolecular 
formation of hydrogen bonds overcoming the problem of self-association and weak 
binding.4  
Various transition metal ions (e.g. Cu2+, Ni2+, Zn2+) bind to the imidazole side chains of 
surface exposed histidines of proteins.5 This coordination interaction (M2+His) is used 
for protein purification by immobilized metal affinity chromatography (IMAC)6 and 
two-dimensional protein crystallization.7 The binding constant of amino acids with a 
series of divalent metal nitrilotriacetates [M(NTA)]- (M = Mn2+, Co2+, Ni2+, Cu2+, Zn2+) 
has been intensively studied over the last decades.8 Especially the (NTA)/histidine-tag 
(HT) technology has become a powerful tool in the bioscience.9
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Figure 2: Coordinative interactions between terminal His and Zn(II)-NTA 
 
Figure 2 shows the binding motif. The Zn2+ ion is coordinated by the lone pairs of the 
imidazole and the amine nitrogens forming an octahedral complex. The NH2-residue of 
His is essentially for the Zn-NTA binding. 
The binding affinity of NTA to peptides in organic solvents was derived from an ITC 
binding experiment of a Li[Ni(NTA)-Gly-Boc]-complex to NH2-His-Leu-Leu-Val-Phe-
OMe in DMSO. A binding affinity of (5.05±0.33)·105 kcal/mole was determined. The 
binding is 500 fold tighter than the affinity of Zn-NTA to H-His-OH in buffered 
aqueous solution. This results from the higher affinity of Ni-NTA to His compared to 
Zn-NTA10 but likely also from the more extended structure of Li[Ni(NTA)-Gly-Boc].  
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3.2. Results and Discussion 
 
Combining rather weak hydrogen binding of PHA receptors to β-peptide strands and the 
rather strong interaction of M-NTA to His, a receptor with superior binding ability 
under physiological conditions can be synthesized. The initial binding event is the 
strong coordinative interactions between the metal complex and histidine. Although 
Ni2+ or Cu2+ NTA complexes show higher affinities to N-terminal His,12 Zn2+ was 
chosen to obtain a diamagnetic compound. This allows the investigation of interactions 
with NMR techniques. After complex formation, the subsequent process of peptide 
backbone binding is intramolecular, which is more favorable than intermolecular 
processes.11 Gly was chosen as the spacer to assist the receptor molecule by two 
additional hydrogen bond binding sites.  
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Figure 3: Assumed binding mechanism 
 
The synthesis of the peptide-binding complex is shown in figure 4. Compound 1,12 
obtained from lysine methyl ester, is coupled to Boc-Gly-OH. After Boc deprotection, 
the PHA unit 4, which we have reported recently,4 was introduced by standard peptide 
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coupling chemistry. Cleavage of the methyl ester under basic conditions generates the 
NTA ligand. The complexation with Zn2+ leads to the desired receptor 6. 
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Figure 4: Synthesis of the receptor 6 
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Structural information about the binding motif of 6 to the pentapeptide NH2-His-Leu-
Leu-Val-Phe-OMe was derived from 2D-NOE NMR experiments in DMSO-[D6].13 
The NMR spectra of 6·H-His-Leu-Leu-Val-Phe-OMe (c = 3.30·10-2 M), obtained by 
dissolving equimolar amounts of 6 and the pentapeptide were analyzed allowing 
complete assignment of the resonance signals. 
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Figure 5: Structure and numbering of the proposed aggregate formed in an equimolar mixture of 6 and  
H-His-Leu-Leu-Val-Phe-OMe (c = 3.30·10-2 M) in DMSO-[D6] 
 
The temperature-induced shift of bounded and free NH signals indicates hydrogen 
bonding.14 While shifts of <-2 ppb/K indicate a strong interaction, values of >-4 ppb/K 
are crucial for solvent expressed atoms.15 The smallest ppb/K value (-2.57 ppb/K) was 
obtained for NH C. This proton is probably hydrogen bound to both the lone pair of the 
oxygen atom of the amide bond and the lone pair of the nitrogen atom in the pyrimidine 
ring. NH G shows another weak intermolecular hydrogen bond by a temperature 
dependent shift of -2.95 ppb/K. All other temperature dependent shifts of 6 show values 
of 3 ppb/K or higher indicating no strong binding of 6 to the receptor as expected. 
Further information about the binding motif was obtained from ROESY experiments. 
Figure 7 shows an expanded part of the spectra indicating interactions between NH 
signals of 6 to the pentapeptide. 
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Figure 3: Part of the ROESY spectra of an equimolar mixture of 6 and  
H-His-Leu-Leu-Val-Phe-OMe (c = 3.30·10-2 M) in DMSO-[D6] 
 
In summary, 2D NOESY and ROESY16 spectra revealed ten intrastrand contacts, which 
are indicated in figure 8 justifying the depicted structure in figure 4.17  
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Figure 4: Spectroscopically detected NOE contacts of 6 and NH2-His-Leu-Leu-Val-Phe-OMe  
in a 3.30·10-2 M solution DMSO-[D6] (arrows) 
 
The determination of the binding affinity between the receptor 6 and the pentapeptide 
was carried out in MeCN. The PHA receptor 6 emits around 320 nm when excitated at 
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215 nm allowing a photochemical investigation of interactions to a peptide strand. The 
fluorescence titration of 6 to the pentapeptide H-His-Leu-Leu-Val-Phe-OMe is shown 
in figure 4. The emission intensities are corrected for dilution during the titration. 
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Figure 5: Fluorescence titration curve of a 2.03·10-4 M solution of H-His-Leu-Leu-Val-Phe-OMe in 
MeCN with 6 (excitation at 215 nm) 
 
The emission of 6 strongly depends on the polarity of the solvent and its 
microenvironment. It is decreased with increasing solvent polarity. The addition of 6 to 
a solution of the pentapeptide leads to an enhanced intensity. This indicates the 
substitution of solvating H2O in the receptors environment by the less polar terminal His 
and hydrogen binding of the PHA moiety to the peptide. A plateau of the emission 
intensity is observed after the injection of 1 equivalent 6. The further addition leads to a 
decrease of intensity due to unbound PHA receptor. A binding affinity of 
1.07·105 L/mol was calculated by non-linear fitting.18 While the PHA moiety shows 
poor binding affinity to oligopeptides with no clear binding motif, the synthesized 
receptor 6 binds well defined with a 100-fold higher affinity. 
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3.3. Conclusions 
 
Divalent metal nitrilotriacetates [M2+(NTA)]- (M = Mn, Co, Ni, Cu, Zn) are part of 
analytical applications in medicinal chemistry. The combination of an imidazole-
coordinating metal complex, which binds to N-terminal His, with a fluorescent 
pyrimidine hydrazine acid (PHA) moiety leads to a luminescent biosensor. The 
synthesis of the receptor, containing Zn, and its binding affinity to the pentapeptide H-
His-Leu-Leu-Val-Phe-OMe is reported. The binding process proceeds in two steps. 
Initially, a strong interaction of the NTA to the imidiazole of the His occurs. The 
weaker hydrogen binding process of the PHA moiety to the backbone of the peptide 
becomes intramolecular in the second step. The binding process is monitored by 
fluorescence spectroscopy showing an emission response of PHA upon peptide binding. 
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3.4. Experimental Part 
 
Emission Titrations:  
A solution of the PHA molecule (c = 5.00·10-3 mol/L) was added in portions by a 
microsyringe to a solution of a peptide (c = 2.03·10-4 mol/L). Volume and concentration 
changes were taken into account for the analysis of the binding event.17 
 
Synthesis of new compounds: 
N 12
19
1516O
O
17
18
20
OO
21
22
13
O
O
14
10
9
8
N
H
7 6
O
5
N
H
411 3
O
O
2
1
 
2-(Bis-ethoxycarbonylmethyl-amino)-6-(2-tert-butoxycarbonylamino-
acetylamino)-hexanoic acid methyl ester: To a solution of 131 mg (0.75 mmol) Boc-
Gly-OH, 122 mg (0.90 mmol) HOBt, 158 µL (140 mg, 0.90 mmol) NEt3, and 447 µL 
(339 mg, 2.63 mmol) Huenig´s Base in 2 mL DMF was added a solution of 302 mg 
(0,75 mmol) amine 1 in 1 mL DMF at 0 °C. The reaction mixture was allowed to warm 
to rt and stirred for 18 h. The solution was diluted with H2O (4 mL) and extracted with 
CH2Cl2 (2·10 mL). The organic phases were dried over Na2SO4, evaporated, and then 
concentrated under reduced pressure. The residue was purified by column 
chromatography (EtOAc, Rf = 0.36) to afford 2 as a colorless oil in 76 % (280 mg, 
0.57 mmol) yield. 
IR (KBr disk): 3362 cm-1, 2981, 2938, 2251, 1740, 1670, 1166. 1H-NMR (CDCl3, 
400 MHz): δ = 1.28 ppm (t, 3J = 7.1 Hz, 6 H; COSY: C18H3, C22H3), 1.47 (s, 9 H; 
COSY: C1H3), 1.48-1.67 (m, 4 H; COSY: C10H2, C9H2), 1.70-1.74 (m, 2 H; COSY: 
C11H2), 3.28-3.31 (m, 2 H; COSY: C8H2), 3.45 (t, 3J = 7.6 Hz, 1 H; COSY: C12H), 3.61 
(s, 2 H; COSY: C15H2), 3.62 (s, 2 H; COSY: C19H2), 3.71 s, 3 H; COSY: C14H3), 3.81-
3.85 (m, 2 H; COSY: C5H2), 4.17 (q, 3J = 7.1 Hz, 4 H; COSY: C21H2, C17H2), 5.42 (bs, 
1 H; COSY: N4H), 6.51 (bs, 1 H; COSY: N7H). 13C-NMR (CDCl3, 100 MHz; HSQC): 
δ = 14.2 ppm (+, C18, C22), 22.5 (-, C10), 28.2 (-, C9), 28.3 (+, C1), 29.3 (-, C11), 39.1 (-, 
C8), 44.2 (-, C5), 51.4 (+, C14), 52.7 (-, C19, C15), 60.7 (-, C17, C21), 64.1 (+, C12), 79.9 
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(Cquat, C2), 156.0 (Cquat, C3), 169.5 (Cquat, C6), 171.5 (Cquat, C16, C20), 173.3 (Cquat, C14). 
MS (ESI, DCM/MeOH + 10 mmol/l NH4Ac): m/z (%) = 490.3 [M+H+] (100). HRMS 
Calcd for C22H39N3O9: 489.2686; Found: 489.2680±0.0004. 
N
O O
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6-(2-Amino-acetylamino)-2-(bis-ethoxycarbonylmethyl-amino)-hexanoic acid 
methyl ester dihydrochloride: Boc protected amine 2 (259 mg, 0.53 mmol) was 
dissolved in 3 mL of ether saturated with HCl. The solution was allowed to warm to rt, 
stirred for 15. The precipitation was filtered off, washed with cold ether and dried in 
vacuum to afford 3 as a colorless, hygroscopic salt in almost quantitative (242 mg, 
0.52 mmol, 99 %). The salt was used without further purifications. 
mp: > 200 °C (decomp). IR (KBr disk): 3423 cm-1, 2955, 1747, 1656, 1558, 1378, 1224, 
1019, 914, 706. 1H-NMR (DMSO-[D6], 300 MHz): δ = 1.17 ppm (t, 3J = 7.1 Hz, 6 H, 
CH3CH2O), 1.30-1.48 (m, 4 H, CH2 Lys), 1.51-1.63 (m, 2 H, CH2 Lys), 3.01-3.14 (m, 
2 H, CH2 Lys), 3.32-3.42 (m, 1 H, CH Lys), 3.34-3.54 (m, 4 H, CH2CO2Et), 3.55-3.61 
(m, 5 H, CH2 Gly, OCH3), 4.04 (q, 3J = 7.0 Hz, 4 H, CH3CH2O), 8.16-8.34 (m, 3 H, 
NH), 8.48-8.52 (m, 1 H, NH Lys), 9.94 (bs, 1 H, NH). 13C-NMR (DMSO-[D6], 
150 MHz): δ = 15.1 ppm (+), 22.6 (-), 28.4 (-), 29.2 (-), 38.4 (-), 39.9 (-), 51.0 (+), 52.1 
(-), 59.0 (-), 63.7 (+), 165.5 (Cquat), 170.7 (Cquat), 172.3 (Cquat). MS (ESI, DCM/MeOH + 
10 mmol/l NH4Ac): m/z (%) = 390.2 [M+H+] (100). 
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2-(Bis-ethoxycarbonylmethyl-amino)-6-(2-{[6-(N'-tert-butoxycarbonyl-hydrazino)-
2-diethylamino-pyrimidine-4-carbonyl]-amino}-acetylamino)-hexanoic acid methyl 
ester: A solution of 120 mg (0.26 mmol) 3, 86 mg (0.26 mmol) 4, 70 mg (0.52 mmol) 
HOBt, 197 mg (0.52 mmol) HBTU and 224 µL (168 mg, 1.30 mmol) Huenig´s Base in 
4 mL DMF was stirred 24 h at rt. The solution was allowed to cool to 0 °C, diluted with 
cold H2O (5 ml), and extracted with CH2Cl2 (3·10 mL). The organic phases were dried 
over MgSO4, evaporated, and then concentrated under reduced pressure. The residue 
was purified by column chromatography (EtOAc, Rf = 0.30) to afford 5 as a white solid 
in 59 % (106 mg, 0.15 mmol) yield. 
mp: 144 °C; IR (KBr disk): 3325 cm-1, 2989, 1735, 1649, 1532, 1380, 1187, 1093. 1H-
NMR (CDCl3, 600 MHz): δ = 1.17 ppm (t, 3J = 6.9 Hz, 6 H; HSQC: C11H3), 1.22-1.28 
(m, 6 H; HSQC: C27H3, C31H3), 1.35-1.45 (m, 2 H; COSY: C19H2), 1.47 (s, 9 H; HSQC: 
C1H3), 1.55-1.60 (m, 2 H; COSY: C18H2), 1.66-1.72 (m, 2 H; COSY: C20H2), 3.23-3.33 
(m, 2 H; COSY: C17H2), 3.40 (t, 3J = 7.6 Hz, 1 H; HSQC: C21H), 3.58-3.62 (m, 8 H; 
HSQC: C10H2, C24H2, C28H2), 3.67 (s, 3 H; HSQC: C23H3), 4.07-4.16 (m, 6 H; HSQC: 
C14H2, C26H2, C30H2), 6.45-6.75 (m, 2 H; HSQC: N4H, N5H), 6.65 (bs, 1 H; HSQC: 
C7H), 6.69 (bs, 1 H; COSY: N16H), 8.51 (t, 3J = 5.0 Hz, 1 H; HSQC: N13H). 13C-NMR 
(CDCl3, 150 MHz): δ = 13.2 ppm (+; HSQC: C11), 14.2 (+; HSQC: C27, C31), 22.9 (-; 
HSQC: C19), 28.2 (+; HSQC: C1), 28.4 (-; HSQC: C18), 29.6 (-; HSQC: C20), 39.1 (-; 
HSQC: C17), 41.9 (-; HSQC: C10), 43.2 (-; HSQC: C14), 51.4 (+; HSQC: C23), 52.7 (-; 
HSQC: C24, C28), 60.6 (-; HSQC: C26, C30), 64.6 (+; HSQC: C21), 81.7 (Cquat; HMBC: 
C2), 115.4 (+; HSQC: C7), 155.7 (Cquat), 155.8 (Cquat; HMBC: C3), 156.9 (Cquat), 160.1 
(Cquat; HMBC: C9), 164.8 (Cquat; HMBC: C12), 168.7 (Cquat; HMBC: C15), 171.5 (Cquat; 
HMBC: C25, C29), 173.2 (Cquat; HMBC: C22). MS (ESI, MeOH + 10 mmol/l NH4Ac): 
m/z (%) = 719.4 [M+Na+] (22), 697.4 [MH+] (100). 
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2-(Bis-carboxymethyl-amino)-6-(2-{[6-(N'-tert-butoxycarbonyl-hydrazino)-2-
diethylamino-pyrimidine-4-carbonyl]-amino}-acetylamino)-hexanoic acid Li-salt:  
73 mg (0.10 mmol) ester 5 and 3 mg (0.30 mmol) LiOH were dissolved in a 4:1 mixture 
acetone/water and stirred 1 d at 40 °C. The solvents are removed under reduced pressure 
to afford the hygroscopic lithium salt (61 mg, 95 %) in almost quantitative yield. The 
salt is used without further purification. 
mp: > 250 °C (decomp). 1H-NMR (D2O, 300 MHz): δ = 0.52-0.73 ppm (m, 6 H), 0.86-
1.69 (m, 15 H), 2.78-3.22 (m, 5 H), 3.34-3.63 (m, 4 H), 3.84-4.06 (m, 4 H), 6.34 (s, 
1 H), 7.12-7.24 (m, 1 H), 7.34-7.45 (m, 1 H). 13C-NMR (D2O, 75 MHz): δ = 12.4 ppm 
(+), 13.6 (+), 23.2 (-), 27.5 (+), 28.1 (+), 28.4 (-), 30.2 (-), 39.2 (-), 41.5 (-, 2 C), 42.6 (-
), 56.8 (- 2 C), 66.2 (+), 166.5 (Cquat), 170.8 (Cquat); further signals could not be labelled. 
MS (ESI, H2O/MeCN/MeOH + 10 mmol/l NH4Ac): m/z (%) = 391.3 [M+H+] (100), 
408.2 [M+NH4+] (22), 798.7 [2M+NH4+] (37), 803.6 [2M+Na+] (23). 
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Zn-NTA-complex 6:  
64 mg (0.10 mmol) 5 is suspended in 10 mL H2O and 13.6 mg (0.10 mmol) ZnCl2 is 
added. The reaction mixture is stirred for 45 min at 40 °C. The mixture is filtered off 
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and the solvent is removed under reduced pressure. The solid is dissolved in EtOH and 
treated with hexanes precipitating 6 in 65 % (47 mg, 0.047 mmol) yield. 
IR (KBr disk): 3412 cm-1, 2987, 2944, 2880, 1931, 1605, 1537, 1418, 1264, 965, 820. 
1H-NMR (MeOH-[D4], 600 MHz): δ = 1.15 ppm (t, 3J = 7.0 Hz; 6 H; COSY: C11H3), 
1.29-1.68 (m, 15 H; HSQC: C1; COSY: C17H2, C18H2, C19H2), 3.03-3.21 (m, 3 H; 
COSY: C20H2, C21H), 3.31-3.34 (m, 4 H; HSQC: C23H2, C25H2), 3.63 (q, 3J = 7.0 Hz, 
4 H; COSY: C10), 4.05-4.10 (m, 2 H; HSQC: C14H2), 6.52 (s, 1 H; HSQC: C7H). 13C-
NMR (MeOH-[D4], 150 MHz): δ = 13.8 ppm (+; HSQC: C11), 26.8 (-; HSQC: C19), 
28.3 (-; HSQC: C18), 28.7 (+; HSQC: C1), 30.3 (-; HSQC: C17), 42.8 (-; HSQC: C10), 
43.6 (-; HSQC: C14), 55.7 (-; HSQC: C23, C25), 60.3 (-; HSQC: C20), 69.1 (+; HSQC: 
C21), 81.7 (Cquat; HMBC: C2), 91.8 (+; HSQC: C7), 157.7 (Cquat), 158.7 (Cquat), 161.9 
(Cquat; HMBC: C34), 167.3 (Cquat), 171.1 (Cquat), 178.1 (Cquat), 178.3 (Cquat), 179.5 
(Cquat), 180.5 (Cquat). MS (ESI, H2O/MeOH + 10 mmol/l NH4Ac): m/z (%) = 687.4 [M-
H+]- (100).  
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4. Synthesis of an Amino Acid with Protected Cyclen Side Chain 
Functionality*
 
4.1. Introduction 
 
Metal ions are an important feature of protein structure and function. In many cases they 
are crucial for the activity of allosteric and catalytic centers.1 During the last years, 
many applications and studies based on functionalized metallopeptides appeared in the 
literature. Burger and Still have accomplished the split/pool synthesis of encoded 
libraries bearing peptidic appendages attached to a cyclen core binding to Cu(II) ions in 
aqueous solution. The structural data indicate that specific amino acid combinations 
produce more effective metal binders.2 Such ligands that display high affinity and 
selectivity for metal ions may find use as sensors. With the goal of developing artificial 
nucleases for DNA hydrolysis, metal-coordinating peptides have been tethered to a 
DNA intercalating Rh(III) complex to position metal ions close to the sugar-phosphate 
backbone. The intercalator provides DNA binding affinity, and a metal binding peptide 
contributes reactivity.3 In a combinatorial approach Long reported a method to optimize 
the desoxyribose-based cleavage of B-DNA by Ni(II)·Xaa-Xaa-His metallopeptides. 
This metallotripeptid domain is based on the amino-terminal, square-planar Ni(II) 
chelating domain of serum albumin.4 Scrimin et al. reported a dinuclear Zn(II) complex 
of a heptapeptide active in catalyzing the intramolecular transphosphorylation of the 
RNA model substrate 2-hydroxypropyl-p-nitrophenyl phosphate.5 In further studies, 
they showed that these Zn(II) complexes in addition have a remarkable activity in the 
hydrolytic cleavage of plasmide DNA.6 Although structure and application of the 
mentioned metallopeptides are different, a common feature are metal ion coordination 
sites created by artificial and natural amino acids. We report here the efficient synthesis 
of an artificial amino acid containing a protected cyclen unit as metal ion chelate in the 
side chain of glutamine. The compound may serve as a versatile building block to 
introduce a metal ion binding site with high affinity in peptide sequences, and in the 
construction of synthetic receptors. 
                                                          
* The results of this chapter have been published: S. Miltschitzky and B. Koenig, Synth. Comm. 2004, 34, 
2077 
139 
4.2. Results and Discussion 
 
Cyclen 1 was converted into the 3-fold Boc protected derivative 2 following reported 
procedures.7 The protected cyclen 2 was used in a peptide coupling reaction with Cbz-
Glu(OH)-OBn. Best results in amide bond formation were obtained with HOAt, HATU 
and collidin. The simultaneous deprotection of the benzyl ester and the Cbz nitrogen 
protecting group of 3 is achieved by hydrogenation on Pd/C. The clean reaction yields 
amino acid 4 after separation from the catalyst by simple filtration in 78%. To prepare 4 
for use in peptide coupling reactions, its amino group was Fmoc protected. Treatment 
with Fmoc-Cl and Na2CO3 as base in aqueous dioxane solution gives 5, which is 
isolated by precipitation after acidification. To demonstrate the ability of 5 to undergo 
peptide coupling a simple dipeptide with glycine was prepared. The benzyl ester of 
glycine hydrotosylate is coupled to 5 using HOAt, HATU and Hünig´s base in DMF 
solution. The resulting dipeptide 6 is precipitated with water.  
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Scheme 1. Synthesis of cyclen amino acid 5 and its coupling to dipeptide 6 
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4.3. Conclusions 
 
In summary, we have reported the synthesis of a protected Glu(cyclen)-Gly dipeptide. 
The protected cyclen side chain moiety serves after deprotection as a high affinity 
ligand for many transition metal ions. The orthogonal protection allows a versatile use 
of the artificial cyclen amino acid in peptide synthesis, including automated solid phase 
synthesis and combinatorial techniques. In combination with natural or non-natural 
amino acids peptides with one or more metal ion coordination sites can be prepared for 
applications in molecular recognition and catalysis.  
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4.4. Experimental Part 
 
General. Compound 2 was prepared by a known method.7 Melting points were 
measured on a hot-plated microscope apparatus and are not corrected. UV/VIS spectra: 
Varian Cary 50 Bio. IR spectra: Bio-Rad FTS 3000 FT-IR. 1H- and 13C-NMR spectra: 
Bruker AC 250 or Bruker Avance 300; at 300 K; samples of  approx. 30 mg of 
substance in 0.8 ml of deuterated solvents with TMS as the internal standard; s = 
singlet, bs = broad singlet, m = multiplet; the multiplicity of the 13C signals was 
determined using the DEPT technique and is quoted as (+) for CH3 or CH, (-) for CH2 
and (Cquat) for quaternary carbons. Elemental analysis were carried out by the 
microanalytical laboratory University of Regensburg. Commercially available reagents 
were used as received. Organic extracts were dried over anhydrous Na2SO4 and 
concentrated in vacuo. TLC was performed on alumina sheets (Merck KgaA, 20 x 20 
cm, Silica gel 60 F254). 
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10-(4-Benzyloxycarbonyl-4-benzyloxycarbonylamino-butyryl)-1,4,7,10-
tetraazacyclododecane-1,4,7-tricarboxylic acid tri-tert-butyl ester (3):1 In a flame 
dried flask, 2 (142 mg, 0.3 mmol), Cbz-Glu(OH)-OBn (122 mg, 0.33 mmol), HOAt 
(49 mg, 0.36 mmol), HATU (137 mg, 0.36 mmol) and collidine (360 µl, 2.74 mmol) 
were dissolved in 5 ml dichlormethane (DCM) under a nitrogen atmosphere and stirred 
for 65 h at room temp. The crude product was purified by column chromatography 
(SiO2, ethyl acetate/hexane, 3:1, Rf = 0.56) to give 198 mg (88 %) of compound 3, as a 
white solid. 
MP: 74 °C. 1H-NMR (250 MHz, CDCl3): δ = 1.45 (m, 27 H, Boc-CH3), 2.05 (m, 1 H, 
CH2-CON-cyclen), 2.18 (m, 1 H, CH2-CON-cyclen), 2.38 (m, 2 H, CH2-CH2-CON-
cyclen), 3.39 (m, 16 H, cyclen-CH2), 4.37 (m, 1 H, CH-CO2Bn), 5.08 (s, 2 H, CH2-Ph), 
5.17 (s, 2 H, CH2-Ph), 6.00 (br s, 1 H, NH-CO), 7.33 (m, 10 H, Ph-H). 13C-NMR (63 
MHz, CDCl3): δ = 27.1 (-, CH2-CON-cyclen), 28.4 (+, CH3-Boc), 28.5 (+, CH3-Boc), 
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29.2 (-, CH2-CH2-CON-cyclen), 49.7 (-, cyclen-CH2), 49.9 (-, cyclen-CH2), 50.3 (-, 
cyclen-CH2), 51.3 (-, cyclen-CH2), 53.9 (+, CH-CO2BN), 66.9 (-, CH2-Ph), 67.1 (-, 
CH2-Ph), 80.3 (Cquat, Boc), 80.4 (Cquat, Boc), 128.1 (+, Ph-H), 128.2 (+, Ph-H), 128.4 
(+, Ph-H), 128.5 (+, Ph-H), 128.6 (+, Ph-H), 135.4 (Cquat, Ph), 136.4 (Cquat, Ph), 155.5 
(Cquat, OCO-NH), 156.2 (Cquat, CON-Cyclen), 157.1 (Cquat, C=O Boc), 171.9 (Cquat, 
CO2-Bn); MS (ESI, DCM/MeOH + 1 % AcOH): m/z (%) = 826.6 [MH]+ (53), 848.6 
[M+Na]+ (100), 864.7 [M+K]+ (5), 1674.0 [2M+Na]+ (30). UV (CH3CN): 
λmax (lg ε) = 258 nm (3.780), 263 (3.785), 267 (3.708). IR (KBr disk): 3030 cm-1, 2976, 
2932, 1737, 1696, 1648, 1527, 753, 698. Anal. calcd. for C43H63N5O11: C: 62.52; H: 
7.69; N, 8.48; Found: C: 62.22; H: 7.56; N: 8.37. 
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10-(4-Aminoxycarboxy-4-carboxy-butyryl)-1,4,7,10-tetraazacyclododecane-1,4,7-
tricarboxylic acid tri-tert-butyl ester (4): A mixture of 3 (1.8 g, 2.2 mmol) in 10 ml of 
dry methanol and 234 mg palladium on activated charcoal was hydrogenated at 10 bar 
at room temp. for 48 h. The catalyst was filtered off, washed thoroughly with methanol 
and the combined filtrate was concentrated under reduced pressure to give 3 (1.1 g, 85 
%), as a colorless solid. 
MP: 147 °C. 1H-NMR (250 MHz, CDCl3): δ = 1.44-1.46 (m, 27 H, Boc-CH3), 2.22-
2.25 (m, 2 H), 2.63-2.67 (m, 2 H), 3.12-3.14 (m, 1 H, C-H), 3.25-3.50 (m, 16 H, cyclen-
CH2).13C-NMR (DMSO-[D6], 75 MHz): δ = 26.8 (- CH2-CO-cyclen), 28.0 (+, Boc-
CH3), 29.3 (-, CH2-CH), 48.6 (-, CH2-cyclen), 48.7 (-, CH2-cyclen), 48.9 (-, CH2-
cyclen), 49.0 (-, CH2-cyclen), 49.2 (-, CH2-cyclen), 49.4 (-, CH2-cyclen), 49.8 (-, CH2-
cyclen), 49.9 (-, CH2-cyclen), 79.3 (Cquat, Boc), 79.4 (Cquat, Boc), 155.1 (Cquat, C=O 
Boc), 155.7 (Cquat, C=O Boc), 156.0 (Cquat, C=O Boc), 169.9 (Cquat, C=O amid), 172.4 
(Cquat, C=O acid). IR (KBr disk): 3448 cm-1, 2976, 2932, 2363, 1699, 1647, 1473, 1411, 
1366, 1163. UV (CH3CN): λmax (lg ε) = 263 nm (3.691). MS (ESI, MeOH + 1 % 
AcOH): m/z (%) = 602.4 [MH]+ (100), 624.4 [M+Na]+ (40), 1203.9 [2M+H]+ (1), 
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1225.8 [2M+Na]+ (1). Anal. calcd. for C28H51N5O9: C: 55.9; H: 8.5; N, 11.6; Found: C: 
55.6; H: 8.7; N: 11.1. 
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10-[4-Carboxy-(9H-fluoren-9-ylmethoxycarbonylamino)-butyryl]-1,4,7,10-
tetraazacyclododecane-1,4,7-tricarboxylic acid tri-tert-butyl ester (5): Compound 4 
(206 mg, 0.34 mmol) was dissolved in 21 ml of a water/dioxane mixture (5:2) and 
cooled to 0 °C. At this temp. Na2CO3 (108 mg, 1 mmol) and a solution of Fmoc-Cl 
(96 mg, 0.37 mmol) in 3 ml dioxane were added. The yellowish solution was stirred 30 
min at 0 °C, allowed to warm up to room temp. and stirred additional 26 h. The solution 
was acidified with 2 N HCl and extracted three times with 25 ml of ethyl acetate. The 
solvent was removed to give 5 (224 mg, 80 %) , as a colorless solid. 
MP.: 157 °C. 1H-NMR (250 MHz, CDCl3): δ = 1.43-1.49 (m, 27 H, Boc-CH3), 2.22-
2.25 (m, 2 H), 2.63-2.67 (m, 2 H), 3.12-3.67 (m, 16 H, cyclen-CH2), 4.23-4.27 (m, 4 H), 
7.30-7.34 (m, 4 H), 7.55-7.62 (m, 2 H), 7.71-7.82 (m, 2 H), 6.12 (br, 1 H, NH). 13C-
NMR (63 MHz, CDCl3): δ = 27.41 (+, Boc-CH3), 27.43 (+, Boc-CH3), 27.47 (+, Boc-
CH3), 27.9 (-, CH2CON), 29.2 (-, CH2CH2CON), 46.1 (+, Fmoc), 48.6 (-, cyclen-CH2), 
48.9 (-, cyclen-CH2), 49.5 (-, cyclen-CH2), 49.6 (-, cyclen-CH2), 50.5 (-, cyclen-CH2), 
52.7 (+, C-H), 66.1 (-, CH2 Fmoc), 79.6 (Cquat, Boc), 79.7 (Cquat, Boc), 79.8 (Cquat, Boc), 
118.9 (+, Ar-H), 119.0 (+, Ar-H), 123.7 (+, Ar-H), 124.1 (+, Ar-H), 124.2 (+, Ar-H), 
126.1 (+, Ar-H), 126.5 (+, Ar-H), 126.7 (+, Ar-H),140.2 (Cquat, Fmoc), 140.5 (Cquat, 
Fmoc), 142.7(Cquat, Fmoc), 142.9 (Cquat, Fmoc), 154.5 (Cquat, C=O Fmoc), 155.1 (Cquat, 
cyclen-C=O), 156.1 (Cquat, C=O Boc), 172.0 (Cquat, C=O acid). IR (KBr disk): 3433 cm-
1, 2975, 2932, 1695, 1470, 1412, 741. UV (CH3CN): λmax (lg ε) = 248 nm (4.987), 256 
(5.122). MS (ESI, MeOH + 1 % AcOH): m/z (%) = 846.7 [M+Na+] (11), 824.6 [M+H+] 
(72), 724.5 [MH+-Boc] (100), 624.4 [MH+-2Boc] (24). Anal. calcd. for C43H61N5O11: C: 
62.7; H: 7.5; N: 8.5; Found: C: 63.0; H: 7.3; N: 7.5. 
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10-[4-(Benzyloxycarbonylmethyl-carbamoyl)-4-(9H-fluoren-9-
ylmethoxycarbonylamino)-butyryl]-1,4,7,10-tetraazacyclododecane-1,4,7-
tricarboxylic acid tri-tert-butyl ester (6): A mixture of Tos-O- +H3N-Gly-OBn 
(101 mg, 0.30 mmol), 5 (275 mg, 0.33 mmol), HOAt (45 mg, 0.33 mmol), HOAT 
(125 mg, 0.33 mmol) and Hunig´s base (102 µl, 0.60 mmol) was stirred at room temp. 
for 26 h. The solution was cooled in a ice bath and the crude product was precipitated 
with water. The solid was filtered off and washed thoroughly with ice water giving 6 as 
a colorless solid (228 mg, 78 %). For analysis a sample was purified by column 
chromatography (SiO2, ethyl acetate/hexane, 3:1, Rf = 0.24). 
MP.: 147 °C. 1H-NMR (600 MHz, CDCl3): δ = 1.43-1.45 (m, 27 H, Boc-CH3), 1.96-
2.05 (m, 1 H), 2.12-2.19 (m, 1 H,), 2.45-2.56 (m, 1 H), 2.68-2.79 (m, 1 H), 3.18-3.74 
(m, 16 H, cyclen-CH2), 3.90-4.46 (m, 6 H, CH Fmoc, CH2 Fmoc, CH Glu, CH2-Gly), 
6.44 (bs, 1 H, N-H Fmoc), 7.20-7.45 (m, 9 H, Ar-H), 7.54 (m, 2 H, Ar-H), 7.69-7.80 (m, 
3 H, Ar-H, N-H amid). 13C-NMR (63 MHz, CDCl3): δ = 28.4 ppm (+, Boc-CH3), 28.5 
(+, Boc-CH3), 29.1 (-), 29.7 (-), 41.4 (-), 47.1 (+, CH), 50.1 (-, cylclen-CH2), 50.6 (-, 
cyclen-CH2), 51.4 (-, cyclen-CH2), 54.3 (+, CH), 67.0 (-, CH2 ester), 67.1 (-, CH2 
Fmoc), 80.4 (Cquat, Boc), 80.5 (Cquat, Boc), 119.9 (+, Ar-H), 125.2 (+, Ar-H), 125.2 (+, 
Ar-H), 125.3 (+, Ar-H), 127.0 (+, Ar-H), 127.1 (+, Ar-H), 127.7 (+, Ar-H), 128.0 (+, 
Ar-H), 128.1 (+, Ar-H), 128.4 (+, Ar-H), 128.5 (+, Ar-H), 128.6 (+, Ar-H), 129.1 (+, 
Ar-H), 135.3 (Cquat), 141.2 (Cquat), 141.3 (Cquat), 143.8 (Cquat), 144.0 (Cquat), 155.5 
(Cquat), 156.4 (Cquat), 157.1 (Cquat), 169.4 (Cquat), 172.1 (Cquat). IR (KBr disk): 3433 cm-1, 
2975, 2932, 1695, 1470, 1412, 741. UV (CH3CN): λmax (lg ε) = 266 nm (5.666). MS 
(ESI, MeCN): m/z (%) = 988.6 [M+NH4+] (28), 971.6 [M+H+] (100). 
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C. Summary 
 
The mimicry of peptide and protein structures has emerged as a focal point of 
bioorganic and medicinal chemistry. Peptidomimetic chemistry can serve as a basis for 
drug development and peptidomimetic model systems can provide fundamental insights 
into the folding and structure of proteins. 
 
In this work, 6-hydrazinopyrimidine-4-carboxylic acids (PHA) as a building block for 
extended β-strand mimics were selected. Molecular modelling calculations on force 
field level (MMFF, program package Spartan) indicate that oligomers of substituted 
PHA adopt a linear conformation required to be complementary to peptide β-sheets. 
 
In the first chapter, the synthesis of substituted PHA molecules and their inter- and 
intramolecular peptide binding properties in organic solvents are reported. Binding 
affinities were determined by NMR spectra and emission changes. The luminescence of 
substituted PHA receptors, which changes in non-polar solvents upon peptide binding, 
allows the use of PHA receptors as chemosensors and emitting probes. The 
incorporation of substituted PHA molecules into an amino acid sequence bearing D-
Pro-Gly leads to turn structures. They allow the investigation of the possible binding 
motif due to intramolecular hydrogen bonds and NOE contacts between the PHA 
moiety and the peptide backbone.  
 
In further studies, highly water-soluble PHA receptors were synthesized in cooperation 
with Dr. Li. Therefore, ethylene-glycol chains were introduced by substitution 
reactions. Binding affinities of these receptors to the biological active peptides 
Somatostatin (SRIF) and Concanavalin A (ConA) were carried out under physiological 
conditions. The binding affinities were determined from the PHA excitation by direct 
light absorption (at 382 nm) or a FRET process utilizing the Trp emission. The native or 
only partially denaturated protein structures of ConA, possessing extended and surface 
exposed β-sheet structures, show higher PHA affinity than the completely denaturated 
or digested protein structures of ConA and SRIF. The protein binding affinity of the 
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PHA changes with the proteins secondary and tertiary structure. Extended β-sheet 
structures, complementary to the PHA structure, lead to higher affinities. 
 
The combination of an imidazole-coordinating metal complex, which binds to N-
terminal His, with a fluorescent PHA moiety results in a luminescent probe. The 
binding affinity to the pentapeptide H-His-Leu-Leu-Val-Phe-OMe was monitored by 
fluorescence titration experiments. Initially, the strong interaction of Zn2+(NTA) 
complex to the terminal His of the pentapeptide occurs, followed by intramolecular 
hydrogen bonds of the PHA moiety to the peptide. 
 
In the fourth chapter, the synthesis of a protected Glu(cyclen)-Gly dipeptide is reported. 
The protected cyclen side chain moiety serves after deprotection as a high affinity 
ligand for many transition metal ions. The orthogonal protection allows a versatile use 
of the artificial cyclen amino acid in peptide synthesis, including automated solid phase 
synthesis and combinatorial techniques. 
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D. Abbreviations 
 
Ala    Alanine 
Ar    Aryl 
Boc    tert-Butoxycarbonyl 
c    Concentration 
calcd.    calculated 
Cbz    Benzyloxycarbonyl 
Cs    Cesium 
d    days 
DCC    Dicyclohexylcarbodiimide 
DCM    Dichloromethane 
DCU    1,3-Dicyclohexylurea 
DIEA    Ethyl diisopropyl amine (Huenig´s base) 
DMF    Dimethylformamide 
EE/AcOEt   Ethylacetate 
EI    Electronic Ionisation 
eq    equivalents 
ESI    Electronic spray ionisation 
ESI    Electronspray Ionisation 
Et    Ethyl 
FAB    Fast-Atom Bombardment 
Gly    Glycine 
h    hour(s) 
HATU O-(7-Azabenzotriazole-1-yl)-N,N,N,N-
tetramethyluroniumhexafluorophosphate 
His    Histidine 
HOAt    1-Hydroxy-7-azabenzotriazole 
HOBt    1-Hydroxybenzotriazole 
HPLC    High Performance Liquid Chromatography 
IR    Infrared spectroscopy 
J    Coupling Constant 
Leu    Leucine 
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MeCN    Acetonitrile 
Mg2SO4   Magnesium sulfate 
min    minutes 
mp.    melting point 
MS    Mass Spectroscopy 
Na2SO4    Sodium sulfate 
NaCl    Sodium chloride 
NEt3     Triethyl amine 
NIR    Near Infrared 
NMR    Nuclear Magnetic Resonance 
NOE    Nuclear-Overhauser-Effect 
NTA    Nitrilotriacetic acid 
Ph    Phenyl 
PHA    Pyrimidine Hydrazine Acid 
Phe    Phenylalanine 
POBr3     Phosphorylbromide 
POCl3     Phosphorylchloride 
Rf     Retention Factor 
rt    room temperature 
sh    shoulder 
Tab.    Table 
TFA    Trifluoroacetic acid 
TLC    Thin Layer Chromatography 
TMS    Tetramethyl silane 
Tos    p-Toluene-sulfonyl 
UV    Ultraviolett Spektroscopy 
Val    Valine 
x    Mole Fraction 
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